

Evidence-based clinical guidelines for immigrants and refugees

Kevin Pottie MD MCIsc, Christina Greenaway MD MSc, John Feightner MD MSc, Vivian Welch MSc PhD, Helena Swinkels MD MHSc, Meb Rashid MD, Lavanya Narasiah MD MSc, Laurence J. Kirmayer MD, Erin Ueffing BHSc MHSc, Noni E. MacDonald MD MSc, Ghayda Hassan PhD, Mary McNally DDS MA, Kamran Kahn MD MPH, Ralf Buhmann MDCM PhD, Sheila Dunn MD MSc, Arunmozhi Dominic MD, Anne E. McCarthy MD MSc, Anita J. Gagnon MPH PhD, Cécile Rousseau MD, Peter Tugwell MD MSc; and coauthors of the Canadian Collaboration for Immigrant and Refugee Health

Competing interests: See end of document for competing interests.

Coauthors of the Canadian Collaboration for Immigrant and Refugee Health:

Deborah Assayag, Elizabeth Barnett, Jennifer Blake, Beverly Brockest, Giovanni Burgos, Glenn Campbell, Andrea Chambers, Angie Chan, Maryann Cheetham, Walter Delpero, Marc Deschenes, Shafik Dharamsim, Ann Duggan, Nancy Durand, Allison Eyre, Jennifer Grant, Doug Gruner, Sinclair Harris, Stewart B. Harris, Elizabeth Harvey, Jenny Heathcote, Christine Heidebrecht, William Hodge, Danielle Hone, Charles Hui, Susan Hum, Praseedha Janakiram, Khairun Jivani, Tomas Jurcik, Jay Keystone, Ian Kitai, Srinivasan Krishnamurthy, Susan Kuhn, Stan Kutcher, Robert Laroche, Carmen Logie, Michelle Martin, Dominique Elien Massenat, Debora Matthews, Barry Maze, Dick Menzies, Marie Munoz, Félicité Murangira, Amy Nolen, Pierre Plourde, Amelia Sandoe, Jennifer Sears, Hélène Rousseau, Andrew G. Ryder, Kevin Schwartzman, William Stauffer, Brett D. Thombs, Patricia Topp, Andrew Toren, Sara Torres, Ahsan Ullah, Sunil Varghese, Bilkis Vissandjee, Michel Welt, Wendy Wobeser, David Wong, Phyllis Zerkowicz, Jianwei Zhong, Stanley Zlotkin.

Editor's note: See Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1, for affiliations and contributions of coauthors.

This document has been peer reviewed.

Correspondence to: Dr. Kevin Pottie, kpottie@uottawa.ca

CMAJ 2011. DOI:10.1503/cmaj.090313

KEY POINTS

- Clinical preventive care should be informed by the person's region or country of origin and migration history (e.g., forced versus voluntary migration).
- Forced migration, low income and limited proficiency in English or French increase the risk of a decline in health and should be considered in the assessment and delivery of preventive care.
- Vaccination (against measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, varicella, hepatitis B and human papillomavirus) and screening (for hepatitis B, tuberculosis, HIV, hepatitis C, intestinal parasites, iron deficiency, dental pain, loss of vision and cervical cancer) should be routinely provided to at-risk immigrants.
- Detecting and addressing malaria, depression, post-traumatic stress disorder, child maltreatment, intimate partner violence, diabetes mellitus and unmet contraceptive needs should be individualized to improve detection, adherence and treatment outcomes.

Conditions covered in systematic reviews

(see Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1 for summary of recommendations and clinical considerations)

Infectious diseases

- Measles, mumps, rubella
- Diphtheria, tetanus, polio, pertussis
- Varicella
- Hepatitis B
- Tuberculosis
- HIV
- Hepatitis C
- Intestinal parasites (*Strongyloides* and *Schistosoma*)
- Malaria

Mental health and maltreatment

- Depression
- Post-traumatic stress disorder
- Child maltreatment
- Intimate partner violence

Chronic and noncommunicable diseases

- Diabetes mellitus
- Iron-deficiency anemia
- Dental disease
- Vision health

Women's health

- Contraception
- Cervical cancer
- Pregnancy

1. Overview: evidence-based clinical guidelines for immigrants and refugees

There are more than 200 million international migrants worldwide,¹ and this movement of people has implications for individual and population health.² The 2009 United Nations *Human Development Report*³ suggested that migration benefits people who move, through increased economic and education opportunities, but migrants frequently face barriers to local health and social services. In Canada, international migrants are a growing⁴ and economically important segment of the population (Table 1A).⁵⁻⁸

Immigrants to Canada are a heterogeneous group. Upon arrival, new immigrants are healthier than the Canadian-born population, both because of immigrant-selection processes and policies and because of sociocultural aspects of diet and health behaviours. However, there is a decline in this “healthy immigrant effect” after arrival.⁵ In addition, compared with the Canadian-born population, subgroups of immigrants are at increased risk of disease-specific mortality; for example, Southeast Asians from stroke (odds ratio [OR] 1.46, 95% con-

fidence interval [CI] 1.00–1.91),⁹ Caribbeans from diabetes mellitus (OR 1.67, 95% CI 1.03–2.32) and infectious diseases (e.g., for AIDS, OR 4.23, 95% CI 2.72–5.74), and immigrant men from liver cancer (OR 4.89, 95% CI 3.29–6.49).¹⁰

The health needs of newly arriving immigrants and refugees often differ from those of Canadian-born men, women and children. The prevalence of diseases differs with exposure to disease, migration trajectories, living conditions and genetic predispositions. Language and cultural differences, along with lack of familiarity with preventive care and fear and distrust of a new health care system, can impair access to appropriate health care services.¹¹ Additionally, patients may present with conditions or concerns that are unfamiliar to practitioners.^{5,10}

Many source countries have limited resources and differing health care systems, and these differences may also contribute to health inequalities among migrants.¹² In these guidelines, we refer to low- and middle-income countries as “developing.”

Table 1A: Classification of international migration to Canada (2007)*

Immigration category	Annual migration (no.)†‡
Permanent residents⁶	
Economic class (business and economic migrants)	131 000
Family class (family reunification)	66 000
Humanitarian class (refugees resettled from abroad or selected in Canada from refugee claimants)	28 000
Others	11 000
Total	237 000
Temporary residents⁶	
Migrant workers	165 000
International students	74 000
Refugee claimants (those arriving in Canada and claiming to be refugees) ⁶	28 000
Other temporary residents ⁶	89 000
Total ⁶	357 000
Other migrants	
Total irregular migrants,§ not annual migration ⁷	~ 200 000
Visitors ⁸	~ 30 100 000

*Reproduced, with permission, from Gushulak et al.⁵

†Numbers rounded to nearest 1000. Total in each category may not match sum of values reported because of rounding.

‡Unless otherwise indicated.

§No official migration status; this population includes those who have entered Canada as visitors or temporary residents and remained to live or work without official status. It also includes those who may have entered the country illegally and not registered with authorities or applied for residence.

Why are clinical guidelines for immigrants needed?

Canadian immigration legislation requires that all permanent residents, including refugees, refugee claimants and some temporary residents, undergo an immigration medical examination. Screening is undertaken to assess the potential burden of illness and a limited number of public health risks. The examination is not designed to provide clinical preventive screening, as is routinely performed in Canadian primary care practice, and it is linked to ongoing surveillance or clinical actions only for tuberculosis, syphilis and HIV infection.⁵

The Canadian Task Force on Preventive Health Care and the US Preventive Services Task Force have produced many high-quality clinical prevention recommendations, but these statements have not explicitly considered the unique preventive needs and implementation issues for special populations such as immigrants and refugees. Evidence-based recommendations can improve uptake and health outcomes related to preventive services, even more so when they are tailored for specific populations.¹³

How are these guidelines different?

Use of evidence-based methods has yet to substantially affect the field of migration medicine.¹⁴ The Canadian Collaboration for Immigrant and Refugee Health explicitly aims to improve patients' health using an evidence-based clinical preventive approach to complement existing public health approaches. In selecting topics, primary care practitioners considered not just the burden of illness but also health inequities and gaps in current knowledge.¹⁵ Public health concerns and predeparture migrant screening and treatment protocols were also consid-

ered, but these were not the driving force for the recommendations. We implemented evidence-based methods, which included searches for evidence on immigrant preferences and values, as well as incorporating the GRADE approach (Grading of Recommendations Assessment, Development and Evaluation), to formulate clinical preventive recommendations.^{16–18} Our evidence reviews synthesized data from around the world, and our recommendations focus on immigrants, refugees and refugee claimants, with special attention given to refugees, women and the challenges of integrating recommendations into primary care. Migrants living without official status are particularly vulnerable, but specific evidence for this population is limited.¹⁹ In these guidelines, the “health settlement period” refers to the first five years of residence in Canada for an immigrant or refugee, the time during which loss of the healthy immigrant effect begins to surface.

In recent years, there has been an increase in development of practice guidelines for international migrants.²⁰ Notable publications have included *Cultural Competency in Health*,²¹ *Immigrant Medicine*²² and guidelines for refugees from the Australasian Society for Infectious Diseases.²³ Many have been designed to address diseases and conditions of public health importance,^{23–25} and some highlight the importance of psychosocial problems and mental illness, issues of women’s health and chronic noninfectious diseases.^{21,26,27} Other practice guidelines include strategies to improve communication (e.g., interpreters), responsiveness to sociocultural background (e.g., cultural competence), empowerment (e.g., health literacy), monitoring (e.g., health and access disparities) and strategies for comprehensive care delivery.²¹

Our recommendations differ from other guidelines because

Box 1A: Fourteen-step process for evidence reviews used by the Canadian Collaboration for Immigrant and Refugee Health

1. Develop clinician summary table
2. Develop logic model and key questions
3. Set the stage for admissible evidence (using search strategy)
4. Assess eligibility of systematic reviews
5. Search for data specific to immigrant and refugee populations
6. Refocus on key clinical preventive actions and key questions
7. Assess quality of systematic reviews
8. Search for evidence to update selected systematic reviews
9. Assess eligibility of new studies
10. Integrate data from updated search
11. Synthesize final evidence bank and draft two key clinical actions
12. Develop table for summary of findings
13. Identify gaps in evidence and needs for future research
14. Develop clinical preventive recommendations using GRADE (Grading of Recommendations Assessment, Development and Evaluation)

*Adapted, with permission, from Tugwell and others.¹⁶

of our insistence on finding evidence for clear benefits before recommending routine interventions. For example, in our guidelines for post-traumatic stress disorder, intimate partner violence and social isolation in pregnancy, we recommend not conducting routine screening, but rather remaining alert. With regard to screening for asymptomatic intestinal parasites, we recommend focusing on serologic testing for high burden of disease parasites, rather than traditional testing of stool for ova and parasites.

How were these guidelines developed?

We followed the internationally recognized Appraisal of Guidelines for Research and Evaluation (AGREE; www.agreetrust.org). We selected guideline topics using a literature review, stakeholder engagement and the Delphi process with equity-oriented criteria.¹⁵ In May 2007, we held a consensus meeting of experts in immigrant and refugee health to develop a systematic process for transparent, reproducible, evidence-based reviews. The guideline committee selected review leaders from across Canada on the basis of their clinical and evaluation expertise (see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-DC1).

The 14-step evidence review process (Box 1A)¹⁶ used validated tools to appraise the quality of existing systematic reviews, guidelines, randomized trials and other study designs. We searched MEDLINE, Embase, the Cochrane Library and other sources for admissible evidence, specifically reviews and related studies, from 1996 to 2010. We identified guidelines developed by other groups but based our recommendations on evidence from primary studies. We identified patient-important outcomes and used the GRADE approach to assess the magnitude of effect on benefits and harms and on quality of evidence. We included both direct evidence from immigrant and refugee populations and indirect evidence from other populations. We downgraded the quality of evidence for indirectness when there was concern that the evidence might not be applicable to immigrant and refugee populations (e.g., because of differences in baseline risk, morbidity and mortality, genetic and cultural factors, and compliance variations). We assessed whether benefits outweighed harms, the quality of evidence, and values and preferences to minimize the potentially negative effects of labelling on patients, families and communities (Table 1B).^{16–18}

Each of the resulting evidence reviews for priority conditions of the Canadian Collaboration for Immigrant and Refugee Health provides detailed methods and results concerning the burden of illness for the immigrant populations relative to Canadian-born populations, along with information about effectiveness of screening and interventions, a discussion of clinical considerations, the basis for recommendations and gaps in research.

How should I begin to assess immigrants for clinical preventive care?

Determine each person’s age, sex, country of origin and migra-

tion history to tailor preventive care recommendations. In caring for socially disadvantaged populations, sequencing of care using checklists or algorithms can improve both the uptake and the delivery of preventive care¹³ and allows other members of the primary health care team to participate in the delivery of care. Working with interpreters, cultural brokers, patients' families and community support networks can support culturally appropriate care.²⁸ Most importantly, clinicians should recognize that the implementation of recommendations (vaccinations, for example) may take three or four visits, a process more akin to the delivery of well-baby care than to an annual examination. Our recommendations are aimed at primary care practitioners, but competencies related to immigrant and cross-cultural care will vary depending on training and experience, and expert support should be sought accordingly.

Which immigrant populations face the most significant health risks?

Refugees, who are by definition forcefully displaced, are at highest risk for past exposure to harmful living conditions, violence and trauma. Refugees undergo medical screening before admission to Canada but are protected by law from exclusion on the basis of noninfectious burden of illness (through the Immigration and Refugee Protection Act).²⁹ The health risks of refugees and other migrants vary greatly depending on exposures (e.g., to vectors of disease such as mosquitos), trauma from war, living conditions (e.g., access to water and sanitation), neglect from long periods in refugee camps, susceptibilities (e.g., related to ethnicity and migration stress), social stratification (e.g., race, sex, income, education and occupation) and access to preventive services (e.g., pre-departure access to primary care, vaccinations and screening, access to Canadian services and access issues related to linguistic and cultural barriers).

Specifically, refugees are at risk for a rapid decline in self-reported health after arrival (OR 2.31, 95% CI 1.1–4.9), as are

low-income immigrants (OR 1.5, 95% CI 1.3–1.7) and immigrants with limited English- or French-language proficiency.^{5,30–35} There is also an increased risk of reporting poor health among immigrants with limited English- or French-language proficiency (OR 2.0, 95% CI 1.5–2.7), those facing cost-related barriers to health care (OR 2.8, 95% CI 1.7–4.5),³⁶ low-income immigrants³² and non-European immigrants (OR 2.3, 95% CI 1.6–3.3).³¹

Clinical recommendations

Considering the burden of illness of immigrant populations, the quality of evidence for screening and interventions, and the feasibility of clinicians implementing the recommendations, we have organized our recommendations into four groups: infectious diseases, mental health and physical and emotional maltreatment, chronic and noncommunicable diseases, and women's health.

Appendix 2 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1) summarizes the evidence review and recommendations for each topic, providing specific comments about how the number needed to screen and treat for net benefits would differ for immigrant populations.

Infectious diseases

Many immigrants are susceptible to vaccine-preventable diseases upon arrival in Canada. For example, 30%–50% of new immigrants are susceptible to tetanus,³⁷ 32%–54% are susceptible to either measles, mumps or rubella,³⁸ and immigrants from tropical countries are 5–10 times more susceptible to varicella,³⁹ which has serious implications for adult immigrants.

A large proportion (20%–80%) of the immigrants who come from countries where chronic hepatitis B virus infection is prevalent are not immune. In addition, immigrants are more likely to be exposed to hepatitis B virus⁴⁰ in their households and during travel to countries where hepatitis B is prevalent. Immigrants from countries where chronic hepatitis B virus infection is prevalent (affecting 2% or more of the population) can benefit from screening and treatment to prevent hepatitis and hepatocellular carcinoma.

Foreign-born people account for 65% of all active tuberculosis in Canada,⁴¹ and screening and treatment for latent tuberculosis remain priorities for immigrants from countries in sub-Saharan Africa, Asia, and Central and South America.⁴² To promote patients' safety and adherence to therapy, patients must be informed of the risks and benefits of treatment in a culturally and linguistically appropriate manner.^{43,44} Refugees may already be aware of their HIV-positive status but may have limited knowledge of effective screening and treatment options. HIV-related stigma and discrimination⁴⁵ put immigrants and refugees at risk for delayed diagnosis and unequal treatment rates for HIV infection. Immigrants are an unrecognized risk group for chronic hepatitis C virus infection and would benefit from early detection and appropriately timed treatment.⁴⁶

Subclinical strongyloidiasis and schistosomiasis can persist for decades after immigration and, if left untreated, can lead to serious morbidity or death through disseminated disease.⁴⁷

Table 1B: Basis of recommendations*

Issue	Process considerations
Balance between desirable and undesirable effects	Those with net benefits or trade-offs between benefits and harms were eligible for a positive recommendation
Quality of evidence	Quality of evidence was classified as "high," "moderate," "low" or "very low" on the basis of methodologic characteristics of available evidence for a specific clinical action
Values and preferences	Values and preferences refer to the worth or importance of health state or consequences of following a particular clinical action

*Reproduced, with permission, from Tugwell et al.¹⁶ Based on GRADE (Grading of Recommendations Assessment, Development and Evaluation).^{17,18}

Serologic tests for these intestinal parasites, rather than traditional stool testing, are recommended.⁴⁸ Malaria is one of the leading causes of death worldwide,⁴⁹ and delay in diagnosis and treatment of *Plasmodium falciparum* may lead to severe disease and even death. Migrant children are especially at risk for malaria and its complications.⁵⁰

Recommendations for infectious diseases are summarized in Box 1B.

Mental health and physical and emotional maltreatment

The mental health of immigrants has emerged as one of the most challenging areas for clinicians.¹⁵ Among refugees, depression commonly co-occurs with post-traumatic stress disorder and other anxiety disorders,⁵¹ which can complicate its detection and treatment.²⁸ Conducting a systematic clinical assessment, or using a validated questionnaire in a language in which the patient is fluent,⁵² is recommended if the clinician practises in an integrated system that links patients with suspected depression to treatment programs with a stepped-care approach. Effective detection and treatment may also require the use of professional interpreters or

trained culture brokers (not children or other family members) to identify patients' concerns, explain illness beliefs, monitor progress, ensure adherence, and address the social causes and the consequences of depression.²⁸ The majority of those who experience traumatic events will heal spontaneously after reaching safety.^{53,54} Empathy, reassurance and advocacy are key clinical elements of the recovery process. Pushing for disclosure of traumatic events could cause more harm than good.

The children of ethnic minorities, including some recently settled immigrants and/or refugees, are disproportionately over-screened (up to 8.75 times more likely) and over-reported as positive (up to four times more likely) for child maltreatment.⁵⁵ False-positive reports could result in harm, leading to psychological distress, inappropriate family separation, impaired clinician–patient rapport and legal ramifications associated with the involvement of child protection services.⁵⁶ Routine screening is not recommended; rather, clinicians should remain alert for maltreatment, either intimate partner violence or child maltreatment.

Recommendations related to mental health and maltreatment, both physical and emotional, are summarized in Box 1C.

Box 1B: Summary of evidence-based recommendations for infectious diseases*

Measles, mumps and rubella

Vaccinate all adult immigrants without immunization records using one dose of measles–mumps–rubella vaccine.

Vaccinate all immigrant children with missing or uncertain vaccination records using age-appropriate vaccination for measles, mumps and rubella.

Diphtheria, pertussis, tetanus and polio

Vaccinate all adult immigrants without immunization records using a primary series of tetanus, diphtheria and inactivated polio vaccine (three doses), the first of which should include acellular pertussis vaccine.

Vaccinate all immigrant children with missing or uncertain vaccination records using age-appropriate vaccination for diphtheria, pertussis, tetanus and polio.

Varicella

Vaccinate all immigrant children < 13 years of age with varicella vaccine without prior serologic testing.

Screen all immigrants and refugees from tropical countries ≥ 13 years of age for serum varicella antibodies, and vaccinate those found to be susceptible.

Hepatitis B

Screen adults and children from countries where the seroprevalence of chronic hepatitis B virus infection is moderate or high (i.e., ≥ 2% positive for hepatitis B surface antigen), such as Africa, Asia and Eastern Europe, for hepatitis B surface antigen, anti-hepatitis B core antibody and anti-hepatitis B surface antibody.

Refer to a specialist if positive for hepatitis B surface antigen (chronic infection).

Vaccinate those who are susceptible (negative for all three markers).

Tuberculosis

Screen children, adolescents < 20 years of age and refugees between 20 and 50 years of age from countries with a high

incidence of tuberculosis as soon as possible after their arrival in Canada with a tuberculin skin test.

If test results are positive, rule out active tuberculosis and then treat latent tuberculosis infection.

Carefully monitor for hepatotoxicity when isoniazid is used.

HIV

Screen for HIV, with informed consent, all adolescents and adults from countries where HIV prevalence is greater than 1% (sub-Saharan Africa, parts of the Caribbean and Thailand).

Link HIV-positive individuals to HIV treatment programs and post-test counselling.

Hepatitis C

Screen for antibody to hepatitis C virus in all immigrants and refugees from regions with prevalence of disease ≥ 3% (this excludes South Asia, Western Europe, North America, Central America and South America).

Refer to a hepatologist if test result is positive.

Intestinal parasites

Strongyloides: Screen refugees newly arriving from Southeast Asia and Africa with serologic tests for *Strongyloides*, and treat, if positive, with ivermectin.

Schistosoma: Screen refugees newly arriving from Africa with serologic tests for *Schistosoma*, and treat, if positive, with praziquantel.

Malaria

Do not conduct routine screening for malaria.

Be alert for symptomatic malaria in migrants who have lived or travelled in malaria-endemic regions within the previous three months (suspect malaria if fever is present or person migrated from sub-Saharan Africa). Perform rapid diagnostic testing and thick and thin malaria smears.

*Order of listing considers clinical feasibility and quality of evidence.

Chronic and noncommunicable diseases

People of certain ethnic backgrounds (specifically Latin Americans, Africans and South Asians) face a twofold to fourfold higher prevalence of type 2 diabetes mellitus than white people,⁵⁷ with earlier onset and poorer outcomes. People with hypertension have the most to gain from treatment of obesity, high cholesterol, hypertension and hyperglycemia. Culturally appropriate diabetes education and lifestyle interventions are effective in preventing the disease or improving disease management.⁵⁸ Iron deficiency is the most common nutritional deficiency in the world,⁵⁹ and immigrant women⁶⁰ and children can benefit from screening and supplementation.

Dental disease is often challenging for medical practitioners, but screening and treating pain with nonsteroidal anti-inflammatory drugs can lead to better outcomes and more effective referrals for oral health care.⁶¹ In addition, there is value in recommending twice-daily tooth-brushing with fluor-

idated toothpaste, as some immigrants may not be familiar with this approach to oral health.⁶² Loss of vision is the final common pathway for all eye diseases,⁶³ and all immigrants can benefit from having their visual acuity assessed soon after arrival in Canada.

Recommendations for chronic and noncommunicable diseases are summarized in Box 1D.

Women's health

To prevent unintended pregnancy, screening for unmet contraceptive needs should begin soon after a woman's arrival in Canada. Giving women their contraceptive method of choice (the intrauterine device being the most common contraceptive worldwide, although personal preferences vary), providing the contraceptive method on site and having a good interpersonal relationship all improve contraceptive-related outcomes.⁶⁴

School vaccination programs vary by province, and immigrant girls and women may miss school programs for human papillomavirus vaccination, depending on their age at the time of arrival. Subgroups of immigrants, most notably South Asian and Southeast Asian women, have substantially lower rates of cervical cytology screening than Canadian-born women.⁶⁵ Women who have never undergone cervical screening and those who have not had cervical screening in the previous five years account for 60%–90% of invasive cervical cancers. Providing information to patients, building rapport

Box 1C: Summary of evidence-based recommendations for mental health and physical and emotional maltreatment*

Depression

If an integrated treatment program is available, screen adults for depression using a systematic clinical inquiry or validated patient health questionnaire (PHQ-9 or equivalent).

Individuals with major depression may present with somatic symptoms (pain, fatigue or other nonspecific symptoms).

Link suspected cases of depression with an integrated treatment program and case management or mental health care.

Post-traumatic stress disorder

Do not conduct routine screening for exposure to traumatic events, because pushing for disclosure of traumatic events in well-functioning individuals may result in more harm than good.

Be alert for signs and symptoms of post-traumatic stress disorder (unexplained somatic symptoms, sleep disorders or mental health disorders such as depression or panic disorder).

Child maltreatment

Do not conduct routine screening for child maltreatment.

Be alert for signs and symptoms of child maltreatment during physical and mental examinations, and assess further when reasonable doubt exists or after patient disclosure.

A home visitation program encompassing the first two years of life should be offered to immigrant and refugee mothers living in high-risk conditions, including teenage motherhood, single parent status, social isolation, low socioeconomic status, or living with mental health or drug abuse problems.

Intimate partner violence

Do not conduct routine screening for intimate partner violence.

Be alert for potential signs and symptoms related to intimate partner violence, and assess further when reasonable doubt exists or after patient disclosure.

Note: PHQ-9 = nine-item Patient Health Questionnaire.

*Order of listing considers clinical feasibility and quality of evidence.

Box 1D: Summary of evidence-based recommendations for chronic and noncommunicable diseases*

Type 2 diabetes mellitus

Screen immigrants and refugees > 35 years of age from ethnic groups at high risk for type 2 diabetes (those from South Asia, Latin America and Africa) with fasting blood glucose.

Iron-deficiency anemia

Women

Screen immigrant and refugee women of reproductive age for iron-deficiency anemia (with hemoglobin).

If anemia is present, investigate and recommend iron supplementation if appropriate.

Children

Screen immigrant and refugee children aged one to four years for iron-deficiency anemia (with hemoglobin).

If anemia is present, investigate and recommend iron supplementation if appropriate.

Dental disease

Screen all immigrants for dental pain. Treat pain with nonsteroidal anti-inflammatory drugs and refer patients to a dentist.

Screen all immigrant children and adults for obvious dental caries and oral disease, and refer to a dentist or oral health specialist if necessary.

Vision health

Perform age-appropriate screening for visual impairment.

If presenting vision < 6/12 (with habitual correction in place), refer patients to an optometrist or ophthalmologist for comprehensive ophthalmic evaluation.

*Order of listing considers clinical feasibility and quality of evidence.

and offering access to female practitioners can improve acceptance of Papanicolaou (Pap) testing.⁶⁶

Finally, newly-arrived pregnant women are at increased risk for maternal morbidity.⁶⁷ We identified social isolation, risks of unprotected or unregulated work environments, and sexual abuse (specifically in forced migrants) as priority areas for research.

Recommendations related to women's health are summarized in Box 1E.

Knowledge translation

We developed a summary of our recommendations and have engaged multiple stakeholders as partners to share these recommendations with their constituencies, including the Public Health Agency of Canada, Citizenship and Immigration Canada, regional health and public health authorities, immigrant community groups and primary care practitioners. These recommendations and their related evidence reviews are avail-

able on the *CMAJ* website (see www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1). Forty primary care practitioners from across Canada with experience working with immigrants pilot-tested the recommendations, provided feedback on the presentation format and are helping to promote the guidelines through their networks. Finally, we sought feedback on our recommendations from our immigrant community partners (specifically, the Edmonton Multicultural Health Brokers Cooperative, which represents 16 ethnic communities) and continue to work with our community partners to improve access to health services.

Directions for future research

Immigrant populations are a heterogeneous group. Because of the selection processes that are in place, most immigrants arrive in good health, although some subgroups are at increased risk of chronic and infectious diseases and mental illness. More research is needed on strategies to address barriers to health services, most urgently for refugees, women and other immigrants with low income and language barriers. There is also a need to develop and study interventions for social isolation and intimate partner violence for pregnant immigrants and refugees. Data remain limited for immigrant children, refugee claimants and nonstatus persons and for many disease areas, including malaria morbidity, post-traumatic stress disorder and interventions for intimate partner violence.

More work must be done to improve immigrants' access to health services. We hope this evidence-based initiative will provide a foundation for improved preventive health care for immigrant populations.

Box 1E: Summary of evidence-based recommendations for women's health

Contraception

Screen immigrant women of reproductive age for unmet contraceptive needs soon after arrival to Canada.

Provide culturally sensitive, patient-centred contraceptive counselling (giving women their method of choice, having contraception on site and fostering a good interpersonal relationship).

Vaccination against human papillomavirus

Vaccinate 9- to 26-year-old female patients against human papillomavirus.

Cervical cytology

Screen sexually active women for cervical abnormalities by Papanicolaou (Pap) test.

Information, rapport and access to a female practitioner can improve uptake of screening and follow-up.

*Order of listing considers clinical feasibility and quality of evidence.

For a summary of recommendations and clinical considerations, see Appendix 2, at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1.

Podcasts for practitioners and additional information for patients can be found at www.ccirhken.ca.

2. Selection of potentially preventable and treatable conditions

Community-based primary health care practitioners see most of the immigrants and refugees who arrive in Canada. This is not only because Canada's health care system centres on primary care practice, but also because people with lower socioeconomic status, language barriers and less familiarity with the system are much less likely to receive specialist care.⁶⁸

Guideline development can be costly in terms of time, resources and expertise.⁶⁹ Setting priorities is critical, particularly when dealing with complex situations and limited resources.⁷⁰ There is no standard algorithm on who should determine top priorities for guidelines or how this should be done, although burden of illness, feasibility and economic considerations are all important.⁷¹ Stakeholder engagement, to ensure relevance and acceptability, and the use of an explicit procedure for developing recommendations are critical in guideline development.⁷²⁻⁷⁴ We chose primary care practitioners, particularly those who care for immigrants and refugees, to help the guideline committee in selecting conditions for clinical preventive guidelines for immigrants and refugees, with a focus on the first five years of settlement. A more detailed description of this Delphi process was published previously.¹⁵

Methods

We used a modified Delphi consensus process to select 20 high-priority conditions for guideline development.^{70,75,76} To begin, we identified key health conditions using an environmental scan, literature review and input from key informants from the Canadian Initiative to Optimize Preventive Care for Immigrants national network, a nascent network of immigrant health providers. This initial step identified 31 conditions. During the ranking process, survey participants were invited to list additional conditions. These conditions, if associated with potentially effective clinical preventive actions, were integrated into the pool of conditions for subsequent ranking.

We developed priority-setting criteria that emphasized inequities in health, building on a process developed for primary care guidelines affecting disabled adults.^{70,77} Importance or burden of illness is often used for setting priorities, usefulness or effectiveness is frequently used, and disparity is now a well-recognized component of many public health measures.⁷⁸ We defined our criteria as importance, usefulness and disparity:

- **Importance:** Conditions that are the most prevalent health issues for newly arriving immigrants and refugees; conditions with a high burden of illness (e.g., morbidity and mortality).
- **Usefulness:** Conditions for which guidelines could be practically implemented and evaluated. Such guidelines refer to health problems that are easy to detect, for which the means of prevention and care are readily available and feasible, and for which health outcomes can be monitored.
- **Disparity:** Conditions that might not be currently addressed

or that are poorly addressed by public health initiatives or illness-prevention measures that target the general population.

We (H.S., K.P., M.R., L.N.) purposively selected 45 primary care practitioners, including family physicians and nurse practitioners, recently or currently working in a setting serving recent immigrants and refugees. We sampled clinical settings from 14 urban centres across Canada to ensure in-depth experience with a variety of migrants. The settings also covered a range of health service funding models: community health centres (centres locaux de services communautaires in Quebec), refugee clinics, group and solo practices, and ethnic community practices. We aimed to select practitioners with substantial experience, academic expertise or local leadership roles who were willing to commit to offering future input into guideline development and dissemination.

Immigrant and refugee health is a new subdiscipline. The skills, knowledge and experience that define expertise have not yet been determined, and there are no examinations, certification or developed courses that can be used as a proxy for expertise. We believed that contextual knowledge, experience arising from engaged care of immigrants and refugees in Canada, and related work experience in international health were important factors in determining expertise. As a measure of expertise, we adapted a formula used by Médecins Sans Frontières. This criterion combines work with Médecins Sans Frontières in developed countries and in the field. Our criterion for experience was set at seven years or more and included all work in developing countries. It was calculated as number of years of experience with migrants in Canada + (2 × years of experience working in developing countries).

As prompts for decision-making, we asked our practitioner panel to make choices based on the defined criteria, imagining that the guidelines under development might be used at a clinic serving new immigrants or by physicians who do not often see immigrant and refugee patients. Just as clinical practice does, these criteria challenged practitioners to make choices based on competing demands.

This first round of the Delphi survey aimed to ensure that we had the appropriate health conditions under consideration and to begin developing some consensus as to priorities. Participants were asked to rank the 31 conditions identified initially and to propose conditions that were not on the initial list. We chose an a priori cut-off of 80% consensus for inclusion in the top 20. In the second round, we presented an unranked, modified version of this list, excluding all conditions that had already reached 80% consensus and adding newly proposed conditions. The remaining conditions to be included in the top 20 were determined by overall ranking in the second round. This list was reviewed by the codirectors of the Edmonton Multicultural Health Brokers Co-operative (www.mchb.org/OldWebsite2008/default.htm), a group representing over 16 ethnic communities that had initially requested preventive health guidance relevant for immigrant

communities. In addition, the panel of experts who would be developing the guidelines reviewed the list. Then, during the final round, we requested approval, through a simple agree/disagree vote, of the process and the resulting list of priorities, with one-on-one interviews to resolve concerns in the two months following the ranking process.

Consent to participate in the Delphi survey was determined by completion of a questionnaire. Demographic questions elicited personal, professional and practice characteristics of the study participants. With each round, we sent to participants (by email) an explanation of the process to date, the priority-setting criteria, instructions for filling out the survey and a link to the SurveyPro survey. Telephone follow-up was used to maximize response rate. We used Microsoft Excel for the analysis.

Results

Ninety per cent (40/45) of the selected practitioners agreed to participate. Four of the five participants who chose not to participate cited reasons of leave of absence or sabbatical leave, and the fifth cited workload. Ninety-five per cent of the consenting participants completed the first round of the survey, and 88% completed the second and third rounds (Figure 2A). The first two rounds of the Delphi consensus process took place between Mar. 5 and May 31, 2007.

The 40 participants consisted of 35 physicians and five nurse practitioners or nurses with expanded roles. Participants were predominantly women and had been in practice for an average of 14 years. They worked an average of 16 hours per week with immigrants and refugees. More than 80% spoke two or more languages (Table 2A).

The average length of experience working with refugees and immigrants in Canada was 7.5 years; 64% of participants had some experience working in developing countries, with a median overseas duration of 16 (range 1–120) months. Thirty-one per cent of primary care practitioners self-identified as being an immigrant or refugee; of the remainder, 38% self-identified as being the child of an immigrant or refugee (of the 35 practitioners who responded to this optional question).

Forty-five per cent of participants identified themselves as having had prior training in the field, which included accredited tropical medicine courses, designated rotations during residency, work exposures before becoming a health care practitioner, and conferences or self-directed studies in multicultural or cross-cultural medicine.

The refugees and immigrants with whom most practitioners interacted came from all parts of the world; using an average of straight ranking (1 to 6) of regions, south and central Africa was estimated as the most frequent source region of immigrants for these practitioners. Children formed, on average, 30% of clientele, and women, 41%. Seventy-one per cent of migrants were estimated to have been in Canada less than five years, and 73% were involuntary migrants. Involuntary migrants included refugee claimants, so-called Convention Refugees and internally displaced persons (although this is not really an issue for Canada).

Box 2A lists the top 20 conditions for which practitioners identified a current need for guidelines on the basis of our criteria. In the first round, 80% consensus was reached to *include* 11 conditions. Eighty per cent consensus was also reached to *exclude* three conditions from the process: Chagas disease, colon cancer and prostate cancer. Three well-defined and unique conditions were proposed for the second round of




Figure 2A: Participant sampling and response rate. *One person was on sabbatical, three were on a leave of absence, and one cited workload. Adapted, with permission, from Swinkels and associates.¹⁵

ranking: osteoporosis, contraception and vision screening. The nine conditions selected in the second round were based on average ranking (Box 2A).

The list of top 20 conditions was reviewed and approved, with one modification, by the panel of key experts who would be developing the guidelines: routine vaccine-preventable diseases were considered a single priority, with tetanus, diphtheria and polio combined with measles, mumps and rubella for the purposes of guideline development. As a final step, we sent the 20 identified conditions to survey participants for approval and discussion; all 35 people who participated in this round approved (i.e., 88% of the 40 original participants).

Discussion

Refugees and many immigrants may have poor or deteriorating health, because of conditions experienced before, during or after arrival to Canada. A health care system that is poorly adapted to their needs compounds this situation, resulting in further marginalization. Our Delphi consensus process used practitioners' years of field experience strategically to identify

preventable and often unrecognized clinical care gaps that can result from such majority-system biases.

An overarching goal of our guideline development project was to supplement guidelines that exist for the general Canadian population⁷⁹ by focusing on health inequities. We therefore selected a high proportion of practitioners who work with refugees, a particularly vulnerable subgroup of immigrants prone to disparities. Using practitioners to select conditions ensured both that the needs of the future guideline-users were given priority and that conditions presenting serious clinical challenges, but that might be under-represented in the literature, were included. In working with perceived needs of practitioners, we risked a reporting bias: overemphasizing popular stereotypes (e.g., the importance of infectious diseases), underemphasizing unrecognized or emerging conditions (e.g., vitamin D deficiency)⁸⁰ and loss of precision in terms of specific populations (e.g., our list does not fully reflect the greatest needs of children).⁸¹ Also, by deliberately selecting participants who work with refugees, we risked falsely stereotyping the health status of all immigrants by overemphasizing refugee-specific conditions and, conversely, by underemphasizing common health risks, such as hypertension, that affect all immigrants.

The Delphi process generated 20 conditions for guideline development that reflected the needs and priorities of primary care practitioners working with immigrants and refugees. Although immigrant screening has historically focused on infectious diseases,⁸² the conditions selected by survey participants extended across a spectrum of diseases, including infectious disease, dentistry, nutrition, chronic disease, maternal

Table 2A: Demographic characteristics of 40 participants in Delphi consensus process*

Characteristic	No. (%) of participants†
Sex, female (<i>n</i> = 40)	25 (62)
Age, yr, mean	42.5
Length of practice, yr, mean	14.0
Province of practice (<i>n</i> = 40)	
British Columbia	7 (18)
Prairies (Alberta, Saskatchewan, Manitoba)	4 (10)
Ontario	17 (42)
Quebec	8 (20)
Maritime (New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador)	4 (10)
Type of practice (<i>n</i> = 39)	
Solo	2 (5)
Group (excluding those in a community health centre)	19 (49)
Community health centre	18 (46)
Level of cross-cultural exposure and expertise	
Experience working with immigrants or refugees, mean, yr	7.5
Medical experience in low- and middle-income countries (<i>n</i> = 39)	25 (64)
≥ 7 years' experience (criteria adapted from Médecins Sans Frontières) (<i>n</i> = 40)	26 (65)
Bilingual (<i>n</i> = 40)	33 (82)
Speaks more than 2 languages (<i>n</i> = 40)	17 (42)

*Adapted, with permission, from Swinkels and associates.¹⁵

†Except where indicated otherwise.

Box 2A: High-priority conditions

1. Abuse and domestic violence*
2. Anxiety and adjustment disorder*
3. Cancer of the cervix
4. Contraception
5. Dental caries, periodontal diseases*
6. Depression*
7. Diabetes mellitus*
8. Hepatitis B*
9. Hepatitis C
10. HIV/AIDS*
11. Intestinal parasites*
12. Iron-deficiency anemia*
13. Malaria
14. Measles, mumps, rubella, diphtheria, tetanus, pertussis, polio and Hib disease
15. Pregnancy screening
16. Syphilis
17. Torture and post-traumatic stress disorder*
18. Tuberculosis*
19. Varicella (chicken pox)
20. Vision screening

*Conditions identified by consensus in first round (the rest were selected in the second round).

and child health, and mental health. Mental health conditions were rated particularly high, and all four of the proposed mental health conditions reached 80% consensus in the first round of the Delphi survey. Four infectious diseases and three chronic diseases also reached 80% consensus. The inclusion of dental caries and periodontal disease in the top 11 conditions is notable, reflecting important cultural, as well as socioeconomic, barriers that refugees and immigrants face in access to dental care.⁸³ This range of conditions suggests that immigrant and refugee medicine covers the full spectrum of primary care. Although infectious disease continues to be an important area of concern, we are now seeing mental health and chronic diseases as key considerations for recently arriving immigrants and refugees.

Take-home messages

Preventable and treatable, but often-neglected, health condi-

tions were selected for the development of guidelines for immigrant populations made vulnerable because of health system bias. Criteria that emphasized addressing inequities in health helped in identifying gaps in clinical care. This evidence-based guideline initiative marks the evolution of immigrant and refugee medicine from a focus on infectious diseases to a more inclusive consideration of such chronic diseases as mental illness, dental disease, diabetes mellitus and cancer. We hope that this practitioner engagement process will improve the practicality of the evidence-based guidelines, help practitioners who already to work in the area to target and streamline their efforts, and encourage new practitioners to enter this challenging and interesting discipline.

For the complete description of the Delphi consensus process, see www.cmaj.ca/lookup/doi/10.1503/cmaj.090290.

3. Evaluation of evidence-based literature and formulation of recommendations

A variety of methods are used for developing clinical guidelines and practice recommendations.⁸⁴ We used the recently developed approach of moving away from recommendations classified by letters and numbers to the simplified classification system recommended by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group⁸⁵ and applied this to clinical preventive actions. Our guideline development process followed the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument (www.agreetrust.org), which is recognized internationally as providing best-practice criteria for evidence-based guideline development.

We developed our recommendations on the basis of a pre-specified process overseen by the guideline committee of the Canadian Collaboration on Immigrant and Refugee Health. Defining a methods process ensured that each guideline was developed in a systematic, reproducible manner and was based on the best evidence available. This process was based on existing guidelines, including the Canadian Medical Association (CMA) handbook on developing clinical practice guidelines⁸⁴ and the ADAPTE framework for adapting existing guidelines.⁸⁶ Our process emphasized identifying immigrant- and refugee-specific evidence on efficacy and population characteristics from guidelines, systematic reviews and primary studies. When immigrant- and refugee-specific evidence was unavailable, we used specific criteria, adapted from the Cochrane Handbook,⁸⁷ to judge how this evidence applied to our intended target population.

Conditions considered most important by practitioners caring for immigrants and refugees in Canada were assigned to groups of content experts, who were asked to develop evidence reviews with clinical conclusions for recent immigrants and refugees to Canada using a logic model and following a structured 14-step process. The guidelines focus on clinical care gaps⁸⁴ during the “health settlement period,” which we define as the first five years of residence in a new country for an immigrant or refugee. This is the period during which health practitioners are likely to have initial contact with this population and the time during which stressors from a person’s country of origin and country of settlement are most likely to manifest. Immigrants and refugees are thus grouped together by this organizing period of resettlement; however, the heterogeneity, complexities and differences between and within these groups were recognized throughout the process.

In our process, we emphasized making clinically relevant recommendations and establishing an extension to existing guidelines rather than a replacement or revision.

Methods

We used the AGREE checklist to guide the overall development process: a panel of experts and a guideline committee set the scope and purpose of the guidelines, and stakeholders

were engaged to select priority conditions and to merge recommendations. To ensure rigour and applicability, we developed 14 standardized steps (described below and summarized in Box 1A in section 1 of this article, above). The guideline committee and other guideline experts and practitioners provided feedback to improve clarity of presentation. We accepted funding only from university and government sources, to ensure editorial independence. Here we describe the steps in our standardized evidence review.

Step 1: Develop clinician summary table

A standardized clinician summary template was used in setting the framework for each selected condition. During subsequent steps, this clinician summary table was used to focus development of the preventive guidelines, on the basis of the condition’s prevalence in the population of interest, population-specific clinical considerations (e.g., stigma and awareness of screening and treatment options), clinical actions upon migration, screening tests, screening interval or timing, and treatment.

Step 2: Develop logic model and key questions

Our logic model, which illustrates a plausible causal pathway for each guideline, was adapted from the US Preventive Services Task Force,⁸⁸ with the addition of a box to consider patient perspectives (for an example, see Figure 3A). The logic model outlines the population of interest (immigrants and refugees); the intervention (i.e., screening); the target condition; adverse effects of screening, diagnosis and treatment; treatment options and outcomes; and the link between treatment and reductions in morbidity and mortality. The model illustrates how identification of the condition can be expected to lead to treatment and reduced morbidity and mortality in the population of interest. This logic model identified the need to consider whether intermediate outcomes would be accepted as the basis for the recommendations, and if so, the strength of association between intermediate and clinical outcomes. For example, high-risk behaviour is an intermediate outcome in reducing morbidity and mortality from HIV.

Review group leaders were asked to use this logic model to define the PICO (population, intervention, comparison and outcome) format for each clinical action. These elements guided the search for evidence.

Step 3: Set the stage for admissible evidence

We followed the process used by the US Preventive Services Task Force and the Canadian Task Force on Preventive Health Care to focus on evidence most critical to making a recommendation.⁸⁴ We began with searches of specific guidelines and systematic reviews for the target population of immigrants and refugees, to document the current state of direct evidence. We extended these searches to capture evidence from the general population. The search strategy was modelled on that used by the Cochrane Collaboration⁸⁹ and

was conducted by one of two clinical librarians. The following databases were searched: MEDLINE, PreMEDLINE, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effectiveness, Embase, CINAHL, National Guideline Clearing House and the CMA Infobase. We also searched the databases and publications of the Canadian Task Force on Preventive Health Care, the US Preventive Services Task Force, the Centers for Disease Control and Prevention, and the World Health Organization. We asked authors to create flow charts of their searches, using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)⁹⁰ framework as a template.

Step 4: Assess eligibility of systematic reviews

Two members of the review group independently reviewed the search strategies, abstracts and relevant full-text articles on the basis of the inclusion criteria and specified outcomes of interest.

Data from each eligible systematic review were extracted and documented in a table with the following headings: author and year, objective, number and types of studies included, setting, participants, intervention and findings. If no eligible systematic review was found, then the review group team searched for the next best available study (randomized controlled trials, observational studies) that addressed the question.

Step 5: Search for data specific to immigrant and refugee populations

A tailored search process was used to gather information on

population-specific considerations relevant to immigrants and refugees in the following areas:

- baseline risk (prevalence) versus the Canadian general population
- rate of clinically important beneficial and harmful outcomes (e.g., mortality, morbidity)
- genetic and cultural factors (e.g., knowledge, attitudes, practices, cultural preferences, dietary preferences)
- compliance variation (e.g., physicians' and patients' adherence to recommendations)

Step 6: Refocus on key clinical preventive actions and key questions

After reviewing the literature and available evidence, review group teams were asked to focus on the most relevant clinical action(s) and immigrant and refugee subpopulation(s) and to select three or fewer candidate recommendations with added value over and above existing guidelines.

Step 7: Assess quality of systematic reviews

For each recommendation, all relevant systematic reviews were compared to ensure consistency among findings. If the conclusions of the systematic reviews were consistent, the most recent review was selected. Any inconsistencies in reviews were explicitly addressed: reasons for inconsistencies, including the evidence base or the interpretation, were explored, and the most appropriate systematic review was selected, considering the purposes of these guidelines.

The most relevant systematic reviews were then assessed




Figure 3A: Sample logic model for HIV (adapted from US Preventive Services Task Force).⁸⁸ Open rectangles designate the potential screening population and patient factors to be considered; shaded rectangles designate interventions and related outcomes; and circles and numbers provide points in the evidence chain that were used to develop the search questions. Note: ARV = antiretroviral, EIA = enzyme immunoassay.

for quality to ensure they met the four criteria assessed in the National Institute for Health and Clinical Excellence (formerly the Health Development Agency) critical appraisal tool for evidence-based briefings or reviews of reviews;⁹¹ systematicity (the review must apply a consistent and comprehensive approach), transparency (the review must be clear about the processes involved), quality (the review must have appropriate methods and analysis) and relevance (the review must be relevant in terms of focus; i.e., populations, interventions, outcomes and settings).

Step 8: Search for evidence to update selected systematic reviews

To find new primary studies published since the selected systematic review, a search was conducted using the same approach as in step 3.

Step 9: Assess eligibility of new studies

As in step 4, two reviewers independently screened for relevant studies and then assessed each study for eligibility. Each relevant study was summarized to describe study design, the clinical intervention, details about length of intervention and follow-up, outcomes, population characteristics and data analysis.

For studies evaluating the effectiveness or safety of treatment or screening, the Cochrane Effective Practice and Organisation of Care Review Group's data collection checklist⁹² and the Newcastle–Ottawa Scale⁹³ for assessing the quality of nonrandomized studies in meta-analyses were used to assess study limitations.

Step 10: Integrate data from updated search

Any new relevant and eligible studies that could modify or substantially strengthen the conclusions of the “reference” systematic review were assessed and added to the worksheet.

Step 11: Synthesize final evidence bank and draft two key clinical actions

The review group teams synthesized the evidence from the updated systematic reviews, explicitly incorporating clinical considerations and value judgments specific to immigrant and refugee populations to draft preferably no more than two key clinical actions, targeting (where necessary) specific populations or regions.

Box 3A: Grades of evidence of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group (www.gradeworkinggroup.org)

- High quality: Further research is very unlikely to change our confidence in the estimate of effect.
- Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- Very low quality: We are very uncertain about the estimate.

Step 12: Develop table for summary of findings

Both desirable and undesirable effects of the intervention were summarized, in both absolute and relative terms, for each patient-important outcome using the summary-of-findings table format adopted by the Cochrane Collaboration.⁹⁴ The quality for each outcome was assessed using the items specified by the GRADE Working Group (indirectness, consistency, precision, reporting bias and study limitations) (Box 3A). Observational studies that met these five criteria were upgraded if they also met one of three additional criteria (dose–response, influence of confounding variables, large effect).⁸⁵ A separate table was developed for each clinical action or question. For dichotomous outcomes, relative risks or odds ratios were extracted from the reference systematic review (or next best available study). Number needed to treat for one person to benefit was calculated as $1/(\text{control event rate} \times [1 - \text{relative risk}])$. The control event rate was taken from the control group of the reference systematic review or best available study.

Step 13: Identify gaps in evidence and needs for future research

The review group teams identified gaps in the literature and outlined recommendations for future research on such topics as implementation, inequalities and vulnerable groups, cost-effectiveness and implications of applying the recommendations in health care settings.

Step 14: Develop clinical preventive recommendations

For each condition, the guideline committee reviewed the clinician summary table, the logic model and the summary-of-findings tables and met with the review group leader to clarify details. Then, for each key clinical action, the guideline committee discussed each of the issues in the GRADE system (see Table 1B in section 1 of this article, above):^{16–18} the balance between desirable and undesirable effects (the relative importance of burden, benefits and harms), quality of the available evidence, and values and preferences. We explicitly decided not to use cost and feasibility in judging the basis of the recommendation because we did not have sufficient confidence in the data. Rather than report the strength of the recommendation as weak or strong, the guideline committee chose to make the recommendation only in the event of net benefits and to report the basis for the recommendation, to provide clinicians with key information to consider when selecting or discussing the preventive recommendation with a patient. The guideline committee took votes if the agreement was not unanimous, and the majority prevailed.

Discussion

This 14-step process was useful for ensuring sufficient uniformity among the transdisciplinary teams for each condition. Specifically, this systematic approach enabled the review group teams to meet the requirements of the GRADE quality-assessment process and the steering group to apply the GRADE recommendation process. These steps were also designed to conform with AGREE, the current quality stan-

dard for guidelines. We worked with each review group leader and team to ensure we met the 23 AGREE criteria in six domains: scope and purpose, stakeholder involvement, rigour of development, clarity and presentation, applicability and editorial independence.¹⁶

Take-home messages

We combined the AGREE best-practice framework, the current quality standard for guidelines, with the recently developed GRADE approach to quality assessment to develop evidence-based clinical preventive guidelines for immigrants and refugees to Canada. Here, we have documented the systematic approach used to produce the evi-

dence reviews and apply the GRADE approach. The 14-step approach included building on evidence from previous systematic reviews, searching for and comparing evidence between general and specific immigrant populations, and applying the GRADE criteria for making recommendations. The basis of each recommendation (balance of benefit and harm, quality of evidence, values) is stated explicitly to ensure transparency.

For a more complete description of the evaluation of the literature and formulation of recommendations, see www.cmaj.ca/lookup/doi/10.1503/cmaj.090289.

12. Depression

Depression is a common and costly health care problem.³⁸³ Nearly all people with major depression are seen only in primary care, but up to 60% of cases go undetected and untreated.³⁸⁴ The level of underdiagnosis and inadequate treatment for depression is higher among migrants, who face cultural, linguistic and other barriers to accessing mental health care.³⁸⁵ Although migration in itself does not lead to an increase in depression, specific stressors and challenges can contribute to the onset of depression or influence its course, particularly among refugees.³⁸⁶ In general, immigrants to Canada have lower rates of depression than the general Canadian population, whereas refugees have comparable rates of depression but higher rates of post-traumatic stress disorder.³⁸⁷ Over time, the rate of depression in immigrant groups increases to match that of the general population. We undertook this review to determine whether existing approaches to screening for depression are appropriate for immigrants and refugees and to identify strategies that could improve the quality of care. The recommendations of the Canadian Collaboration for Immigrant and Refugee Health on screening for depression are outlined in Box 12A.

Box 12A: Recommendations from the Canadian Collaboration for Immigrant and Refugee Health: depression

If an integrated treatment program is available, screen adults for depression using a systematic clinical inquiry or validated patient health questionnaire (PHQ-9 or equivalent).

Link suspected cases of depression with an integrated treatment program and case management or mental health care.

Basis of recommendations

Balance of benefits and harms

The number needed to treat to prevent one case of persistent depression was 18 (95% confidence interval 10–91) in studies of 1–12 months' duration. Treatment in enhanced depression-care models accounts for an additional 1%–2% reduction in depressive symptoms relative to usual care. The prevalence of depression is similar among Canadians and among immigrants and refugees (10.7%), but access to care may be limited for migrants. No data on harms were reported, which would include patients' out-of-pocket costs and adverse effects of medication.

Quality of evidence

Moderate

Values and preferences

The committee attributed more value to screening and treating depression to improve quality of life and less value to concerns about impairing rapport in therapeutic relationships, cultural acceptability and potential stigma of diagnostic labels, the cost and inconvenience of additional follow-up assessments, and the possible adverse effects or costs associated with treating patients with an incorrect diagnosis.

Note: PHQ-9 = nine-item Patient Health Questionnaire.

Methods

We used the 14-step approach developed by the Canadian Collaboration for Immigrant and Refugee Health¹⁶ (summarized in section 3 of this article, above). We considered the epidemiology of depression in immigrant populations and defined clinical preventive actions (interventions), outcomes and key clinical questions. We searched MEDLINE, Embase, CINAHL, PsychLIT, the Cochrane Library and other sources from Jan. 1, 1998, to Jan. 1, 2010. Detailed methods, search terms, case studies and clinical considerations can be found in the complete evidence review for depression (Appendix 10, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1).

Results

Recommendations from the Canadian Task Force on Preventive Health Care³⁸⁸ and the US Preventive Services Task Force^{389,390} make scant mention of immigrants and refugees. In its guidelines for the treatment of depression,³⁹¹ the American Psychiatric Association notes that language and other cultural variables may hamper accurate diagnostic assessment and treatment; it also mentions ethnic differences in the response to pharmacotherapy. The guidelines of the UK National Institute for Health and Clinical Evidence include statements on ethnic variations in prevalence and on the importance of social and cultural factors in choice of treatment.³⁹² More recent studies, discussed in the complete evidence review (Appendix 10, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1), provide evidence that can inform the implementation of screening for depression and integrated care for immigrants and refugees in primary care.

What is the burden of depression in immigrant populations?

The Canadian Community Health Survey (version 1.2) revealed a lifetime prevalence of depression of 10.8% in the general population.³⁹³ Immigrants who had arrived in Canada in the previous four years had the lowest rates of depression (3.3%–3.5%). Among those who had arrived 10–14 years ago (rate 8.5%) or more than 20 years ago (rate 6.8%–7.2%), rates were similar to those of the Canadian-born population.³⁹⁴ Proficiency in English or French and employment status did not affect these rates. A meta-analysis of studies on serious mental disorders among refugees found rates of depression similar to those in the general population but much higher levels of post-traumatic stress disorder, often in association with depression.⁵¹

Pregnancy and the postpartum period have been associated with symptoms of depression in immigrant women.³⁹⁵ Risk factors may include stressful life events, lack of social support

or isolation, physical health problems, inability to speak the language of the host country, the demands of multiple roles and separation from children who have remained in the country of origin.^{396,397}

Does screening for depression decrease morbidity and mortality?

Screening tools

Many screening instruments for depression have been validated in primary care settings, and little evidence suggests that any particular instrument performs better than other instruments, although brief tools tend to be less specific.³⁹⁸ Both brief screening tools (two or three items) and longer ones tend to have relatively high false-positive rates (60%–70%) when the prevalence of depression is 10%.³⁹⁹ Therefore, positive results on screening must be confirmed by a full diagnostic interview. Most screening instruments have not been validated for many of the immigrant groups commonly seen in primary care in Canada, although the patient health questionnaire has been validated with Chinese, South Asian and other populations.

Relative benefits and harms of treatment

In a systematic review of screening for depression conducted in 2002, the US Preventive Services Task Force found that clinical trials of integrated programs have demonstrated modest improvements in patient outcomes, but benefits have not been observed when screening results are simply reported to physicians without coordinated treatment and follow-up.⁴⁰⁰ Subsequent reviews have confirmed this finding.⁴⁰¹ Adverse effects among immigrants have not been systematically studied, but they may include impaired rapport and less use of general medical services if patients believe they are being labelled and stigmatized or are being treated improperly, the cost and inconvenience of additional follow-up assessments, and possible adverse effects or costs associated with treating patients with an incorrect diagnosis.

In a recent meta-analysis, Gilbody and associates³⁹⁸ found no benefit for screening alone, although there was some benefit in high-risk populations. However, a cumulative meta-analysis showed modest benefit when an integrated system of collaborative care was in place for follow-up (Table 12A).⁴⁰² In a low-quality longitudinal study conducted in the United States, Wells and colleagues⁴⁰³ examined the effect of screening for depression within an integrated system of care, with follow-up by nurses and with other quality-associated improvements. The greatest improvement was seen for minority groups, specifically African Americans and Latinos.⁴⁰⁴

Clinical considerations

Screening

Screening should be conducted in a language in which the patient is fluent, either with translated instruments or through a trained interpreter. Cultural variations in presentation of symptoms, ways of coping and the stigma attached to mental health problems may complicate detection and treatment.⁴⁰⁵ The presence of prominent somatic symptoms and patients' tendency to attribute their depressed mood to somatic distress can also reduce primary care physicians' recognition of depression.⁴⁰⁶

Among refugee patients with depression, more than half also have post-traumatic stress disorder, and this comorbidity can complicate the recognition of depression.⁵¹ Many cultures strongly stigmatize mental health problems, which may limit disclosure of behavioural or emotional difficulties.⁴⁰⁵ Depression can be distinguished from other forms of mental health problems and can be explained as a state of "energy depletion" and demoralization, which may provide a rationale for psychosocial assessment and treatment.

Child-bearing women

Guidelines from obstetrical groups have proposed that women be screened for depressive symptoms in each trimester of pregnancy, at 1–2 weeks postpartum, and possibly at 2, 4, and 6

Table 12A: Summary of findings for effects of collaborative care for depression

Patient or population: Patients with depression

Setting: Primary care

Intervention: Collaborative care

Comparison: Usual care

Source: Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. *Arch Intern Med* 2009;166:2314–21.⁴⁰²

Outcome	Absolute effect		Relative effect (95% CI)	No. of participants (studies)	GRADE quality of evidence	Comments (95% CI)
	Risk for control group	Difference with collaborative care				
Depression at 6 mo*	See comment	0.25 (0.18–0.32)	NA	12 344 (35)	Moderate†	NNT 18 (10–91)

Note: CI = confidence interval; GRADE = Grading of Recommendations Assessment, Development and Evaluation; NA = not applicable; NNT = number needed to treat.

*Standardized depression scales.

†Directness uncertain because the studies were conducted in the US health system setting, and it is unclear whether their results would apply to immigrants and refugees in the Canadian health care system.

months postpartum.^{407–409} The Edinburgh Postnatal Depression Scale or nine-item patient health questionnaire have been used with immigrant women. Immigrant women's multiple roles in the home and the workplace may impede access to health services.^{395,396} Availability of child care facilities, transportation and support from family members and spouses can facilitate their seeking help. Group meetings can be an effective way to provide social support and health-promotion information.

Adolescents and children

The US Preventive Services Task Force has recommended screening adolescents (age 12–18 years) when integrated systems of treatment are available, including assessment, psychotherapy and follow-up.^{410,411} It is unclear which of the more than 30 available depression scales is best for screening and diagnosing depression among immigrant and refugee youth.

Elderly people

Migrant elderly people have not been well studied but may have a high risk of depression because of social isolation, loss of familiar surroundings and the changing nature of the family as members adapt to the new social context.⁴¹²

What are the potential implementation issues?

Linguistic and cultural differences may constitute substantial barriers to recognition of depression and subsequent treatment negotiation and delivery.^{413,414} Medical interpreters, “culture brokers,” bilingual and bicultural mental health practitioners, clinician training in cultural competence and cultural consultation may mitigate these potential barriers.^{52,415–417} Screening for depression produces benefits only when it is linked to an integrated system of care. An integrated system involves the following elements: systematic patient education, availability of allied health professionals to support continuity of care, frequent follow-up, a caseload registry to track patients, caseload supervision by a psychiatrist if indicated, stepped care and a plan for preventing relapse.⁴¹⁸ Stepped care involves a progression of levels from patient education and self-management to medication or psychotherapy and, for complex cases, referral to a mental health practitioner.⁴¹⁹

The clinical relationship is central to detection and treatment of mental health problems in primary care. Screening with structured questionnaires cannot replace clinical sensitivity, systematic inquiry and relationship-building. Given the

great diversity of immigrant and refugee patients, no single approach is likely to be sufficient for optimal recognition and appropriate treatment of depression.

Recommendations of other groups

The Canadian Task Force on Preventive Health Care recommends screening adults for depression in primary care when integrated systems that include diagnostic, treatment and follow-up components are in place.³⁸⁸ The US Preventive Services Task Force recommends screening adolescents (age 12–18 years) when integrated systems of treatment, including assessment, psychotherapy and follow-up, are in place; however, it concludes that evidence is insufficient to make any recommendation for children 7–11 years of age.^{410,411} Our recommendations highlight the value of screening for depression in the context of integrated treatment programs.

Take-home messages

- Rates of depression are lower among new immigrants to Canada, but over time these rates generally rise to match the rate in the general population.
- The prevalence of depression among refugees is comparable to that in the general population.
- Existing guidelines for depression suggest that all patients should be screened for depression when integrated systems are in place to provide follow-up treatment.
- For immigrants, use information about depression in relevant languages, translated screening questions and trained interpreters, as well as systematic inquiries about losses, stressors and symptoms.
- Moderate to severe depression should be treated with a stepped-care model, beginning with psychoeducation and antidepressant medication, close follow-up and culturally appropriate counselling.

For the complete evidence review for depression in immigrant populations, see Appendix 10, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1.

More detailed information and resources for screening, assessment and treatment of depression can be found at: www.mmhrc.ca.

13. Post-traumatic stress disorder

A large proportion of new immigrants to Canada come from countries experiencing social turmoil, and some are directly affected by protracted conflicts or war.⁴²⁰ Refugees and others who face significant trauma and loss are at risk for mental health consequences, including post-traumatic stress disorder. For three main reasons, primary care practitioners play a key role in the recognition and management of post-traumatic stress disorder in immigrants and refugees. First, immigrants and refugees underutilize formal mental health services.⁴²⁰ Second, an integrated treatment approach is often needed for extreme traumas, common in refugees, such as torture and rape, which have severe and long-lasting consequences for both physical and mental health.⁴²¹ Third, a family perspective is essential because trauma stemming from organized violence tends to affect the whole family, particularly children, who may not display dramatic or easily recognizable symptoms. We conducted an evidence review to determine the burden of post-traumatic stress disorder within immigrant and refugee populations, to evaluate the effectiveness of screening and treatment, and to identify barriers for primary care. The recommendations of the Canadian Collaboration for Immigrant and Refugee Health on post-traumatic stress disorder are outlined in Box 13A.

Box 13A: Recommendations from the Canadian Collaboration for Immigrant and Refugee Health: post-traumatic stress disorder

Do not conduct routine screening for exposure to traumatic events, because pushing for disclosure of traumatic events in well-functioning individuals may result in more harm than good.

Be alert for signs and symptoms of post-traumatic stress disorder, especially in the context of unexplained somatic symptoms, sleep disorders or mental health disorders such as depression or panic disorder, and perform clinical assessment as needed to address functional impairment.

Basis of recommendation

Balance of benefits and harms

Many persons who have been exposed to trauma do fine once they find safety and social supports. Brief screening instruments overestimate the rate of disease because they focus on symptoms and do not measure functional impairment. Detailed inquiry and pushing for disclosure without indications of distress or disorder could be harmful. There are no clinical trials demonstrating the benefits of routine screening for post-traumatic stress disorder.

Quality of evidence

Low (evidence available for refugee populations)

Values and preferences

The committee attributed more value to preventing potential harms from routine screening in the absence of clear evidence of benefits and determined that post-traumatic stress disorder was best dealt with through primary care practitioners remaining alert for signs and symptoms of this condition and performing clinical assessment to address functional impairment.

Methods

We used the 14-step method developed by the Canadian Collaboration for Immigrant and Refugee Health¹⁶ (summarized in section 3 of this article, above). We considered the epidemiology of post-traumatic stress disorder in immigrant populations and defined clinical preventive actions (interventions), outcomes and key clinical questions. We searched MEDLINE, Embase, CINAHL, PsychLIT, the Cochrane Library and other sources from Jan. 1, 2002, to Dec. 31, 2010. Detailed methods, search terms, case studies and clinical considerations can be found in the complete evidence review for post-traumatic stress disorder (Appendix 11, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1).

Results

We identified 16 systematic reviews relevant to immigrants and refugees and five guidelines. We selected the 2005 guidelines commissioned by the National Institute for Clinical Excellence for the management of post-traumatic stress disorder in primary care,⁴²² but none of the selected intervention studies in those guidelines provided evidence for immigrants or refugees. We also selected four Cochrane reviews on treatment of post-traumatic stress disorder,^{423–426} the practice guidelines from the International Society for Traumatic Stress Studies⁴²⁷ and a systematic review on treatment of this condition in refugees and asylum seekers.⁴²⁸

What is the burden of illness of post-traumatic stress disorder in immigrant populations?

Most persons who experience traumatic events have a favourable mental health prognosis.⁵³ When symptoms of post-traumatic stress disorder or acute stress disorder develop, there is, in most cases, substantial natural recovery (estimated at about 80%). However, those in whom post-traumatic stress develops may remain symptomatic for years and are at risk of secondary problems, such as substance abuse.⁵⁴ A meta-analysis of studies involving adult refugees resettled in developed countries reported a 9% prevalence of post-traumatic stress disorder, and 5% had major depression. Among refugees with major depression, 71% also had post-traumatic stress disorder. Conversely, 44% of refugees with post-traumatic stress disorder also had major depression.⁵¹ Studies of child refugees report 11% prevalence of post-traumatic stress disorder.^{429,430} Symptoms may be reactivated when faced with new traumas, particularly if reminiscent of earlier traumatic experiences.⁴³¹ Torture and cumulative trauma are the strongest predictors of post-traumatic stress disorder and are associated with chronic physical and mental health problems.⁴³⁰ Fear of repatriation may exacerbate consequences of premigratory traumas.

Longitudinal studies from Canada indicate that most adults and children with refugee status adapt well, in spite of a high level of exposure to premigratory trauma.^{432,433} A population-based health survey from Quebec similarly found that non-refugee immigrants also experienced high levels of premigratory trauma, but that most immigrants were in good mental health.⁴³⁴

Does screening for post-traumatic stress disorder decrease morbidity and mortality?

Screening

Several short screening instruments practical for primary care settings have been developed.⁴³⁵ The four-item primary care post-traumatic stress disorder screening scale⁴³⁶ and the Breslau seven-item screening scale (available at <http://ajp.psychiatryonline.org/cgi/content/full/156/6/908#T2>) are two simple means of identifying symptoms in primary care patients. In both cases, their cultural validity is unknown. Very few screening instruments have been tested for diagnostic accuracy among immigrants, refugees and asylum seekers. However, it may be reasonable to use questionnaires to assist in identifying symptoms, as part of a clinical assessment when addressing functional impairment.

Relative benefits and harms of psychological treatment (adults and children)

The systematic review and meta-analysis commissioned by the National Institute for Clinical Excellence⁴²² provided evidence that psychological treatments, including trauma-focused cognitive-behavioural therapy and eye movement desensitization and processing, reduce the symptoms of post-traumatic stress disorder. We rated the quality of this evidence as low because of study limitations and inconsistency of results. Two Cochrane reviews^{425,426} provided similar evidence of effectiveness. A recent systematic review⁴²⁸ showed that psychological treatments (cognitive-behavioural therapy and narrative exposure therapy) can reduce symptoms of post-traumatic stress disorder among refugees, but we rated this evidence as very low quality. Other authors have reported that patients may experience adverse effects with therapy, such as re-experiencing traumatic events, and rates of withdrawal from active therapy may approach 30%.⁴³⁷

Clinical considerations

What are the potential implementation issues?

Primary care practitioners need to be aware that immigrants and refugees may have been exposed to traumatic events. If a patient discloses a traumatic experience, it may be helpful to acknowledge the pain and suffering associated with the experience, to explain that a reaction is common for anyone who has undergone trauma and to offer empathetic reassurance that the situation is likely to get better. Several Canadian cities have centres and experts available to help care for survivors of trauma and torture.

Exploration of trauma and its consequences is not recom-

mended in the first meeting with a patient unless it is the patient's primary complaint. However, certain symptom presentations should alert clinicians to the need for assessment for post-traumatic stress disorder, including unexplained physical complaints, sleep disorders,⁴²² depression, panic disorder and somatoform disorder.⁵¹ Other presentations, such as severe dissociation mimicking brief reactive psychosis, dissociative disorders (amnesia and conversion) and psychotic depression, although less frequent, may also be related to post-traumatic stress disorder. Key elements of the assessment include level of psychological distress, the impairment associated with the symptoms in the patient and his or her family, substance abuse and suicidality.

Familiarity with the cultural background of the patient is recommended, and assessment should involve a professional interpreter if the patient's language ability is inadequate to express psychological distress and narrate the experience.⁴²² Disclosing traumatic experience through relatives, family members or, particularly, children can be traumatic.⁴³⁸

Although not supported by clinical trials, the National Institute for Clinical Excellence⁴²² recommends a phased intervention model, reflecting a pragmatic approach for refugees and asylum seekers who face the possibility of being returned to a traumatic environment. Phase I is defined as the period in which safety has not yet been established and during which intervention should focus on practical, family and social support. Phases II and III should focus on the patient's priorities, which may include social integration and/or treatment of symptoms. Unemployment, isolation and discrimination may overshadow the efficacy of mental health treatment in many patients,⁴³⁰ which suggests that multifaceted interventions that include primary care, community organizations and other social institutions may be effective.⁴³²

Recommendations of other groups

The UK National Institute for Clinical Excellence⁴²² recommends against routine systematic provision of brief, single-session interventions. It recommends that consideration be given to the use of a brief screening instrument to detect post-traumatic stress disorder among refugees and asylum seekers, but does not suggest any specific instrument for screening or provide evidence of effectiveness of treatment in refugees. It also recommends that children and youth with post-traumatic stress disorder be offered a course of trauma-focused cognitive behaviour therapy. For sleep disorders, the National Institute for Clinical Excellence recommends the short-term use of hypnotic medication for adults or, if longer-term treatment is required, the use of suitable antidepressants to reduce the risk of dependence. For significant comorbid depression or severe hyperarousal, the National Institute for Clinical Excellence recommends paroxetine and mirtazapine. The US Centers for Disease Control and Prevention state that, in general, the majority of people who experience reactions to stress after disasters and emergencies show resilience and do not go on to experience long-term psychopathology.⁴³⁹ Our recommendations highlight the paucity of evidence for routine screening and the potential for harms.

Take-home messages

- Forty percent of Canadian immigrants and refugees from countries involved in war or with significant social unrest have been exposed to traumatic events before migration.
- Most (estimated at 80%) individuals who experience traumatic events heal spontaneously after reaching safety.
- Empathy, reassurance and advocacy are key clinical elements of the recovery process.
- Pushing for disclosure of traumatic events by well-functioning individuals may result in more harm than good.

For the complete evidence review for post-traumatic stress disorder in immigrants, see Appendix 11, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1.

More detailed information and resources for assessment and treatment of trauma and survivors of torture can be found at: www.mmhrc.ca.

14. Child maltreatment

Child maltreatment is an important public health problem worldwide.⁴⁴⁰ The 2003 Canadian incidence study of reported child abuse and neglect estimated an incidence rate of 22 per thousand for child maltreatment.⁴⁴¹ Of reported cases, 15% involved emotional maltreatment, 28% involved exposure to domestic violence, 24% involved physical abuse, 30% involved neglect and 3% involved sexual abuse. Surveys conducted with nonrepresentative ethnic minority samples (which have likely included immigrants and refugees) have yielded higher rates of maltreatment than appear in official reports.⁴⁴² This review was undertaken to clarify reports of child maltreatment in ethnic communities, to determine whether existing tools to screen for child maltreatment are appropriate for immigrant and refugee children, and to recommend strategies to improve the quality of care for these populations. The recommendations of the Canadian Collaboration for Immigrant and Refugee Health related to child maltreatment are outlined in Box 14A.

Methods

We used the 14-step approach developed by the Canadian Collaboration for Immigrant and Refugee Health¹⁶ (summarized in section 3 of this article, above). We considered the epidemiology of child maltreatment in immigrant populations and defined clinical preventive actions (interventions), outcomes and key clinical questions. We searched MEDLINE, Embase CINAHL, PsychLIT, the Cochrane Library and other sources from Jan. 1, 1995, to Dec. 31, 2010. Detailed methods, search terms, case studies and clinical considerations can be found in

the complete evidence review for child maltreatment (Appendix 12, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1).

Results

We found no systematic reviews or guidelines on screening, prevention or treatment for child maltreatment in recently settled immigrants or refugees. The general literature search identified 180 titles with reference to child maltreatment. Seventeen citations were selected, and five key reviews retained as evidence.^{443–447} Studies conducted with general population and ethnic minority samples provided additional evidence that informed our recommendations related to child maltreatment among immigrants and refugees.

What is the burden of child maltreatment in immigrant populations?

The prevalence and incidence of child maltreatment among immigrant and/or refugee children in Canada are unknown. The evidence on maltreatment among ethnic minority children in the United States and Canada suggests that some ethnic minority children are disproportionately over- and under-represented in child protection services.⁴⁴⁸ These children are more likely to be screened for child maltreatment and also more likely to be reported to child protection services. Higher rates of screening result in a higher rate of

Box 14A: Recommendations from the Canadian Collaboration for Immigrant and Refugee Health: child maltreatment

Screening

Do not conduct routine screening for child maltreatment.
Be alert for signs and symptoms of child maltreatment during physical and mental examinations, and assess further when reasonable doubt exists or after patient disclosure.

Basis of recommendations

Balance of benefits and harms

The committee recommends against routine screening because of poor performance of screening instruments and the potential harms caused by the very high false-positive rates. Sensitivity ranged between 25% and 100%, specificity between 16.5% and 94.3%, and positive predictive value (when available) between 1.7% and 28.2%.

Quality of evidence

Low

Values and preferences

The committee attributed more value to evidence for the negative effects of screening in relation to the high potential for harms. Harms could result from false positives leading to inappropriate labelling, psychological distress, inappropriate family separation, impaired clinician–patient rapport, potential reduction in use of general medical services and legal ramifications associated with involvement of child protection services.

Prevention of child maltreatment and associated outcomes

A home visitation program encompassing the first two years of life should be offered to immigrant and refugee mothers living in high-risk conditions, including teenage motherhood, single parent status, social isolation, low socioeconomic status, or living with mental health or drug abuse problems.

Basis of recommendation

Balance of benefits and harms

Home visitation programs for high-risk mothers, provided by nurses, reduced days in hospital for children ($p < 0.001$). Harms from surveillance and reporting to child protection services were not clearly demonstrated.

Quality of evidence

Moderate

Values and preferences

The committee attributed more value to supporting high-risk mothers with an offer of a home visitation program to provide practical support for families and the program's potential to improve health outcomes for children than to the potential risks associated with increased reporting to child protection services.

inappropriate referral to child protection services. Ethnic minority children who received medical examinations were twice as likely ($p < 0.001$) to be reported to child protection services.⁵⁵

The Canadian incidence study of reported child abuse and neglect⁴⁴¹ found that ethnic minority children had a 1.8 times greater likelihood to be over-represented, whereas white and Arab children were under-represented. The higher rates were found among Aboriginals, Blacks, Latinos and Asians (the latter group for only physical abuse). This racial bias⁴⁴⁹ may be one explanation why ethnic minority children are disproportionately represented at all levels of the child protection process,^{450–452} despite the fact that they do not seem to be at higher risk of maltreatment.⁴⁵³ Another explanation may be professionals' divergent views as to what should be considered grounds for clinical suspicion of child maltreatment,⁴⁵⁴ which is associated with recency of training in child abuse, prejudices about the perpetrator^{454,455} and the professionals' beliefs in the positive or negative consequences of reporting a given family to child protection services.⁴⁵⁴

Does screening for child maltreatment reduce harm and premature death or disability?

Screening tools

Most screening methods consist of self-administered questionnaires generally completed by the mother, interviews or checklists completed by the professional who collects information directly from the child or clinical judgments by nurse or professional teams.^{443,445} All screening methods attempt to predict child maltreatment on the basis of either parents' potential for maltreatment or the presence or level of risk factors associated with maltreatment, rather than on the occurrence of actual maltreatment. Three systematic reviews have reported that these instruments tend to have high sensitivity but poor specificity and false-positive rates too high for use in clinical settings.^{443–445} Sensitivity ranged between 25% and 100%, specificity between 16.5% and 94.3%, and positive predictive value (when available) between 1.7% and 28.2%.

Table 14A: Summary of findings for home visitation by nurses to prevent child maltreatment

Patient or population: Pregnant first-time mothers with at least one "sociodemographic risk characteristic"

Settings: US clinic with free prenatal services and private obstetricians' offices;⁴⁶² US public system of obstetric care⁴⁵⁹

Intervention: Home visitation by nurses

Comparison: Usual care

Sources: MacMillan HL; Canadian Task Force on Preventive Health Care. Preventive health care, 2000 update: prevention of child maltreatment. *CMAJ* 2000;163:1451-8.⁴⁴⁴ Olds DL, Eckenrode J, Henderson CR Jr, et al. Long-term effects of home visitation on maternal life course and child abuse and neglect: fifteen-year follow-up of a randomized trial. *JAMA* 1997;278:637-43.⁴⁵⁹ Kitzman H, Olds DL, Henderson CR Jr, et al. Effect of prenatal and infancy home visitation by nurses on pregnancy outcomes, childhood injuries, and repeated childbearing: a randomized controlled trial. *JAMA* 1997;278:644-52.⁴⁶²

Outcome	Absolute effect		Relative effect (95% CI)	No. of participants (studies)	GRADE quality of evidence	Comments
	Risk for control group	Difference with home visitation by nurses (95% CI)				
Out-of-home placements (follow-up: 16 mo)	226 per 1000	31 more per 1000 (70 fewer to 201 more per 1000)	RR 1.14 (0.69–1.89)*†	197 (1)	Moderate‡§	NNT not statistically significant
Mean no. of substantiated reports of child abuse and neglect over 15 yr	0.54¶	0.25 fewer¶	0.77 (0.34–1.19)**	245 (1) ⁴⁶²	Moderate	NA
Mean no. of days in hospital for injuries and ingestions over 2 yr	0.16	0.13 fewer	NA	697 (1) ⁴⁶²	Moderate	$p < 0.001$
Mean no. of health care encounters for injuries and ingestions over 2 yr	0.55	0.12 fewer	NA	697 (1) ⁴⁶²	Low	$p = 0.05$

Note: CI = confidence interval; GRADE = Grading of Recommendations Assessment, Development and Evaluation; NA = not applicable; NNT = number needed to treat; RR = risk ratio.

*Calculated using <http://statpages.org/ctab2x2.html>.

†Because RR crosses 0 (i.e., not statistically significant), the NNT could not be estimated.

‡Pregnant women with "specified psychosocial risk factors": substance abuse, homelessness, domestic violence, psychiatric illness, incarceration, HIV infection or lack of social support.

§"When the recommendation is in favour of an intervention and the 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes no effect and the upper confidence limit includes an effect that, if it were real, would represent a benefit that would outweigh the downsides" (GRADE Pro software).

¶Adjusted for socioeconomic status, marital status, maternal age, education, locus of control, support from husband or boyfriend, working status, and husband or boyfriend use of public assistance at registration.

**Estimate = (comparison log incidence) – (intervention log incidence).

Relative benefits and harms from screening

False-positive ratings, which are the most common result in low-risk populations, can lead to a number of negative consequences, such as inappropriate labelling and punitive attitudes, psychological distress,⁵⁶ inappropriate separation of children from family support systems, destruction of family supports, loss of resources and loss of autonomy for those falsely accused.⁴⁵⁶ This may leave parents wary of any subsequent assistance that may be offered,⁵⁶ thus reducing their access to care. A systematic review of the performance of screening tests concluded that adding a screening protocol to the clinical encounter yielded additional false-positives that exceeded additional abused children detected.⁴⁵⁷

Compared with the general population, immigrant and refugee families may be more likely to suffer from the direct and indirect harms related to screening. Screening instruments have not been culturally validated and are less likely to be accurate because of factors such as language barriers, different cultural norms of behaviours and different attitudes toward institutional authority.⁴⁵⁸ Given the limited state of knowledge in immigrant populations, potential harms from routine screening for child maltreatment outweigh benefits, which have not yet been clearly established.

Relative benefits and harms of preventing child maltreatment

Home visitation programs by nurses aim to prevent child

maltreatment by assessing and supporting families. To date, the 15-year longitudinal study by Olds and associates⁴⁵⁹ has provided the best evidence for the effectiveness of a nurse–family partnership program in reducing actual child maltreatment. The effectiveness of this program is particularly evident for first-time mothers who are younger than 19 years of age, single or economically disadvantaged (Table 14A).^{444,446,460,461} Another prevention program (the Early Start Program) has also shown efficacy in reducing hospital admissions for child injuries at 36 months (17.5% v. 26.3% for control group).⁴⁶³

Relative benefits and harms of treatment for child maltreatment

Several specific forms of intervention have been devised to reduce the consequences of child maltreatment. Trauma-focused cognitive–behavioural therapy reduces sexually abused children's symptoms of anxiety, depression and sexual behaviour problems⁴⁶⁴ in both general population and ethnic minority children. Table 14B presents the outcomes of cognitive behavioural interventions.⁴⁴⁷ Parent–child interaction therapy⁴⁶⁵ showed a reduction in repeated reports of physical abuse in treatment relative to control groups (standard psychoeducational program) (19% v. 49%). In most other studies, the outcomes were not statistically significant but there was a consistent tendency in favour of treatment programs. The lack of evidence of efficacy for immigrant or

Table 14B: Summary of findings for cognitive–behavioural therapy for sexually abused children

Patient or population: Sexually abused children aged 2–18 yr

Settings: United States and Australia, communities and hospitals

Intervention: Cognitive–behavioural therapy for children

Comparison: Variable: group information-based approach, cognitive–behavioural therapy for parents and children, community control, wait-list control

Source: Macdonald G, Higgins JPT, Ramchandani P. Cognitive-behavioural interventions for children who have been sexually abused. *Cochrane Database Syst Rev* 2006;(4):CD001930.⁴⁴⁷

Outcome	Absolute effect, mean score		Relative effect, % (95% CI)	No. of participants (studies)	GRADE quality of evidence
	Risk for control group	Difference with cognitive– behavioural therapy (95% CI)			
Depression, by Child Depression Inventory	5.47*	1.8 lower (3.98 lower to 0.38 higher)	–33 (–73 to 7)	443 (5)	Moderate†
Anxiety, by various scales	27.76*	0.21 lower (0.40 to 0.02 lower)	–0.8 (–1.4 to –0.1)	456 (5)	High
Post-traumatic stress disorder, by various scales	2.32	0.43 lower (0.69 to 0.16 lower)	–19 (–0 to –7)	464 (6)	High
Sexualized behaviour	8.2	0.65 lower (3.53 lower to 2.24 higher)	–8 (–43 to 27)	451 (5)	Very low†‡
Externalizing behaviour	13.82	0.14 lower (0.44 lower to 0.15 higher)	–1 (–3 to 1)	560 (7)	Moderate§

Note: CI = confidence interval; GRADE = Grading of Recommendations Assessment, Development and Evaluation.

*Representative study chosen on basis of sample size.

†95% CI includes no effect and the upper or lower confidence limit crosses the minimal important difference (MID), either for benefit or harm. (GRADE Pro software recommends that “if the MID is not known or the use of different outcomes measures required calculation of an effect size [E5], we suggest downgrading if the upper or lower confidence limit crosses an effect size of 0.5 in either direction.”)

‡Test for heterogeneity $p = 0.02$.

§Test for heterogeneity $p = 0.01$.

refugee children precludes extrapolation of the findings to these groups.

Clinical considerations

What are the potential implementation issues?

Some forms of child discipline may be unusual or outside Canadian social norms but are not pathological⁴⁶⁶ or dangerous for the child. Immigrant or refugee families may resort to other disciplinary behaviours (e.g., hitting a child with an object) that are condoned in their cultural context but that contravene child protection laws in Canada. Some cultural practices (e.g., scarification as part of life cycle rituals among some African children or cupping, a common traditional healing method in some Asian cultures that leaves circular ecchymoses) may be misinterpreted as signs of child abuse. Other culture-specific practices (e.g., female genital cutting) contravene child protection and civil laws in Canada. In situations where child maltreatment is suspected, observed or disclosed, the practitioner must take action in accordance with the child protection law in his or her region.

Language barriers, fear of separation from the child, fear of punitive institutional power and fear of deportation may constitute major barriers to disclosure of child maltreatment. Failure to investigate family dynamics and inter-generational conflicts, after disclosure of maltreatment by an immigrant child, may further disempower the parents and attribute greater power to the child, consequently aggravating his or her problem. Immigrant and refugee children placed in foster care may suffer from loss of connection with language of origin and religious, familial and cultural traditions. As a preventive strategy, clinicians may want to provide families with sources of information about their province's child protection law, their legal rights and their obligations regarding children, in addition to addressing other risk factors for child maltreatment. Recent research is showing that the SEEK (Safe Environment for Every Kid) model is promising.⁴⁶⁷

Recommendations of other groups

The US Preventive Services Task Force concluded that there is insufficient evidence for or against routine screening of child abuse.⁴⁵⁶ The Canadian Task Force on Preventive Health Care concluded that there is fair evidence to exclude screening for child maltreatment.⁷⁹ The American Academy of Paediatrics⁴⁶⁸ and the American Medical Association^{469,470} do not support universal screening, but recommend that physicians be alert for signs and symptoms of child maltreatment during routine physical examination. The Task Force on Community Preventive Services of the US Centers for Disease Control and Prevention recommends early childhood home visitation for the prevention of child maltreatment in high-risk families and families with low-birth-weight infants.⁴⁷¹ Our recommendations highlight the importance of prevention and the potential harms of routine screening in the context of cultural and linguistic diversity.

Take-home messages

- Children from ethnic minorities, including recently settled immigrants and refugees, are eight times more likely to be subjected to screening for child maltreatment than children in the general population.
- Immigrant and refugee families may be particularly vulnerable to the harms that can occur because of legal and institutional interventions consequent to false-positive screening results, such as over-reporting for child maltreatment and unnecessary separation of the child from his or her family.

For the complete evidence review for child maltreatment in immigrant populations, see Appendix 12, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1.

More detailed information and resources on cultural aspects of child maltreatment can be found at: www.mmhrc.ca.

15. Intimate partner violence

Intimate partner violence, defined as physical, emotional, financial and/or sexual abuse perpetrated against the victim by his or her intimate partner,⁴⁷² is a significant public health problem worldwide.⁴⁴⁰ In Canada, a 1999 study of a nationally representative sample of 26 000 participants reported 8% intimate partner violence against a female and 7% against a male by a previous or current partner in the past five years.⁴⁷³ Women, however, are more likely than men to be the victims of serious violent acts such as sexual abuse, beatings (25% v. 10%), being choked (20% v. 4%) or being threatened or having a weapon used against them (13% v. 7%).⁴⁷⁴ They are also more likely than men to be injured during the violent act (40% v. 13%) and to be fearful for their lives (40% v. < 10%).⁴⁷⁴ In this review we aimed to determine whether existing screening tools and approaches for intimate partner violence are appropriate for immigrant and refugee women and to identify care barriers for these populations. The recommendations of the Canadian Collaboration for Immigrant and Refugee Health related to intimate partner violence are outlined in Box 15A.

Methods

We used the 14-step approach developed by the Canadian Collaboration for Immigrant and Refugee Health¹⁶ (summarized in section 3 of this article, above). We considered the epidemiology of intimate partner violence in immigrant populations and defined clinical preventive actions (interventions), outcomes and key clinical questions. We searched MEDLINE, Embase, CINAHL, PsychLIT, the Cochrane Library and other sources from Jan. 1, 1995, to Dec. 31, 2010. Detailed methods, search terms, case studies and clinical considerations can be found in the complete evidence review for intimate partner violence (Appendix 13, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1).

Results

We found no systematic reviews or evidence-based guidelines on screening, prevention or treatment for intimate partner violence in immigrants or refugees. The general literature search identified 409 titles on intimate partner violence, and after appraisals, we retained two key reviews as evidence.^{475,476} After the search update, we selected two additional key reviews and one randomized controlled trial.^{477–479} Studies conducted with general population and ethnic minority samples informed our clinical recommendations.

What is the burden of intimate partner violence in immigrant populations?

Three studies provided secondary analyses of the 1999 Statistics Canada General Social Survey. Women born in developing countries reported the highest prevalence rates of intimate partner violence, followed by Canadian-born women and

immigrant women from developed countries. However, when all other variables in the model were controlled for, the analysis showed that recently settled immigrant women (i.e., in Canada for less than 10 years) had significantly lower odds of intimate partner violence victimization than longer-term immigrants and Canadian-born women.⁴⁸⁰ Single, divorced, separated or widowed immigrant women were 10 times more likely to report intimate partner violence than immigrant women married or in a common-law relationship.⁴⁸¹ Immigrant women reported higher rates of emotional abuse than Canadian-born women (14.7% v. 8.7%), with the strongest risk factor being their partner's low educational level.⁴⁸²

Regional surveys on intimate partner violence have yielded higher rates. MacMillan and colleagues⁴⁸³ reported rates that ranged from 4.1% to 17.7% for Canadian-born women and 12.6% for foreign-born women. Ahmad and coauthors⁴⁸⁴ reported a 22% rate of intimate partner violence following computer screening. Prevalence rates also vary in relation to the health care setting (highest prevalence in emergency departments). Finally, women in war zones, disaster zones, during flight or displaced in refugee camps in countries of asylum may be at higher risk for intimate partner violence.⁴⁸⁵

Does screening for intimate partner violence reduce morbidity or mortality?

Screening tools

Screening for intimate partner violence differs from tradi-

Box 15A: Recommendations from the Canadian Collaboration for Immigrant and Refugee Health: intimate partner violence

Do not conduct routine screening for intimate partner violence.

Be alert for potential signs and symptoms related to intimate partner violence, and assess further when reasonable doubt exists or after patient disclosure.

Basis of recommendation

Balance of benefits and harms

Current evidence does not demonstrate clear benefits from screening women for intimate partner violence, and harms have resulted from screening. Compared with the general population, there may be greater risk among immigrant and refugee women for harm directly related to screening (e.g., risk of loss of migration status and sponsorship agreements). Harm may occur indirectly through impaired patient–physician rapport and subsequent reduction in use of medical and mental health services.

Quality of evidence

Moderate

Values and preferences

The committee attributed more value to evidence of harms and lack of evidence of benefits and less value to recommending uncertain interventions, even in the face of significant concerns.

tional screening for medical disorders because the target of clinical concern is a behavioural event, which women usually recognize as a problem but which they may not view as appropriate for medical attention.^{485,486} Four short self-report questionnaires have received the most study. The “Hurt, Insulted, Threatened, or Screamed at” questionnaire (four items) yields sensitivity ranging from 30% to 100% and specificity from 86% to 99%.⁴⁷⁶ The Partner Violence Screen (three items) provides sensitivity from 35% to 71% and specificity from 80% to 94%.⁴⁷⁷ The Women Abuse Screening Tool (eight items) yields 47% sensitivity and 96% specificity.⁴⁷⁹ The Abuse Assessment Screen (five items) yields sensitivity ranging from 32% to 94% and specificity from 55% to 99%.⁴⁸⁷

A Canadian randomized controlled trial found women preferred self-completed approaches.⁴⁸³ However, other studies comparing administration methods of screening instruments (e.g., face-to-face interviews, computer screening, written screening) have shown inconsistent results.^{484,488,489} Furthermore, it is unknown whether these results apply to immigrant and refugee women.

Relative benefits and harms of screening

A Canadian trial on the effect of screening found no statistically significant differences between women screened or not screened at 6, 12 or 18 months follow-up for recurrence of intimate partner violence (Table 15A).⁴⁷⁸ More than half of the

women who disclosed being victims of intimate partner violence on screening did not discuss the violence with their practitioner during the health care visit. An important study limitation was that no specific intervention was provided to women who disclosed or screened positive.⁴⁷⁸

Other studies have found screening benefits such as decreasing isolation, increasing support, relief, breaking the silence and validating women's feelings.^{485,490} However, these same studies identified several harms, including feeling that the practitioner is too busy or not interested, feeling judged and being disappointed by the practitioner's response, increased anxiety, concerns about privacy,⁴⁸⁴ breaches of confidentiality and legal repercussions, fear of being reported to child protective services,⁴⁸⁵ and concern about or actual increased risk of retaliation or further harm from the partner.⁴⁸⁵

Relative benefits and harms of treatment

The strongest evidence for treatment has come from studies of the Experimental Social Innovation and Dissemination program,^{491,492} which reported decreased physical and emotional abuse at 12–24 months follow-up and improvement of women's quality of life at 12 months follow-up. Ramsay and coworkers⁴⁷² reported that, while promising, the results were inconclusive. In Table 15B, we report the efficacy of the Experimental Social Innovation and Dissemination advocacy and counselling intervention program in decreasing the incidence of intimate partner violence⁴⁷⁵ in an ethnically

Table 15A: Summary of findings on screening for intimate partner violence to reduce morbidity due to such violence

Patient or population: English-speaking female patients

Settings: Health care settings in Ontario

Intervention: Screening for intimate partner violence

Comparison: No screening

Source: Macmillan HL, Wathen CN, Jamieson E, et al. Screening for intimate partner violence in health care settings: a randomized trial. *JAMA* 2009;302:493-501.⁴⁷⁸

Outcome (18-mo follow-up)	Absolute effect		Relative effect (95% CI)*	No. of participants (studies)	GRADE quality of evidence	Comments (95% CI)
	Risk for control group	Difference with screening (95% CI)				
Intimate partner violence, by Composite Abuse Scale	530 per 1000	74 fewer per 1000 (159 fewer to 32 more per 1000)	RR 0.86 (0.70–1.06)*	379 (1)	Moderate†‡	NNT not statistically significant
Post-traumatic stress disorder screening, by SPAN (startle, physically upset by reminders, anger, numbness)	601 per 1000	162 fewer per 1000 (246 to 66 fewer per 1000)	RR 0.73 (0.59–0.89)*	379 (1)	Moderate†‡	NNT 7 (5–16)
Quality of life, by WHO Brief	Mean score 52.7	Mean score 5.8 higher (2.14 to 9.46 higher)	NA	379 (1)	Moderate†§	NA
Depression	Mean score 24.4	Mean score 3.4 lower (5.8 to 1.0 lower)	NA	379 (1)	Moderate†§	NA

Note: CI = confidence interval; GRADE = Grading of Recommendations Assessment, Development and Evaluation; NA = not applicable; NNT = number needed to treat; RR = relative risk; WHO = World Health Organization.

*Calculated using Review Manager on the basis of observed counts.

†Only one study.

‡Dichotomous outcome: total number of events was less than 300.

§Continuous outcome: total population size was less than 400.

diverse sample of women who had spent at least one night in a shelter.

Clinical considerations

What are potential implementation issues?

Signs and symptoms of intimate partner violence differ significantly among women. They may be absent in some women or be of a psychological (depression, anxiety, suicidal ideation, alcohol or drug abuse), social (social isolation) and/or physical (injuries, bruises and aches) nature in other women. Patient–physician rapport thus remains a key element in the detection of intimate partner violence.

Recently settled immigrant women in Canada are more likely to report intimate partner violence to the police than women in the general population but are less likely to use social services.⁴⁹⁴ Barriers to help-seeking included fear of deportation or not accessing Canadian citizenship, lack of knowledge of services or language-specific services, experiences of racism or discrimination.⁴⁹⁴ Culturally specific perceptions of spousal relationships, gender roles, negative experiences with authorities, aggression and abuse may affect reporting and disclosure.⁴⁸⁵ Involvement with police or criminal proceedings may put immigrant women at risk of losing their sponsorship agreements.^{485,494}

Intimate partner violence is now considered a form of child maltreatment. Women may delay disclosure of violence because of fear of losing custody of their children (child protection services often cite the mother's failure to protect her children).^{485,494} In addition, some women feel coerced into staying in a shelter to keep custody of their children. Although

this may protect them from further intimate partner violence, it may also isolate them from extended family and community networks that might otherwise be integrated effectively into the intervention plan.⁴⁵⁸

Services that can defuse conflict situations and reduce family stress include social welfare, reliable childcare, safe housing, language classes, and other educational and vocational training opportunities. Community grassroots organizations can provide information and support groups in appropriate languages and in a culturally competent manner.^{495–498} Research is beginning to show benefits when screening and interventions target women with specific conditions, for example pregnancy, mental illness and substance abuse, but this work has yet to consider the immigrant context.

Recommendations of other groups

National clinical preventive screening committees, the Canadian Task Force on Preventive Health Care, the UK National Screening Committee and the US Preventive Services Task Force have not found sufficient evidence to recommend for or against screening all women for intimate partner violence.^{476–478} The UK National Screening Committee concluded that “screening for domestic violence should not be introduced” in periodic health examinations. The American Medical Association, the American Academy of Family Physicians and the American College of Obstetricians and Gynecologists have recommended routinely screening all women for intimate partner violence.⁴⁷⁹ However, these organizations have not based their recommendations on systematic reviews of effectiveness. Our guidelines

Table 15B: Summary of findings for advocacy programs to prevent further intimate partner violence

Patient or population: Women in a Midwest shelter program for women with abusive partners who had (i) spent at least one night in the shelter and (ii) planned on staying in the general vicinity for the first three months after leaving the shelter

Setting: Community setting

Intervention: Advocacy programs

Comparison: No advocacy program

Sources: Wathen CN, Macmillan HL. Interventions for violence against women: scientific review. *JAMA* 2003;289:589-600.⁴⁷⁵

Sullivan CM, Bybee DI. Reducing violence using community-based advocacy for women with abusive partners. *J Consult Clin Psychol* 1999;67:43-53.⁴⁹¹

Outcome	Absolute effect, mean score		No. of participants (studies)	GRADE quality of evidence
	Risk for control group	Difference with advocacy programs (95% CI)		
Self-reported severity or frequency of abuse (scale 0–3; follow-up 24 mo)	0.85	0.15 higher	265 (1) ⁴⁹³	Low*†‡
Effectiveness in obtaining community resources (scale 1–4; follow-up 10 wk)	2.7	0.50 higher (0.34 higher to 0.66 higher)	265 (1)	Low*†‡
Quality of life (scale 1–7; follow-up 24 mo)	4.94§	0.25 higher (0.02 lower to 0.52 higher)	265 (1)	Low*†‡
Depression (scale 0–3; follow-up 24 mo)	2.00	0.08 lower (0.24 lower to 0.08 higher)	265 (1)	Low*†‡

Note: CI = confidence interval; GRADE = Grading of Recommendations Assessment, Development and Evaluation.

*Only one study.

†Concerns about directness and applicability only to women seen in primary care who have been in a shelter.

‡Fewer than 300 events.

§ Postintervention scores.

highlight the paucity of data on the effectiveness of screening programs and the concern for potential harms from routine screening.

Take-home messages

- The rate of reporting of intimate partner violence is lower among recently settled immigrant women than among longer-term immigrants and Canadian-born women.
- Linguistic barriers, financial dependencies, fear of losing custody of children and limited knowledge of laws and health services constitute significant barriers to both disclosure and adherence to interventions among immigrant and refugee women.

- To decrease the rate of abuse, practitioners should refer women who report spending at least one night in a shelter to a structured program of patient-centred (advocacy) support services.

For the complete evidence review for intimate partner violence in immigrant populations, see Appendix 13, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.090313/-/DC1.

More detailed information and resources on cultural aspects of intimate partner violence can be found at: www.mmhrc.ca.

References

- International Organization for Migration. *The world migration report 2008: managing labour mobility in the evolving global economy*. Geneva (Switzerland): The Organization; 2008.
- MacPherson DW, Gushulak BD, Macdonald L. Health and foreign policy: influences of migration and population mobility. *Bull World Health Organ* 2007;85:200-6.
- Human development report 2009. Overcoming barriers: human mobility and development*. New York (NY): United Nations Development Program, Human Development Report Office; 2009. Available: <http://hdr.undp.org/en/reports/global/hdr2009/chapters/> (accessed 2010 May 25).
- Projections of the diversity of the Canadian population 2006–2031*. Ottawa (ON): Statistics Canada; 2010.
- Gushulak BD, Pottie K, Hatcher Roberts J, et al. Migration and health in Canada: health in the global village. *CMAJ* 2010 June 28 [Epub ahead of print].
- Facts and figures 2007*. Ottawa (ON): Citizenship and Immigration Canada; 2008. Cat. no. C11-8/2007E.PDF.
- Reitz JG. *Closing the gaps between skilled immigration and Canadian labour markets: emerging policy issues and priorities*. Toronto (ON): University of Toronto; 2007.
- Visiting Canada*. Ottawa (ON): Citizenship and Immigration Canada; 2007. Available: www.cic.gc.ca/english/visit/index.asp (accessed 2010 Apr. 21).
- Wilkins R, Tjepkema M, Mustar C, et al. The Canadian census mortality follow-up study, 1991 through 2001. *Health Rep* 2008;19:25-43.
- DesMeules M, Gold J, McDermott S, et al. Disparities in mortality patterns among Canadian immigrants and refugees, 1980–1998: results of a national cohort study. *J Immigr Health* 2005;7:221-32.
- Steele LS, Lemieux C, Clark J, et al. The impact of policy changes on the health of recent immigrants and refugees in the inner city. *Can J Public Health* 2002;93:118-22.
- Commission on Social Determinants of Health. *Closing the gap in a generation: health equity through action on the social determinants of health. Final report*. Geneva (Switzerland): World Health Organization; 2008. Available: www.who.int/social_determinants/en/ (accessed 2011 Feb. 10).
- Beach MC, Gary T, Price E, et al. Improving health care quality for racial/ethnic minorities: a systematic review of the best evidence regarding provider and organization interventions. *BMC Public Health* 2006;6:104.
- Pottie K, Torres S. *Systematic review for guidelines for immigrants and refugees: policy report for the Public Health Agency of Canada*. Ottawa (ON): Canadian Collaboration for Immigrant and Refugee Health; 2005. Available: www.ccihrh.uottawa.ca/eng/index.html (accessed 2011 Feb. 10).
- Swinkels H, Pottie K, Tugwell P, et al. Development of guidelines for recently arrived immigrants and refugees to Canada: Delphi consensus on selecting preventable and treatable conditions. *CMAJ* 2010 June 28 [Epub ahead of print].
- Tugwell P, Pottie K, Welch V, et al. Evaluation of evidence-based literature and formation of recommendations for the clinical preventive guidelines for immigrants and refugees in Canada. *CMAJ* 2010 June 23 [Epub ahead of print].
- Schünemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. *Am J Respir Crit Care Med* 2006;174:605-14.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:1049-51.
- San Martin C, Ross N. Experiencing difficulties accessing first-contact health services in Canada. *Health Policy* 2006;1:103-19.
- Gushulak BD, MacPherson DW. *Migration medicine and health: principles and practice*. Hamilton (ON): BC Decker; 2006.
- Australian Government, National Health and Medical Research Council AG. *Cultural competency in health: a guide for policy, partnerships and participation*. Canberra (Australia): The Council; 2005.
- Walker PF, Barnett ED, Stauffer WM, editors. *Immigrant medicine*. Philadelphia (PA): Saunders Elsevier; 2007.
- Murray R, Davis J, Krause V, et al. *Diagnosis, management and prevention of infections in recently arrived refugees*. Sydney (Australia): Australasian Society for Infectious Diseases; 2009. Available: www.asid.net.au/downloads/RefugeeGuidelines.pdf (accessed 2011 May 5).
- Barnett ED. Infectious disease screening for refugees resettled in the United States. *Clin Infect Dis* 2004;39:833-41.
- Stauffer WM, Karnat D, Walker PF. Screening of international immigrants, refugees, and adoptees. *Prim Care* 2002;29:879-905.
- Gavagan T, Brodyaga L. Medical care for immigrants and refugees. *Am Fam Physician* 1998;57:1061-8.
- HPA migrant health guide*. London (UK): Health Protection Agency; 2011. Available: www.hpa.org.uk/migranthealthguide (accessed 2011 Feb. 10).
- Kirmayer LJ, Narasiah L, Munoz M, et al. Common mental health problems in immigrants and refugees: general approach in primary care. *CMAJ* 2010 July 5 [Epub ahead of print].
- Immigration and Refugee Protection Act, S.C. 2001, c. 27.
- Hyman I. *Immigration and health: reviewing evidence of the healthy immigrant effect in Canada*. CERIS Working Paper No. 55. Toronto (ON): Joint Centre of Excellence for Research on Immigration and Settlement; 2007.
- Ng E, Wilkins R, Gendron F, et al. *Dynamics of immigrants' health in Canada: evidence from the National Population Health Survey*. Ottawa (ON): Statistics Canada; 2005.
- Newbold KB, Danforth J. Health status and Canada's immigrant population. *Soc Sci Med* 2003;57:1981-95.
- Dunn JR, Dyck I. Social determinants of health in Canada's immigrant population: results from the National Population Health Survey. *Soc Sci Med* 2000;51:1573-93.
- McDonald JT, Kennedy S. Insights into the 'healthy immigrant effect': health status and health service use of immigrants to Canada. *Soc Sci Med* 2004;59:1613-27.
- Ng E, Pottie K, Spitzer D. Limited official language proficiency and decline in health status: a dynamic view from the longitudinal survey of immigrants to Canada. *Health Rep*. In press.
- Pottie K, Ng E, Spitzer D, et al. Language proficiency, gender and self-reported health: an analysis of the first two waves of the Longitudinal Survey of Immigrants to Canada. *Can J Public Health* 2008;99:505-10.
- Yuan L, Lau W, Thipphawong J, et al. Diphtheria and tetanus immunity among blood donors in Toronto. *CMAJ* 1997;156:985-90.
- Greenaway C, Dongier P, Boivin JF, et al. Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees. *Ann Intern Med* 2007;146:20-4.
- Christiansen D, Barnett ED. Comparison of varicella history with presence of varicella antibody in refugees. *Vaccine* 2004;22:4233-7.
- Greenaway C, Dongier P, Boivin JF, et al. Viral hepatitis in newly arrived immigrants and refugees. 56th Annual Meeting of American Society of Tropical Medicine and Hygiene; 2007 Nov. 4–8.
- Public Health Agency of Canada. *Tuberculosis in Canada 2006: pre-release*. Ottawa (ON): The Agency; 2007.
- Greenaway C, Sandoe A, Vissandjee B, et al. Tuberculosis: evidence review for newly arriving immigrants and refugees. *CMAJ* 2010 July 15 [Epub ahead of print].
- Hirsch-Moverman Y, Daftary A, Franks J, et al. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. *Int J Tuberc Lung Dis* 2008;12:1235-54.
- Cass AD, Talavera GA, Gresham LS, et al. Structured behavioral intervention to increase children's adherence to treatment for latent tuberculosis infection. *Int J Tuberc Lung Dis* 2005;9:415-20.
- Newman PA, Williams CC, Massaquoi N, et al. HIV prevention for black women: structural barriers and opportunities. *J Health Care Poor Underserved* 2008;19:829-41.
- Pattullo V, Heathcote J, Wong D. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. *Hepatol Int* 2010;4:723-31.
- Chan MS. The global burden of intestinal nematode infections — fifty years on. *Parasitol Today* 1997;13:438-43.
- Biggs BA, Caruana S, Mirshahi S, et al. Management of chronic strongyloidiasis in immigrants and refugees: Is serologic testing useful? *Am J Trop Med Hyg* 2009;80:788-91.
- World Health Organization. *World malaria report*. Geneva (Switzerland): The Organization; 2008.
- Kain KC, Harrington MA, Tennyson S, et al. Imported malaria: prospective analysis of problems in diagnosis and management. *Clin Infect Dis* 1998;27:142-9.
- Fazel M, Wheeler J, Danesh J. Prevalence of serious mental disorder in 7000 refugees resettled in Western countries: a systematic review. *Lancet* 2005;365:1309-14.
- Bhui K, Warfa N, Edonya P, et al. Cultural competence in mental health care: a review of model evaluations. *BMC Health Serv Res* 2007;7:15.
- Copeland WE, Keeler G, Angold A, et al. Traumatic events and posttraumatic stress in childhood. *Arch Gen Psychiatry* 2007;64:577-84.
- Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the Nation Comorbidity Survey. *Arch Gen Psychiatry* 1995;52:1048-60.
- Lane WG, Rubin D, Monteith R, et al. Racial differences in the evaluation of pediatric fractures for physical abuse. *JAMA* 2002;288:1603-9.
- Taylor J, Baldwin N, Spencer N. Predicting child abuse and neglect: ethical, theoretical and methodological challenges. *J Clin Nurs* 2008;17:1193-200.
- Creatore MI, Moineddin R, Booth G, et al. Age- and sex-related prevalence of diabetes mellitus among immigrants to Ontario, Canada. *CMAJ* 2010;182:781-9.
- Hawthorne K, Robles Y, Cannings-John R, et al. Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. *Cochrane Database Syst Rev* 2008;(3):CD006424.
- World Health Organization. *Worldwide prevalence of anaemia 1993–2005*. Geneva (Switzerland): The Organization; 2008. Available: http://whqlibdoc.who.int/publications/2008/9789241596657_eng.pdf (accessed 2008 Sept. 10).
- Bindra GS, Gibson RS. Iron status of predominantly lacto-ovo vegetarian East Indian immigrants to Canada: a model approach. *Am J Clin Nutr* 1986;44:643-52.
- Matthews DC, Sutherland S, Basrani B. Emergency management of acute apical abscesses in the permanent dentition: a systematic review of the literature. *J Can Dent Assoc* 2003;69:660.
- Bader JD, Rozier RG, Lohr KN, et al. Physicians' roles in preventing dental caries in preschool children: a summary of the evidence for the U.S. Preventive Services Task Force. *Am J Prev Med* 2004;26:315-25.
- Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. *Bull World Health Organ* 2004;82:844-51.
- Halpern V, Grimes DA, Lopez L, et al. Strategies to improve adherence and acceptability of hormonal methods for contraception. *Cochrane Database Syst Rev* 2006;(1):CD004317.
- Lam TK, McPhee SJ, Mock J, et al. Encouraging Vietnamese-American women to obtain Pap tests through lay health worker outreach and media education. *J Gen Intern Med* 2003;18:516-24.
- Maxwell CJ, Bancej CM, Snider J, et al. Factors important in promoting cervical

- cancer screening among Canadian women: findings from the 1996–97 National Population Health Survey (NPHS). *Can J Public Health* 2001;92:127–33.
67. Gagnon AJ, Dougherty G, Platt RW, et al. Refugee and refugee-claimant women and infants post-birth: migration histories as a predictor of Canadian health system response to needs. *Can J Public Health* 2007;98:287–91.
 68. van Doorslaer E, Masseria C, Koolman X. Inequalities in access to medical care by income in developed countries. *CMAJ* 2006;174:177–83.
 69. Schünemann HJ, Hill SR, Kakad M, et al. Transparent development of the WHO rapid advice guidelines. *PLoS Med* 2007;4:e119.
 70. Oxman AD, Schünemann HJ, Fretheim A. Improving the use of research evidence in guideline development: 2. Priority setting. *Health Res Policy Syst* 2006;4:14.
 71. Battista RN, Hodge MJ. Setting priorities and selecting topics for clinical practice guidelines. *CMAJ* 1995;153:1233–7.
 72. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care* 2003;12:18–23.
 73. Schünemann H, Fretheim A, Oxman A. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. *Health Res Policy Syst* 2006;4:22.
 74. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004;328:1490.
 75. Jones J, Hunter D. Qualitative research: consensus methods for medical and health services research. *BMJ* 1995;311:376–80.
 76. Loo R. The Delphi method: a powerful tool for strategic management. *Int J Policy Strat Manage* 2002;25:762–9.
 77. Sullivan WF, Heng J, Cameron D, et al. Consensus guidelines for primary health care of adults with developmental disabilities. *Can Fam Physician* 2006;52:1410–8.
 78. Briss PA, Zasa S, Pappaioanou M, et al. Developing an evidence-based guide to community preventive services — methods. *Am J Prev Med* 2000;18:35–43.
 79. Canadian Task Force on Preventive Health Care. What the Task Force does. Ottawa (ON): The Task Force; 2009. Available: www.canadiantaskforce.ca (accessed 2007 Sept. 25).
 80. Benson J, Skull S. Hiding from the sun — vitamin D deficiency in refugees. *Aust Fam Physician* 2007;36:355–7.
 81. Canadian Paediatrics Society. *Children and youth new to Canada: a healthcare guide*. Ottawa (ON): The Society; 1999.
 82. Gushulak BD, MacPherson DW. Population mobility and health: an overview of the relationships between movement and population health. *J Travel Med* 2004;11:171–8.
 83. Selikowitz HS. Acknowledging cultural differences in the care of refugee and immigrants. *Int Dent J* 1994;44:59–61.
 84. Davis D, Goldman J, Palda VA. *Handbook on clinical practice guidelines*. Ottawa (ON): Canadian Medical Association; 2007. Available: www.cma.ca/multimedia/CMA/Content/Images/CMAInfoBase/EN/handbook.pdf (accessed 2009 Sept. 17).
 85. Schünemann H, Brozek J, Oxman A, editors. *GRADE handbook for grading quality of evidence and strength of recommendations*. Version 3.2. The GRADE Working Group; 2009. Available: www.cc-ims.net/grade (accessed 2010 Jun. 9).
 86. Fervers B, Burgers JS, Haugh MC, et al. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. *Int J Qual Health Care* 2006;18:167–76.
 87. Schünemann HJ, Oxman AD, Vist GE, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors. *Cochrane handbook for systematic reviews of interventions*. Version 5.0.2. The Cochrane Collaboration; 2009. Available: www.cochrane-handbook.org (accessed 2009 Oct. 17).
 88. US Department of Health and Human Services, Agency for Healthcare Research and Quality. *Procedure manual [US Preventive Services Task Force]*. Publ. No. 08-05118-EF. Washington (DC): The Agency; 2008. Available: www.ahrq.gov/clinic/uspstf08/methods/procmmanual.htm (accessed 2010 Jun. 17).
 89. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editors. *Cochrane handbook for systematic reviews of interventions*. Version 5.0.2. The Cochrane Collaboration; 2009. Available: www.cochrane-handbook.org (accessed 2009 Oct. 17).
 90. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
 91. Swann C, Falce C, Morgan A, et al. *HDA evidence base. Process and quality standards manual for evidence briefings*. 3rd ed. London (UK): Health Development Agency; 2005. Available: [www.nice.org.uk/niceMedia/docs/Process_And_Quality_Standards_Manual_For_Evidence_Briefings-March2005\[1\].pdf](http://www.nice.org.uk/niceMedia/docs/Process_And_Quality_Standards_Manual_For_Evidence_Briefings-March2005[1].pdf) (accessed 2009 Sept. 17).
 92. Cochrane Effective Practice and Organisation of Care Review Group. *Data collection checklist*. Ottawa (ON): The Cochrane Collaboration; 2002. Available: <http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/datacollectionchecklist.pdf> (accessed 2007 Sept. 14).
 93. Wells GA, Shea B, O'Connell D, et al. Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. Ottawa (ON): The Ottawa Hospital Research Institute; 2007. Available: www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed 2007 Dec. 13).
 94. Glasziou P, Oxman AD, Higgins J. Summary of findings tables within Cochrane reviews: draft specification for RevMan 5.0, December 2004. In: Oxman AD, Glasziou P, Higgins J, editors. *Obtaining a consensus on the content and methods of a summary of findings table for Cochrane reviews: report to the Cochrane Collaboration Steering Group*. Ottawa (ON): Cochrane Collaboration Steering Group; 2005.
 95. Plotkin SA, Orenstein WA, Offit P. *Vaccines*. 5th ed. Elsevier; 2008.
 96. Maciosek MV, Coffield AB, Edwards NM, et al. Priorities among effective clinical preventive services. results of a systematic review and analysis. *Am J Prev Med* 2006;31:52–61.
 97. Roush SW, Murphy DG; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. *JAMA* 2007;298:2155–63.
 98. Peltola H, Kulkarni P, Kapre S, et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. *Clin Infect Dis* 2007;45:459–66.
 99. World Health Organization. Poliomyelitis in Tajikistan — update. *Wkly Epidemiol Rec* 2010;85:165–6.
 100. 2006 Census: immigration and citizenship. Ottawa (ON): Statistics Canada; 2007. Available: <http://www12.statcan.ca/census-recensement/2006/rt-id/immcit-eng.cfm> (accessed 2011 May 6).
 101. World Health Organization. *WHO vaccine-preventable diseases: monitoring system. 2004 global summary*. Geneva: The Organization; 2004.
 102. Walker PF, Jaranson J. Refugee and immigrant health care. *Med Clin North Am* 1999;83:1103–20.
 103. Cheffins T, Chan A, Keane RJ, et al. The impact of rubella immunisation on the incidence of rubella, congenital rubella syndrome and rubella-related terminations of pregnancy in South Australia. *Br J Obstet Gynaecol* 1998;105:998–1004.
 104. McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. *Ann Intern Med* 2002;136:660–6.
 105. Danovaro-Holliday MC, LeBaron CW, Allensworth C, et al. A large rubella outbreak with spread from the workplace to the community. *JAMA* 2000;284:2733–9.
 106. Craig AS, Reed GW, Mohon RT, et al. Neonatal tetanus in the United States: a sentinel event in the foreign-born. *Pediatr Infect Dis J* 1997;16:955–9.
 107. Tiong ACD, Patel MS, Gardiner J, et al. Health issues in newly arrived African refugees attending general practice clinics in Melbourne. *Med J Aust* 2006;185:602–6.
 108. King A, Varughese P, De Serres G, et al.; Working Group on Measles Elimination. Measles elimination in Canada. *J Infect Dis* 2004;189(Suppl 1):S236–42.
 109. Plotkin S, Orenstein W. *Vaccines*. 4th ed. Philadelphia (PA): Saunders; 2004.
 110. Anderson RM. The concept of herd immunity and the design of community-based immunization programs. *Vaccine* 1992;10:928–35.
 111. Public Health Agency of Canada, National Advisory Committee on Immunization. *Canadian immunization guide*. 7th ed. Ottawa (ON): The Agency; 2006.
 112. Quinlisk MP. Mumps control today. *J Infect Dis* 2010;202:655–6.
 113. Demicheli V, Jefferson T, Rivetti A, et al. Vaccines for measles, mumps and rubella in children. *Cochrane Database Syst Rev* 2005;(4):CD004407.
 114. Jefferson T, Price D, Demicheli V, et al. Unintended events following immunization with MMR: a systematic review. *Vaccine* 2003;21:3954–60.
 115. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet* 1998;351:637–41. Retraction in: *Lancet* 2010;375:445.
 116. Madsen KM, Hviid A, Vestergaard M, et al. Population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med* 2002;347:1477–82.
 117. Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. *Lancet Infect Dis* 2004;4:84–90.
 118. Cohen AL, Veenstra D. Economic analysis of prevaccination serotesting compared with presumptive immunization for polio, diphtheria, and tetanus in internationally adopted and immigrant infants. *Pediatrics* 2006;117:1650–5.
 119. Murray TS, Groth ME, Weitzman C, et al. Epidemiology and management of infectious diseases in international adoptees. *Clin Microbiol Rev* 2005;18:510–20.
 120. Barnett ED. Immunizations and infectious disease screening for internationally adopted children. *Pediatr Clin North Am* 2005;52:1287–309.
 121. Guttman A, Manuel D, Stukel TA, et al. Immunization coverage among young children of urban immigrant mothers: findings from a universal health care system. *Ambul Pediatr* 2008;8:205–9.
 122. Falagas ME, Zarkadoulia E. Factors associated with suboptimal compliance to vaccinations in children in developed countries: a systematic review. *Curr Med Res Opin* 2008;24:1719–41.
 123. Skull SA, Ngeow JYY, Hogg G, et al. Incomplete immunity and missed vaccination opportunities in East African immigrants settling in Australia. *J Immigr Minor Health* 2008;10:263–8.
 124. Infectious Diseases Society of America, National and Global Health Committee, Immunization Work Group. Executive summary — actions to strengthen adult and adolescent immunization coverage in the United States: policy principles of the Infectious Diseases Society of America. *Clin Infect Dis* 2007;44:1529–31.
 125. Figueira M, Christiansen D, Barnett ED. Cost-effectiveness of serotesting compared with universal immunization for varicella in refugee children from six geographic regions. *J Travel Med* 2003;10:203–7.
 126. Nysse LJ, Pinsky NA, Bratberg JP, et al. Seroprevalence of antibody to varicella among Somali refugees. *Mayo Clin Proc* 2007;82:175–80.
 127. Knowles SJ, Grundy K, Cahill I, et al. Susceptibility to infectious rash illness in pregnant women from diverse geographical regions. *Commun Dis Public Health* 2004;7:344–8.
 128. Merrett P, Schwartzman K, Rivest P, et al. Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis. *Clin Infect Dis* 2007;44:1040–8.
 129. Guess HA, Broughton DD, Melton LJ 3rd, et al. Population-based studies of varicella complications. *Pediatrics* 1986;78:723–7.
 130. Gabutti G, Fedele A, Aprile V, et al. Immigration flows and new epidemiological

- evidence in southern Italy. *Vaccine* 2003;21:399-400.
131. Public health dispatch: varicella outbreaks among Mexican adults — Alabama, 2000. *Morb Mortal Wkly Rep* 2000;49:735-6.
 132. Hastie IR. Varicella-zoster virus affecting immigrant nurses. *Lancet* 1980;2:154-5.
 133. Deny P, Lepout C, Jestin C. Chickenpox in one hundred Sri Lankan immigrants in France. *Med Mal Infect* 1986;16:595-8.
 134. Longfield JN, Winn RE, Gibson RL, et al. Varicella outbreaks in army recruits from Puerto Rico. Varicella susceptibility in a population from the tropics. *Arch Intern Med* 1990;150:970-3.
 135. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. *N Engl J Med* 2005;352:450-8.
 136. Zhou F, Harpaz R, Jumaan A, et al. Impact of varicella vaccination on health care utilization. *JAMA* 2005;294:797-802.
 137. Kjersem H, Jepsen S. Varicella among immigrants from the tropics, a health problem. *Scand J Soc Med* 1990;18:171-4.
 138. Danovaro-Holliday MC, Gordon ER, Jumaan AO, et al. High rate of varicella complications among Mexican-born adults in Alabama. *Clin Infect Dis* 2004;39:1633-39.
 139. Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. *N Engl J Med* 1994;330:901-5.
 140. Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. *N Engl J Med* 1986;314:1542-6.
 141. Zambrano MA, Martinz A, Minguez JA, et al. Varicella pneumonia complicating pregnancy. *Acta Obstet Gynecol Scand* 1995;74:318-20.
 142. Breuer J, Schmid DS, Gershon AA. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. *J Infect Dis* 2008;197(Suppl 2):S147-51.
 143. Holmes CN. Predictive value of a history of varicella infection. *Can Fam Physician* 2005;51:60-5.
 144. McMahon E, Brown LJ, Bexley S, et al. Identification of potential candidates for varicella vaccination by history: questionnaire and seroprevalence study. *BMJ* 2004;329:551-2.
 145. Seward JF, Marin M, Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review. *J Infect Dis* 2008;197:1.
 146. Marin M, Guris D, Chaves SS, et al.; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2007;56(RR-4):1-40.
 147. National Advisory Committee on Immunization (NACI). Varicella vaccination two-dose recommendations. *Can Commun Dis Rep* 2010;36(ACS-8):1-36.
 148. Chaves SS, Haber P, Walton K, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. *J Infect Dis* 2008;197(Suppl 2):S170-7.
 149. National Advisory Committee on Immunization (NACI). Updated recommendations for the use of varicella and MMR vaccines in HIV-infected individuals. *Can Commun Dis Rep* 2010;36(ACS-7):1-19.
 150. Kwong JC, Tanuseputro P, Zagorski B, et al. Impact of varicella vaccination on health care outcomes in Ontario, Canada: Effect of a publicly funded program? *Vaccine* 2008;26:6006-12.
 151. Rozenbaum MH, Van Hoek AJ, Vegter S, et al. Cost-effectiveness of varicella vaccination programs: an update of the literature. *Expert Rev Vaccines* 2008;7:753-82.
 152. Zhou F, Ortega-Sanchez IR, Guris D, et al. An economic analysis of the universal varicella vaccination program in the United States. *J Infect Dis* 2008;197(Suppl 2):S156-64.
 153. Mills E, Jadad AR, Ross C, et al. Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination. *J Clin Epidemiol* 2005;58:1081-8.
 154. Pickering LK, Baker CJ, Freed GL, et al. Immunization programs for infants, children, adolescents and adults: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;49:817-40.
 155. Jacobson VJC, Szilagyi P. Patient reminder and patient recall systems to improve immunization rates. *Cochrane Database Syst Rev* 2005;(3):CD003941.
 156. Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. *Am J Prev Med* 2000;18(1 Suppl):97-140.
 157. Custer B, Sullivan S, Hazlet T, et al. Global epidemiology of hepatitis B virus. *J Clin Gastroenterol* 2004;38(Suppl):S158-68.
 158. Armstrong L, Goldstein S. Hepatitis B: global epidemiology, diagnosis and prevention. In: Walker P, Barnett E, editors. *Immigrant medicine*. Philadelphia (PA): Saunders Elsevier; 2007. p. 321-41.
 159. Public Health Agency of Canada. Immunization & vaccines: immunization schedules. Ottawa (ON): The Agency; 2008. Available: www.phac-aspc.gc.ca/im/is-vc-eng.php (accessed 2009 Sept. 14).
 160. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. *Health Technol Assess* 2007;11:1-206.
 161. Kao JH, Chen DS. Global control of hepatitis B virus infection. *Lancet Infect Dis* 2002;2:395-403.
 162. Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. *Clin Liver Dis* 2007;11:817-37.
 163. Pohani G, Zou S, Tepper M. Trends of hepatitis B and hepatitis C mortality in Canada 1979–1997. *Can J Public Health* 2001;92:250-4.
 164. ElSaadany S, Tepper M, Mao Y, et al. An epidemiologic study of hepatocellular carcinoma in Canada. *Can J Public Health* 2002;93:443-6.
 165. Gilca V, Duval B, Boulianne N, et al. Impact of the Quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program. *Pediatr Infect Dis J* 2006;25:372-4.
 166. *Manual of clinical microbiology*. 9th ed. Washington (DC): ASM Press; 2007.
 167. Mandell G, Bennett J, Dolin R. *Principles and practice of infectious diseases*. 5th ed. Philadelphia (PA): Churchill Livingstone; 2000.
 168. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004;351:1521-31.
 169. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med* 1996;334:1422-7.
 170. Shamiyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development conference. *Ann Intern Med* 2009;150:111-24.
 171. Sherman M, Shafraan S, Burak KW, et al. Management of chronic hepatitis B: consensus guidelines. *Can J Gastroenterol* 2007;21(Suppl C):5C-24C.
 172. Keefe EB, Dieterich DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. *Clin Gastroenterol Hepatol* 2008;6:1315-41.
 173. Lok AS, McMahon BJ. AASLD practice guidelines: chronic hepatitis B. *Hepatology* 2007;45:507-39.
 174. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005;42:1208-36.
 175. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004;130:417-22.
 176. Lin K, Vickery J. Screening for hepatitis B virus infection in pregnant women: evidence for the US Preventive Services Task Force Reaffirmation Recommendation Statement. *Ann Intern Med* 2009;150:874-6.
 177. Mast EE, Weinbaum CM, Fiore AE, et al.; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. *MMWR Morb Mortal Wkly Rep* 2006;55(RR-16):1-40.
 178. Lee C, Gong Y, Brok J, et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. *Cochrane Database Syst Rev* 2006;(2):CD004790.
 179. Mast EE, Margolis HS, Fiore AE, et al.; Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part I: immunization of infants, children, and adolescents. *MMWR Recomm Rep* 2005;54(RR-16):1-39.
 180. McMahon BJ, Rhoades ER, Heyward W, et al. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. *Lancet* 1987;2:1134-6.
 181. Wilson N, Ruff T, Jung Rana B, et al. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu. *Vaccine* 2000;18:3059-66.
 182. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Ann Intern Med* 2001;135:796-800.
 183. Del Poggio P, Mazzoleni M. Screening in liver disease. *World J Gastroenterol* 2006;12:5272-80.
 184. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. *N Engl J Med* 1997;336:1855-9.
 185. Chen W, Glud C. Vaccines for preventing hepatitis B in health care workers. *Cochrane Database Syst Rev* 2005;(4):CD000100.
 186. Yuan L, Robinson G. Hepatitis B vaccination and screening for markers at a sexually transmitted disease clinic for men. *Can J Public Health* 1994;85:338-41.
 187. Blostein J, Clark P. Cost-effectiveness of preimmunization hepatitis B screening in high-risk adolescents. *Public Health Rep* 2001;116:165-8.
 188. Hutton DW, Tan D, So SK, et al. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. *Ann Intern Med* 2007;147:460-9.
 189. Huerga H, Lopez-Velez R. Infectious diseases in sub-Saharan African immigrant children in Madrid, Spain. *Pediatr Infect Dis J* 2002;21:830-4.
 190. Hayes EB, Talbot SB, Matheson ES, et al. Health status of pediatric refugees in Portland, Me. *Arch Pediatr Adolesc Med* 1998;152:564-8.
 191. Hislop TG, Teh C, Low A, et al. Hepatitis B knowledge, testing and vaccination levels in Chinese immigrants to British Columbia, Canada. *Can J Public Health* 2007;98:125-9.
 192. Nguyen TT, Taylor V, Chen MS Jr, et al. Awareness, knowledge, and screening among Asian Americans. *J Cancer Educ* 2007;22:266-72.
 193. Vryheid RE. A survey of vaccinations of immigrants and refugees in San Diego County, California. *Asian Am Pac Isl J Health* 2001;9:221-30.
 194. Kim YO. Access to hepatitis B vaccination among Korean American children in immigrant families. *J Health Care Poor Underserved* 2004;15:170-82.
 195. Kim YOR, Telleen S. Predictors of hepatitis B immunization status in Korean American children. *J Immigr Health* 2001;3:181-92.
 196. Centers for Disease Control and Prevention. Recommendations for identification and public health management of person with chronic hepatitis B virus infection. *MMWR Morb Mortal Wkly Rep* 2008;57(RR-8):1-20.

197. Menzies D, Oxlade O, Lewis M. *Costs for tuberculosis care in Canada*. Ottawa (ON): Public Health Agency of Canada; 2006.
198. *Canadian tuberculosis standards*. 6th ed. Ottawa (ON): Tuberculosis Prevention and Control, Public Health Agency of Canada, Canadian Lung Association/Canadian Thoracic Society; 2007.
199. World Health Organization. WHO Report 2008. Global tuberculosis control. Surveillance, planning, financing. Geneva (Switzerland): The Organization; 2008.
200. Public Health Agency of Canada. *Tuberculosis in Canada 2004*. Ottawa (ON): The Agency; 2007.
201. *Tuberculosis in Canada 2000*. Ottawa (ON): Health Canada, Tuberculosis and Bacterial Respiratory Diseases; 2003.
202. Cain KP, Haley CA, Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. *Am J Respir Crit Care Med* 2007;175:75-9.
203. Creatore MI, Lam M, Wobeser WL. Patterns of tuberculosis risk over time among recent immigrants to Ontario, Canada. *Int J Tuberc Lung Dis* 2005;9:667-72.
204. Farah MG, Meyer HE, Selmer R, et al. Long-term risk of tuberculosis among immigrants in Norway. *Int J Epidemiol* 2005;34:1005-11.
205. Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of tuberculosis: a review. *Int J Tuberc Lung Dis* 2000;4:895-903.
206. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. *Lancet Infect Dis* 2008;8:359-68.
207. Tuberculosis among Indochinese refugees — an update. *MMWR Morb Mortal Wkly Rep* 1981;30:603-6.
208. Enarson DA. Active tuberculosis in Indochinese refugees in British Columbia. *CMAJ* 1984;131:39-42.
209. Wilcke JT, Poulsen S, Askgaard DS, et al. Tuberculosis in a cohort of Vietnamese refugees after arrival in Denmark 1979–1982. *Int J Tuberc Lung Dis* 1998;2:219-24.
210. Thorpe LE, Laserson K, Cookson S, et al. Infectious tuberculosis among newly arrived refugees in the United States. *N Engl J Med* 2004;350:2105-6.
211. Marras TK, Wilson J, Wang EEL, et al. Tuberculosis among Tibetan refugee claimants in Toronto: 1998 to 2000. *Chest* 2003;124:915-21.
212. Menzies D, Gardiner G, Farhat M, et al. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. *Int J Tuberc Lung Dis* 2008;12:498-505.
213. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Ann Intern Med* 2008;149:177-84.
214. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: What is the absolute effect of BCG and non-tuberculous mycobacteria? *Int J Tuberc Lung Dis* 2006;10:1192-204.
215. Marcus JH, Khassisi Y. Tuberculin sensitivity in BCG vaccinated infants and children in Israel. *Acta Tuberc Pneumol Scand* 1965;46:113-22.
216. Karalliede S, Katugha LP, Urugoda CG. Tuberculin response of Sri Lankan children after BCG vaccination at birth. *Tubercle* 1987;68:33-8.
217. Reid JK, Ward H, Marciniuk D, et al. The effect of neonatal BCG vaccination on PPD testing on Canadian Aboriginal children. *Chest* 2007;131:1806-10.
218. Sepulveda RL, Ferrer X, Latrach C, et al. The influence of Calmette–Guérin bacillus immunization on the booster effect of tuberculin testing in healthy young adults. *Am Rev Respir Dis* 1990;142:24-8.
219. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). *Can Commun Dis Rep* 2008;34:1-13.
220. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. *Int J Tuberc Lung Dis* 2007;11:16-26.
221. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. *Cochrane Database Syst Rev* 1999;(1):CD001363.
222. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. *AIDS* 1999;13:501-7.
223. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. *Bull World Health Organ* 1982;60:555-64.
224. Fountain FF, Tolley E, Chrsman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. *Chest* 2005;128:116-23.
225. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? *Int J Tuberc Lung Dis* 1999;3:847-50.
226. Public Health Agency of Canada. *Tuberculosis drug resistance in Canada 2007*. Ottawa (ON): The Agency; 2007.
227. Khan K, Muennig P, Behta M, et al. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. *N Engl J Med* 2002;347:1850-9.
228. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. *JAMA* 1999;281:1014-8.
229. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. *Am J Respir Crit Care Med* 2003;168:443-7.
230. Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. *Pediatrics* 2004;114:1175-201.
231. Saukkonen J, Cohn D, Jasmer R, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med* 2006;174:935-52.
232. Mandalakas AM, Starke JR. Current concepts of childhood tuberculosis. *Semin Pediatr Infect Dis* 2005;16:93-104.
233. Carvalho AC, Saleri N, El-Hamad I, et al. Completion of screening for latent tuberculosis infection among immigrants. *Epidemiol Infect* 2005;133:179-85.
234. Wyss LL, Alderman MK. Using theory to interpret beliefs in migrants diagnosed with latent TB. *Online J Issues Nurs* 2006;12:7.
235. Brewin P, Jones A, Kelly M, et al. Is screening for tuberculosis acceptable to immigrants? A qualitative study. *J Public Health (Oxf)* 2006;28:253-60.
236. Coreil J, Lauzardo M, Heurtehou M. Cultural feasibility assessment of tuberculosis prevention among persons of Haitian origin in South Florida. *J Immigr Health* 2004;6:63-9.
237. Griffiths C, Sturdy P, Brewin P, et al. Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled trial. *Lancet* 2007;369:1528-34.
238. Ailing RL, Dear MR. Adherence to tuberculosis preventive therapy among Latino immigrants. *Public Health Nurs* 1998;15:19-24.
239. Carlos EK, Cantwell MF, Bhatia G, et al. Public health interventions to encourage TB class A/B1/B2 immigrants to present for TB screening. *Am J Respir Crit Care Med* 1998;158:1037-41.
240. Goldberg SV, Wallace J, Jackson JC, et al. Cultural case management of latent tuberculosis infection. *Int J Tuberc Lung Dis* 2004;8:76-82.
241. *AIDS epidemic update 2007*. Geneva (Switzerland): Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization; 2007. Available: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf (accessed 2010 June 1).
242. Public Health Agency of Canada. *Population-specific HIV/AIDS status report: people from countries where HIV is endemic — Black people of African and Caribbean descent living in Canada*. Ottawa (ON): The Agency; 2009. Available: www.phac-aspc.gc.ca/aids-sida/publication/ps-pd/africacaribbe/frw-avpro-eng.php (accessed 2010 June 24).
243. Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Surveillance and Risk Assessment Division. *HIV/AIDS epi updates 2006*. Ottawa (ON): The Agency; 2006. Available: www.phac-aspc.gc.ca/publicat/epi-aeipi/epi-06/index-eng.php (accessed 2010 June 1).
244. Adrien A, Leane V, Remis RS, et al. Migration and HIV: an epidemiological study of Montréalers of Haitian origin. *Int J STD AIDS* 1999;10:237-42.
245. Spiegel PB, Bennesden AR, Claess J, et al. Prevalence of HIV infection in conflict-affected and displaced people in seven sub-Saharan African countries: a systematic review. *Lancet* 2007;369:2187-95.
246. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. *PLoS Med* 2007;4:e298.
247. Siegfried NL, Van Deventer PJU, Mahomed FA, et al. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. *Cochrane Database Syst Rev* 2006;(2):CD004535.
248. US Preventive Services Task Force. Screening for HIV: recommendation statement. *Ann Intern Med* 2005;143:32-7.
249. Weinhardt LS, Carey MP, Johnson BT, et al. Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985–1997. *Am J Public Health* 1999;89:1397-405.
250. Elwy AR, Hart GJ, Hawkes S, et al. Effectiveness of interventions to prevent sexually transmitted infections and human immunodeficiency virus in heterosexual men — a systematic review. *Arch Intern Med* 2002;162:1818-30.
251. HIV Trialists Collaborative Group. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. *Lancet* 1999;353:2014-25.
252. Ioannidis JPA, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. *J Infect Dis* 1998;178:349-59.
253. Rogstad KE, Palfreeman A, Rooney G, et al. *United Kingdom national guidelines on HIV testing*. London (UK): British Association for Sexual Health and HIV, Clinical Effectiveness Group; 2006.
254. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior — a meta-analytic review. *JAMA* 2004;292:224-36.
255. Burdette DR, Money DM, Forbes JC, et al. Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). *CMAJ* 2003;168:1671-4.
256. Enanoria WTA, Ng C, Saha SR, et al. Treatment outcomes after highly active antiretroviral therapy: a meta-analysis of randomised controlled trials. *Lancet Infect Dis* 2004;4:414-25.
257. Merson MH, Dayton JM, O'Reilly K. Effectiveness of HIV prevention interventions in developing countries. *AIDS* 2000;14:S68-84.
258. Samson L, King S. Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada. *CMAJ* 1998;158:1449-57.
259. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep* 2006;55:1-17.
260. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1998;338:853-60.
261. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. *JAMA* 2003;289:2978-82.

262. Zencovich M, Kennedy K, MacPherson DW, et al. Immigration medical screening and HIV infection in Canada. *Int J STD AIDS* 2006;17:813-6.
263. Public Health Agency of Canada, Surveillance and Risk Assessment Division. *HIV/AIDS in Canada. Surveillance report to December 31, 2006*. Ottawa (ON): The Agency; 2007.
264. amfAR (Foundation for AIDS Research). *Women and HIV/AIDS*. Fact sheet no. 2. Washington (DC): The Foundation, Public Policy Office; 2008.
265. Welz T, Hosegood V, Jaffer S, et al. Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. *AIDS* 2007;21:1467-72.
266. Rodriguez C. Sexual violence in South Kivu, Congo. *Forced Migr Rev* 2007;27:45-6.
267. Martino JL, Vermund SH. Vaginal douching: evidence for risks or benefits to women's health. *Epidemiol Rev* 2002;24:109-24.
268. Castilla J, del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. *J Acquir Immune Defic Syndr* 2005;40:96-101.
269. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. *N Engl J Med* 2005;352:586-95.
270. Lawson E, Gardezi F, Calzavara L, et al. *HIV/AIDS stigma, denial, fear and discrimination, experiences and responses of people from African and Caribbean communities in Toronto*. Toronto (ON): African and Caribbean Council on HIV/AIDS in Ontario and University of Toronto, HIV Social, Behavioural and Epidemiological Studies Unit; 2006.
271. Vermund SH, Wilson CM. Barriers to HIV testing — Where next? *Lancet* 2002;360:1186-7.
272. Herek GM, Capitanio JP, Widaman KF. Stigma, social risk, and health policy: public attitudes toward HIV surveillance policies and the social construction of illness. *J Health Psychol* 2003;22:533-40.
273. Tharao E, Massaquoi N, Teclom S. *The silent voices of HIV/AIDS epidemic: African and Caribbean women in Toronto 2002–2004*. Toronto (ON): Women's Health in Women's Hands; 2006.
274. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. *Clin Liver Dis* 2010;14:1-21.
275. Remis R. *A study to characterize the epidemiology of hepatitis C infection in Canada, 2002*. Ottawa (ON): Health Canada, Population and Public Health Branch, Centre for Infectious Disease Prevention and Control, Hepatitis C Prevention Support and Research Program; 2003.
276. Nordenstedt H, White D, El-Serag H. The changing pattern of epidemiology in hepatocellular carcinoma. *Dig Liver Dis* 2010;42:S206-14.
277. Sherman M, Shafraan S, Burak KW, et al. Management of chronic hepatitis C: consensus guidelines. *Can J Gastroenterol* 2007;21(Suppl C):25C-34C.
278. Ghany MG, Strader DB, Thomas DL, et al.; American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009;49:1335-74.
279. Asselah T, Marcellin P. New direct-acting antivirals combination for the treatment of chronic hepatitis C. *Liver Int* 2011;31(Suppl 1):68-77.
280. Manzano C, Treviño B, Cabezas J, et al. Communicable diseases in the immigrant population attended to in a tropical medicine unit: epidemiological aspects and public health issues. *Travel Med Infect Dis* 2008;6:4-11.
281. Batash S, Khaykisi I, Raicht RF, et al. High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program. *Am J Gastroenterol* 2008;103:922-7.
282. Lopez-Velez R, Hueriga H, Turrientes MC. Infectious diseases in immigrants from the perspective of a tropical medicine referral unit. *Am J Trop Med Hyg* 2003;69:115-21.
283. World Health Organization. Global prevalence of hepatitis A, B and C. *Wkly Epidemiol Rec* 2002;77:41-8.
284. World Health Organization. Hepatitis C – global prevalence (update). *Wkly Epidemiol Rec* 1999;74:425-7.
285. Hauri AM, Armstrong G, Hutin YJF. The global burden of disease attributable to contaminated injections given in the health care setting. *Int J STD AIDS* 2004;15:7-16.
286. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. *Gastroenterology* 2008;134:1699-714.
287. Sherman M, Bain V, Villeneuve JP, et al. The management of chronic viral hepatitis: a Canadian consensus conference 2004. *Can J Gastroenterol* 2004;18:715-28.
288. Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. *Health Technol Assess* 2007;11:1-205.
289. Hartwell D, Shepherd J. Pegylated and non-pegylated interferon-alpha and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis. *Int J Technol Assess Health Care* 2009;25:56-62.
290. Simin M, Brok J, Stimac D, et al. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. *Aliment Pharmacol Ther* 2007;25:1153-62.
291. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. *Health Technol Assess* 2004;8:iii-iv, 1-125.
292. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *Hepatology* 2007;45:579-87.
293. Veldt BJ, Heathcote J, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Ann Intern Med* 2007;147:677-84.
294. Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. *Liver Int* 2011;31(Suppl 1):18-22.
295. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. *Aliment Pharmacol Ther* 2008;28:397-404.
296. Petta S, Craxi A. Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. *Liver Int* 2011;31(Suppl 1):36-44.
297. Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. *Liver Int* 2011;31(Suppl 1):45-52.
298. Antaki N, Craxi A, Kamal Sanaa M, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. *Liver Int* 2010;30:342-55.
299. Borroni G, Andreoletti M, Casiraghi M, et al. Effectiveness of pegylated interferon/ribavirin combination in "real world" patients with chronic hepatitis C virus infection. *Aliment Pharmacol Ther* 2008;27:790-7.
300. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well? *Ann Intern Med* 2004;140:370-81.
301. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. *N Engl J Med* 2000;343:1673-80.
302. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. *Liver Int* 2011;31(Suppl 1):62-7.
303. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. *Eur J Public Health* 2009;19:245-53.
304. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. *Am J Obstet Gynecol* 2005;192:1153-61.
305. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. *Am J Med* 2001;111:614-21.
306. Caruana SR, Kelly HA, De Silva SL, et al. Knowledge about hepatitis and previous exposure to hepatitis viruses in immigrants and refugees from the Mekong region. *Aus N Z J Public Health* 2005;29:64-8.
307. O'Connor CC, Shaw M, Wen LM, et al. Low knowledge and high infection rates of hepatitis in Vietnamese men in Sydney. *Sex Health* 2008;5:299-302.
308. Zickmund SL, Brown KE, Bielefeldt K. A systematic review of provider knowledge of hepatitis C: Is it enough for a complex disease? *Dig Dis Sci* 2007;52:2550-6.
309. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. *J Viral Hepat* 2001;8:377-83.
310. Cozzolongo R, Cuppone R, Petrucci J, et al. Approach of primary care physicians to hepatitis C: an educational survey from a southern Italian area. *J Infect* 2005;51:396-400.
311. Ferrante JM, Winston D, Chen P, et al. Family physicians' knowledge and screening of chronic hepatitis and liver cancer. *Fam Med* 2008;40:345-51.
312. Chou R, Clark EC, Helfand M, et al. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2004;140:465-79.
313. Boulware DR, Stauffer WM, Hendel-Paterson BR, et al. Maltreatment of *Strongyloides* infection: case series and worldwide physicians-in-training survey. *Am J Med* 2007;120:545.e1-8.
314. Genta RM. Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. *Am J Clin Pathol* 1988;89:391-4.
315. Sudarshi S, Stumpfle R, Armstrong M, et al. Clinical presentation and diagnostic sensitivity of laboratory tests for *Strongyloides stercoralis* in travellers compared with immigrants in a non-endemic country. *Trop Med Int Health* 2003;8:728-32.
316. Gyorkos TW, Genta RM, Viens P, et al. Seroepidemiology of strongyloides infection in the Southeast Asian refugee population in Canada. *Am J Epidemiol* 1990;132:257-64.
317. Whitty CJ, Mabey DC, Armstrong M, et al. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a nonendemic country. *Trans R Soc Trop Med Hyg* 2000;94:531-4.
318. Kumar V, Gryseels B. Use of praziquantel against schistosomiasis: a review of current status. *Int J Antimicrob Agents* 1994;4:313-20.
319. Saconato H, Atallah A. Interventions for treating schistosomiasis mansoni. *Cochrane Database Syst Rev* 2000;(2):CD000528.
320. Toma H. Comparative studies on the efficacy of three anthelmintics on treatment of human strongyloidiasis in Okinawa, Japan. *Southeast Asian J Trop Med Public Health* 2000;31:147-51.
321. *Refugee health guidelines: domestic guidelines. Guidelines for evaluation of refugees for intestinal and tissue-invasive parasitic infections during domestic medical examination*. Atlanta (GA): Centers for Disease Control and Prevention. Available: <http://198.246.98.21/immigrantrefugeehealth/pdf/intestinal-parasites-domestic.pdf> (accessed 2011 May 5).
322. Buchwald D, Lam M, Hooton TM. Prevalence of intestinal parasites and association with symptoms in Southeast Asian refugees. *J Clin Pharm Ther* 1995;20:271-5.
323. Lifson AR, Thai D, O'Fallon A, et al. Prevalence of tuberculosis, hepatitis B virus, and intestinal parasitic infections among refugees to Minnesota. *Public Health Rep* 2002;117:69-77.
324. Martin JA, Mak DB. Changing faces: a review of infectious disease screening of refugees by the Migrant Health Unit, Western Australia in 2003 and 2004. *Med J Aust* 2006;185:607-10.
325. McLeod A, Reeve M. The health status of quota refugees screened by New Zealand's Auckland Public Health Service between 1995 and 2000. *N Z Med J* 2005;118:U1702.

326. Miller JM, Boyd HA, Ostrowski SR, et al. Malaria, intestinal parasites, and schistosomiasis among Barawan Somali refugees resettling to the United States: a strategy to reduce morbidity and decrease the risk of imported infections. *Am J Trop Med Hyg* 2000;62:115-21.
327. Molina CD, Molina MM, Molina JM. Intestinal parasites in Southeast Asian refugees two years after immigration. *West J Med* 1988;149:422-5.
328. Brodine SK, Thomas A, Huang R, et al. Community based parasitic screening and treatment of Sudanese refugees: application and assessment of Centers for Disease Control guidelines. *Am J Trop Med Hyg* 2009;80:425-30.
329. Caruana SR, Kelly HA, Ngeow JY, et al. Undiagnosed and potentially lethal parasite infections among immigrants and refugees in Australia. *J Travel Med* 2006;13:233-9.
330. de Silva S, Saykao P, Kelly H, et al. Chronic strongyloides stercoralis infection in Laotian immigrants and refugees 7–20 years after resettlement in Australia. *Epidemiol Infect* 2002;128:439-44.
331. Posey DL, Blackburn BG, Weinberg M, et al. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. *Clin Infect Dis* 2007;45:1310-5.
332. Rice JE, Skull SA, Pearce C, et al. Screening for intestinal parasites in recently arrived children from East Africa. *J Paediatr Child Health* 2003;39:456-9.
333. Seybolt LM, Christiansen D, Barnett ED. Diagnostic evaluation of newly arrived asymptomatic refugees with eosinophilia. *Clin Infect Dis* 2006;42:363-7.
334. Franco-Paredes C, Dismukes R, Nicolls D, et al. Persistent and untreated tropical infectious diseases among Sudanese refugees in the United States. *Am J Trop Med Hyg* 2007;77:633-5.
335. Chitsulo L, Engels D, Montresor A, et al. The global status of schistosomiasis and its control. *Acta Trop* 2000;77:41-51.
336. Garg PK, Perry S, Dorn M, et al. Risk of intestinal helminth and protozoan infection in a refugee population. *Am J Trop Med Hyg* 2005;73:386-91.
337. Davis J, Webber M. A prospective audit of 215 newly arrived African refugees. *J Paediatr Child Health* 2007;42(Suppl 1):A11.
338. Gibney KB, Mhrshahi S, Torresi J, et al. The profile of health problems in African immigrants attending an infectious disease unit in Melbourne, Australia. *Am J Trop Med Hyg* 2009;80:805-11.
339. Nielsen PB, Mojon M. Improved diagnosis of *Strongyloides stercoralis* by seven consecutive stool specimens. *Zentralbl Bakteriol Mikrobiol Hyg [A]* 1987;263:616-8.
340. Karunajeewa H, Kelly H, Leslie D, et al. Parasite-specific IgG response and peripheral blood eosinophil count following albendazole treatment for presumed chronic strongyloidiasis. *J Travel Med* 2006;13:84-91.
341. Kobayashi J, Sato Y, Toma H, et al. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. *Diagn Microbiol Infect Dis* 1994;18:19-23.
342. Lindo JF, Atkins NS, Lee MG, et al. Short report: long-term serum antibody isotype responses to *Strongyloides stercoralis* filariform antigens in eight patients treated with ivermectin. *Am J Trop Med Hyg* 1996;55:474-6.
343. Loutfy MR, Wilson M, Keystone JS, et al. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. *Am J Trop Med Hyg* 2002;66:749-52.
344. *Drugs for parasitic infections*. New Rochelle (NY): The Medical Letter Inc.; 2007.
345. Lim S, Katz K, Krajden S, et al. Complicated and fatal *Strongyloides* infection in Canadians: risk factors, diagnosis and management. *CMAJ* 2004;171:479-84.
346. Lagacé-Wiens PR, Harding GK. A Canadian immigrant with coinfection of *Strongyloides stercoralis* and human T-lymphotropic virus 1. *CMAJ* 2007;177:451-3.
347. *Drugs and health products* [database] Ottawa (ON): Health Canada; 2008 Available: www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogués/index-eng.php (accessed 2010 Nov. 1).
348. World Health Organization. *Guidelines for the treatment of malaria*. 2nd ed. Geneva (Switzerland): The Organization; 2010.
349. Taylor SM, Molyneux ME, Simel DL, et al. Does this patient have malaria? *JAMA* 2010;304:2048-56.
350. Canadian recommendations for the prevention and treatment of malaria among international travellers. *Can Commun Dis Rep* 2009;35(Suppl 1):1-82.
351. Mali S, Steele S, Slutsker L, et al. Malaria surveillance — United States, 2007. *MMWR Surveill Summ* 2009;58(SS02):1-16.
352. Monge-Maillo B, Jiménez C, Pérez-Molina JA, et al. Imported infectious diseases in mobile populations, Spain. *Emerg Infect Dis* 2009;15:1745-52.
353. Prematunga C, McCarthy A. Severe malaria surveillance and treatment delays in Canada [abstract 51.024]. *Int J Infect Dis* 2010;14(Suppl 1):e211.
354. Kain KC, MacPherson DW, Kelton T, et al. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. *CMAJ* 2001;164:654-9.
355. Lavoie PM, Carceller A, Robert M, et al. Malaria in immigrant and traveler children: clinical presentation and risk factors for complications. *J Pediatr Infect Dis* 2006;1:29-37.
356. Skarbinski J, Eliades J, Causer LM, et al. Malaria surveillance — United States, 2004. *MMWR Surveill Summ* 2006;55(SS04):23-37.
357. Thwing J, Skarbinski J, Newman RD, et al. Malaria surveillance — United States. *MMWR Surveill Summ* 2007;56(SS06):23-40.
358. Dal-Bianco MP, Koster KB, Kombila UD, et al. High prevalence of asymptomatic *Plasmodium falciparum* infection in Gabonese adults. *Am J Trop Med Hyg* 2007;77:939-42.
359. Marangi M, Di Tullio R, Mens PF, et al. Prevalence of *Plasmodium* spp. in malaria asymptomatic African migrants assessed by nucleic acid sequence based amplification. *Malar J* 2009;8:12.
360. Njama-Meya D, Kamya MR, Dorsey G. Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. *Trop Med Int Health* 2004;9:862-8.
361. Stauffer WM, Newberry AM, Cartwright CP, et al. Evaluation of malaria screening in newly arrived refugees to the United States by microscopy and rapid antigen capture enzyme assay. *Pediatr Infect Dis J* 2006;25:948-50.
362. Omari AAA, Gamble CL, Garner P. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. *Cochrane Database Syst Rev* 2005;(4):CD005564.
363. Osei-Akoto AO, Owusu-Ofori S. Atovaquone-proguanil for treating uncomplicated malaria. *Cochrane Database Syst Rev* 2005;(4):CD004529.
364. Maroushek SR, Aguilar EF, Stauffer W, et al. Malaria among refugee children at arrival in the United States. *Pediatr Infect Dis J* 2005;24:450-2.
365. Oliario P, Pinoges L, Checchi F, et al. Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment. *Trop Med Int Health* 2008;13:83-90.
366. Benson J, Davis J. Malaria in the Australian refugee population. *Aust Fam Physician* 2007;36:639-41.
367. Stauffer WM, Weinberg M. Emerging clinical issues in refugees. *Curr Opin Infect Dis* 2009;22:436-42.
368. Miller K, Banerji A. Epidemiology of malaria presenting at British Columbia's Children's Hospital, 1984–2001: lessons for prevention. *Can J Public Health* 2004;95:245-8.
369. Wongsrichanalai C, Barcus MJ, Muth S, et al. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). *Am J Trop Med Hyg* 2007;77(Suppl 6):119-27.
370. Murray CK, Gasser RAJ, Magill AJ, et al. Update on rapid diagnostic testing for malaria. *Clin Microbiol Rev* 2008;21:97-110.
371. Mens P, Spieker N, Omar S, et al. Is molecular biology the best alternative for diagnosis of malaria to microscopy? A comparison between microscopy, antigen detection and molecular tests in rural Kenya and urban Tanzania. *Trop Med Int Health* 2007;12:238-44.
372. Ndao M, Bandyayera E, Kokoskin E, et al. Comparison of blood smear, antigen detection, and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in Quebec, Canada. *J Clin Microbiol* 2004;42:2694-700.
373. Phares C, Kapella B, Casano A, et al. Imported *Plasmodium falciparum* malaria disease in newly arrived refugees: United States [poster presentation]. 46th Annual Meeting of Infectious Diseases Society of America; 2008 Oct. 25–28; Washington (DC).
374. Cherian S, Fagan JM, Thambiran A, et al. Severe *Plasmodium falciparum* malaria in refugee children despite reported predeparture antimalarial treatment. *Med J Aust* 2006;185:611.
375. Malaria in refugees from Tanzania: King County, Washington, 2007. *MMWR Morb Mortal Wkly Rep* 2008;57:869-72.
376. Cooke G, Hargreaves S, Natkunarajah J, et al. Impact on and use of an inner-city London Infectious Diseases Department by international migrants: a questionnaire survey. *BMC Health Serv Res* 2007;7:113.
377. Dias SF, Severo M, Barros H. Determinants of health care utilization by immigrants in Portugal. *BMC Health Serv Res* 2008;8:207.
378. Lenz K. Migrants in Germany: delay of diagnosis and treatment. *J Travel Med* 2006;13:133-7.
379. Eliades MJ, Shah S, Nguyen-Dinh P, et al. Malaria surveillance — United States, 2003. *MMWR Surveill Summ* 2005;54(SS02):25-40.
380. Smith AD, Bradley DJ, Smith V, et al. Imported malaria and high risk groups: observational study using UK surveillance data 1987–2006. *BMJ* 2008;337:a120.
381. Spinazzola F, Nicastri E, Vlassi C, et al. Imported malaria at Italy's National Institute for Infectious Diseases. *Eur J Clin Microbiol Infect Dis* 2007;26:175-9.
382. Recommendations for pre-departure presumptive treatment and directed treatment for malaria for all refugees from sub Saharan Africa. Atlanta (GA): Centers for Disease Control and Prevention; 2010. Available: www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/malaria-guidelines-overseas.html (accessed 2011 May 5).
383. Patten SB, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. *J Affect Disord* 2009;117(Suppl 1):S5-14.
384. Bland R. Depression and its management in primary care. *Can J Psychiatry* 2007;52:75-6.
385. Kirmayer LJ, Weinfeld M, Burgos G, et al. Use of health care services for psychological distress by immigrants in an urban multicultural milieu. *Can J Psychiatry* 2007;52:295-304.
386. Beiser M. Resettling refugees and safeguarding their mental health: lessons learned from the Canadian Refugee Resettlement Project. *Transcult Psychiatry* 2009;46:539-83.
387. Kandula NR, Kersey M, Lurie N. Assuring the health of immigrants: what the leading health indicators tell us. *Annu Rev Public Health* 2004;25:357-76.
388. MacMillan HL, Patterson CJ, Wathen CN, et al. Screening for depression in primary care: recommendation statement from the Canadian Task Force on Preventive Health Care. *CMAJ* 2005;172:33-5.
389. U.S. Preventive Services Task Force. Screening for depression: recommendations and rationale. *Ann Intern Med* 2002;136:760-4.
390. Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2009;151:784-92.
391. American Psychiatric Association. Practice guideline for the treatment of patients

- with major depressive disorder (revision). *Am J Psychiatry* 2000;157(Suppl):1-45.
392. *Depression: management of depression in primary and secondary care*. Clinical Guideline 23. London (UK): National Institute for Clinical Excellence; 2004.
 393. Patten SB, Wang JL, Williams JV, et al. Descriptive epidemiology of major depression in Canada. *Can J Psychiatry* 2006;51:84-90.
 394. Ali J. Mental health of Canada's immigrants. *Health Rep* 2002;13(Suppl):1-11.
 395. Stewart DE, Gagnon A, Saucier JF, et al. Postpartum depression symptoms in newcomers. *Can J Psychiatry* 2008;53:121-4.
 396. Zerkowicz P, Schinazi J, Katofsky L, et al. Factors associated with depression in pregnant immigrant women. *Transcult Psychiatry* 2004;41:445-64.
 397. Vesga-Lopez O, Blanco C, Keyes K, et al. Psychiatric disorders in pregnant and postpartum women in the United States. *Arch Gen Psychiatry* 2008;65:805-15.
 398. Gilbody S, Sheldon T, House A. Screening and case-finding instruments for depression: a meta-analysis. *CMAJ* 2008;178:997-1003.
 399. Mitchell AJ, Coyne JC. Do ultrashort screening instruments accurately detect depression in primary care? A pooled analysis and meta-analysis of 22 studies. *Br J Gen Pract* 2007;57:144-51.
 400. Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2002;136:765-76.
 401. O'Connor EA, Whitlock EP, Beil TL, et al. Screening for depression in adult patients in primary care settings: a systematic evidence review. *Ann Intern Med* 2009;151:793-803.
 402. Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. *Arch Intern Med* 2006;166:2314-21.
 403. Wells K, Sherbourne C, Schoenbaum M, et al. Five-year impact of quality improvement for depression: results of a group-level randomized controlled trial. *Arch Gen Psychiatry* 2004;61:378-86.
 404. Schraufnagel TJ, Wagner AW, Miranda J, et al. Treating minority patients with depression and anxiety: What does the evidence tell us? *Gen Hosp Psychiatry* 2006;28:27-36.
 405. Kirmayer LJ. Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. *J Clin Psychiatry* 2001;62(Suppl 13):22-8, discussion 29-30.
 406. Kirmayer LJ, Robbins JM, Dworkind M, et al. Somatization and the recognition of depression and anxiety in primary care. *Am J Psychiatry* 1993;150:734-41.
 407. *Reproductive mental health guideline 4. Mental illness during the perinatal period: major depression*. Vancouver (BC): British Columbia Reproductive Care Program; 2003.
 408. McQueen K, Montgomery P, Lappan-Gracon S, et al. Evidence-based recommendations for depressive symptoms in postpartum women. *J Obstet Gynecol Neonatal Nurs* 2008;37:127-36.
 409. ACOG Committee on Health Care for Underserved Women. ACOG Committee Opinion No. 343: psychosocial risk factors: perinatal screening and intervention. *Obstet Gynecol* 2006;108:469-77.
 410. U.S. Preventive Services Task Force. Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement. *Pediatrics* 2009;123:1223-8.
 411. Williams SB, O'Connor EA, Eder M, et al. Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force. *Pediatrics* 2009;123:e716-35.
 412. Minas H, Klimidis S, Ranieri N, et al. Relative prevalence of psychological morbidity in older immigrants. *Int J Cult Ment Health* 2008;1:58-72.
 413. Scheppers E, van Dongen E, Dekker J, et al. Potential barriers to the use of health services among ethnic minorities: a review. *Fam Pract* 2006;23:325-48.
 414. Chen AW, Kazanjian A, Wong H. Why do Chinese Canadians not consult mental health services: health status, language or culture? *Transcult Psychiatry* 2009;46:623-41.
 415. Betancourt JR, Green AR, Carrillo JE, et al. Cultural competence and health care disparities: key perspectives and trends. *Health Aff (Millwood)* 2005;24:499-505.
 416. Goode TD, Dunne MC, Bronheim SM. *The evidence base for cultural and linguistic competency in health care*. New York (NY): The Commonwealth Fund; 2006.
 417. Beach MC, Price EG, Gary TL, et al. Cultural competence: a systematic review of health care provider educational interventions. *Med Care* 2005;43:356-73.
 418. Katon WJ, Seelig M. Population-based care of depression: team care approaches to improving outcomes. *J Occup Environ Med* 2008;50:459-67.
 419. Kates N, Mach M. Chronic disease management for depression in primary care: a summary of the current literature and implications for practice. *Can J Psychiatry* 2007;52:77-85.
 420. Whitley R, Kirmayer L, Groleau D. Understanding immigrants' reluctance to use mental health services: a qualitative study from Montreal. *Can J Psychiatry* 2006;51:205-9.
 421. Steel Z, Chey T, Silove D, et al. Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. *JAMA* 2009;302:537-49.
 422. National Collaborating Centre for Mental Health, Royal College of Psychiatrists' Research Unit. *Post-traumatic stress disorder. The management of PTSD in adults and children in primary and secondary care*. National Clinical Practice Guideline no. 26. London (UK): Gaskell and the British Psychological Society; 2005.
 423. Ipser J, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. *Cochrane Database Syst Rev* 2006;(4):CD005473.
 424. Stein DJ, Ipser J, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). *Cochrane Database Syst Rev* 2006;(1):CD002795.
 425. Roberts NP, Kitchiner NJ, Knardly J, et al. Early psychological interventions to treat acute traumatic stress symptoms. *Cochrane Database Syst Rev* 2010;(3):CD007944.
 426. Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). *Cochrane Database Syst Rev* 2007;(3):CD003388.
 427. Foa EB, Keane TM, Friedman MJ, et al., editors. *Effective treatment for PTSD: practice guidelines from the International Society for Traumatic Stress*. 2nd ed. New York (NY): The Guilford Press; 2009.
 428. Crumlish N, O'Rourke K. A systematic review of treatments for post-traumatic stress disorder among refugees and asylum-seekers. *J Nerv Ment Dis* 2010;198:237-51.
 429. Lustig SL, Kia-Keating M, Knight WG, et al. Review of child and adolescent refugee mental health. *J Am Acad Child Adolesc Psychiatry* 2004;43:24-36.
 430. Carlson JM. *Mental health and health-related quality of life in tortured refugees*. Copenhagen (Denmark): University of Copenhagen; 2005.
 431. Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. *Am J Psychiatry* 2004;161:3-31.
 432. Beiser M. *Strangers at the gate: the "boat people's" first ten years in Canada*. Toronto (ON): University of Toronto Press; 1999.
 433. Rousseau C, Drapeau A. Are refugee children an at-risk group? A longitudinal study of Cambodian adolescents. *J Refug Stud* 2003;16:67-81.
 434. Rousseau C, Drapeau A. Premigration exposure to political violence among independent immigrants and its association with emotional distress. *J Nerv Ment Dis* 2004;192:852-6.
 435. Davis SM, Whitworth JD, Rickett K. What are the most practical primary care screens for post-traumatic stress disorder? *J Fam Pract* 2009;58:100-1.
 436. Prins A, Quimette P, Kimerling R, et al. The primary care PTSD screen (PC-PTSD): development and operating characteristics. *Prim Care Psychiatry* 2003;9:9-14.
 437. Hackmann A, Ehlers A, Speckens A, et al. Characteristics and content of intrusive memories of PTSD and the changes with treatment. *J Trauma Stress* 2004;17:231-40.
 438. Moreno A, Grodin MA. Torture and its neurological sequelae. *Spinal Cord* 2002;40:213-23.
 439. Guidelines for mental health screening during the domestic medical examination for newly arrived refugees. Atlanta (GA): Centers for Disease Control and Prevention; 2011. Available: www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/mental-health-screening-guidelines.html (accessed 2011 July 1).
 440. Prévention de la violence. In: Cinquantième Assemblée mondiale de la santé; 1997 May 5-14; Geneva. Available: www.who.int/violence_injury_prevention/resources/publications/en/WHA5019_fre.pdf
 441. Trocmé N, Fallon B, MacLaurin B, et al. Canadian incidence study of reported child abuse and neglect — 2003: major findings. Ottawa (ON): Minister of Public Works and Government Services Canada; 2005.
 442. Wyatt GE, Peters SD. Issues in the definition of child sexual abuse in prevalence research. *Child Abuse Negl* 1986;10:231-40.
 443. Nygren P, Nelson HD, Klein J. Screening children for family violence: a review of the evidence for the US Preventive Services Task Force. *Ann Fam Med* 2004;2:161-9.
 444. MacMillan HL; Canadian Task Force on Preventive Health Care. Preventive health care, 2000 update: prevention of child maltreatment. *CMAJ* 2000;163:1451-8.
 445. Peters R, Barlow J. Systematic review of instruments designed to predict child maltreatment during the antenatal and postnatal periods. *Child Abuse Rev* 2003;12:416-39.
 446. Barlow J, Johnston I, Kendrick D, et al. Individual and group-based parenting programmes for the treatment of physical child abuse and neglect. *Cochrane Database Syst Rev* 2006;(3):CD005463.
 447. Macdonald G, Higgins JPT, Ramchandani P. Cognitive-behavioural interventions for children who have been sexually abused. *Cochrane Database Syst Rev* 2006;(4):CD001930.
 448. Hill RB. *Synthesis of research on disproportionality in child welfare: an update*. Seattle (WA): Casey-CSSP Alliance for Racial Equity; 2006.
 449. Trocmé N, Knoke D, Fallon B, et al. *CIS-2003: Understanding the case substantiation decision*. Ottawa (ON): Public Health Agency of Canada; 2006.
 450. Elliott K, Urquiza A. Ethnicity, culture, and child maltreatment. *J Soc Issues* 2006;62:787-809.
 451. Dezerotes DM, Poertner J, Testa MF, editors. *Race matters in child welfare: the overrepresentation of African Americans in the system*. Washington (DC): Child Welfare League of America Press; 2005.
 452. Eckenrode J, Powers J, Doris J, et al. Substantiation of child abuse and neglect reports. *J Consult Clin Psychol* 1988;56:9-16.
 453. Sedlak A, Schultz D. Racial differences in child protective services investigation of abused and neglected children. In: Dezerotes D, Testa MF, Poertner J, editors. *Race matters in child welfare: the overrepresentation of African Americans in the system*. Washington (DC): Child Welfare League of America Press; 2005. p. 97-118.
 454. Terao SY, Borrego J Jr, Urquiza AJ. A reporting and response model for culture and child maltreatment. *Child Maltreat* 2001;6:158-68.
 455. Zellman GL. The impact of case characteristics on child abuse reporting decisions. *Child Abuse Negl* 1992;16:57-74.
 456. U.S. Preventive Service Task Force. Screening for family and intimate partner violence: recommendation statement. *Ann Intern Med* 2004;140:382-6.
 457. Woodman J, Pitt M, Wentz R, et al. Performance of screening tests for child physical abuse in accident and emergency departments. *Health Technol Assess* 2008;12:iii, xi-xiii, 1-95.

458. Morh WK, Tulman LJ. Children exposed to violence: measurement considerations within an ecological framework. *ANS Adv Nurs Sci* 2000;23:59-68.
459. Olds DL, Eckenrode J, Henderson CR Jr, et al. Long-term effects of home visitation on maternal life course and child abuse and neglect: fifteen-year follow-up of a randomized trial. *JAMA* 1997;278:637-43.
460. Mikton C, Butchart A. Child maltreatment prevention: a systematic review of reviews. *Bull World Health Organ* 2009;87:353-61.
461. Olds D, Henderson C, Kitzman H, et al. Effects of prenatal and infancy nurse home visitation on surveillance of child maltreatment. *Pediatrics* 1995;95:365-72.
462. Kitzman H, Olds DL, Henderson CR Jr, et al. Effect of prenatal and infancy home visitation by nurses on pregnancy outcomes, childhood injuries, and repeated child-bearing: a randomized controlled trial. *JAMA* 1997;278:644-52.
463. Macmillan HL, Wathen CN, Barlow J, et al. Interventions to prevent child maltreatment and associated impairment. *Lancet* 2009;373:250-66.
464. Cohen JA, Mannarino AP, Murray LK, et al. Psychosocial interventions for maltreated and violence-exposed children. *J Soc Issues* 2006;62:737-66.
465. Chaffin M, Silovsky JF, Funderburk B, et al. Parent-child interaction therapy with physically abusive parents: efficacy for reducing future abuse reports. *J Consult Clin Psychol* 2004;72:500-10.
466. Larrière MC, Tourigny M, Bouchard C. Child physical abuse with and without other forms of maltreatment: dysfunctionality versus dysnormality. *Child Maltreat* 2007;12:303-13.
467. Dubowitz H, Feigelman S, Lane W, et al. Pediatric primary care to help prevent child maltreatment: the Safe Environment for Every Kid (SEEK) model. *Pediatrics* 2009;123:858-64.
468. American Academy of Pediatrics, Committee on Child Abuse and Neglect. Guidelines for the evaluation of sexual abuse of children. *Pediatrics* 1991;87:254-60.
469. American Medical Association. Diagnostic and treatment guidelines on child sexual abuse. *Arch Fam Med* 1993;2:19-27.
470. American Medical Association. Diagnostic and treatment guidelines on child physical abuse and neglect. *Arch Fam Med* 1992;1:187-97.
471. Violence prevention focused on children and youth: early childhood home visitation. In: *Guide to community preventive services*. Atlanta (GA): Centers for Disease Control and Prevention; 2010. Available: www.thecommunityguide.org/violence/home/index.html (accessed 2011 May 5).
472. Ramsay J, Carter Y, Davidson L, et al. Advocacy interventions to reduce or eliminate violence and promote the physical and psychosocial well-being of women who experience intimate partner abuse. *Cochrane Database Syst Rev* 2009;(3):CD005043.
473. Canadian Centre for Justice Statistics. *A profile of criminal victimization: results of the 1999 General Social Survey*. Ottawa (ON): The Centre; 2000. Cat. no. 85-553-XIE. Available: www.statcan.gc.ca/pub/85-553-x/85-553-x1999001-eng.pdf (accessed 2011 May 6).
474. *Family violence in Canada: a statistical profile*. Ottawa (ON): Statistics Canada; 2002. Cat. no. 85-224-XWE.
475. Wathen CN, Macmillan HL. Interventions for violence against women: scientific review. *JAMA* 2003;289:589-600.
476. Nelson HD, Nygren P, McInerney Y. *Screening for family and intimate partner violence: systematic evidence review*. Rockville (MD): US Preventive Services Task Force; 2004.
477. Feder G, Ramsay J, Dunne D, et al. How far does screening women for domestic (partner) violence in different health-care settings meet criteria for a screening programme? Systematic reviews of nine UK National Screening Committee criteria. *Health Technol Assess* 2009;13:iii-iv, xi-xiii, 1-113, 137-347.
478. Macmillan HL, Wathen CN, Jamieson E, et al. Screening for intimate partner violence in health care settings: a randomized trial. *JAMA* 2009;302:493-501.
479. Rabin RF, Jennings JM, Campbell JC, et al. Intimate partner violence screening tools: a systematic review. *Am J Prev Med* 2009;36:439-45.
480. Brownridge DA, Halli SS. Double jeopardy: violence against immigrant women in Canada. *Violence Vict* 2002;17:455-71.
481. Hyman I, Forte T, Du Mont J, et al. The association between length of stay in Canada and intimate partner violence among immigrant women. *Am J Public Health* 2006;96:654-9.
482. Ahmad F, Ali M, Stewart DE. Spousal-abuse among Canadian immigrant women. *J Immigr Health* 2005;7:239-46.
483. Macmillan HL, Wathen CN, Jamieson E. Approaches to screening for intimate partner violence in health care settings: a randomized trial. *JAMA* 2006;296:530-6.
484. Ahmad F, Hogg-Johnson S, Stewart DE, et al. Computer-assisted screening for intimate partner violence and control: a randomized trial. *Ann Intern Med* 2009;151:93-102.
485. Charniak D, Grant L, Mason R, et al. Intimate partner violence consensus statement. *J Obstet Gynaecol Can*. 2005;27:365-388.
486. Taket A, Wathen CN, Macmillan H. Should health professionals screen all women for domestic violence? *PLoS Med* 2004;4. [Epub 2004 Oct 19].
487. Macmillan HL, Wathen CN. *Prevention and treatment of violence against women: systematic review and recommendations*. London (ON): Canadian Task Force on Preventive Health Care; 2001.
488. Glass N, Dearwater S, Campbell J. Intimate partner violence screening and intervention: data from eleven Pennsylvania and California community hospital emergency departments. *J Emerg Nurs* 2001;27:141-9.
489. Furbee PM, Sikora R, Williams JM, et al. Comparison of domestic violence screening methods: a pilot study. *Ann Emerg Med* 1998;31:495-501.
490. Chang JC, Decker M, Moracco KE, et al. What happens when health care providers ask about intimate partner violence? A description of consequences from the perspectives of female survivors. *J Am Med Womens Assoc* 2003;58:76-81.
491. Sullivan CM, Bybee DI. Reducing violence using community-based advocacy for women with abusive partners. *J Consult Clin Psychol* 1999;67:43-53.
492. Sullivan CM. Using the ESID model to reduce intimate male violence against women. *Am J Community Psychol* 2003;32:295-303.
493. Sullivan CM, Tan C, Basta J, et al. An advocacy intervention program for women with abusive partners: initial evaluation. *Am J Community Psychol* 1992;20:309-32.
494. Hyman I, Forte T, Du Mont J, et al. Help-seeking rates for intimate partner violence (IPV) among Canadian immigrant women. *Health Care Women Int* 2006;27:682-94.
495. Dutton MA, Orloff LE, Aguilar Hass G. Characteristics of help-seeking behaviors, resources and service needs of battered immigrant latinas: legal and policy implications. *Georgetown J Poverty Law Policy* 2000;7:245-305.
496. Bhuyan R, Senturia K. Understanding domestic violence resource utilization and survivor solutions among immigrant and refugee women: introduction to the special issue. *J Interpers Violence* 2005;20:895-901.
497. Crandall M, Senturia K, Sullivan M, et al. "No way out": Russian-speaking women's experiences with domestic violence. *J Interpers Violence* 2005;20:941-58.
498. Sullivan M, Senturia K, Negash T, et al. "For us it is like living in the dark": Ethiopian women's experiences with domestic violence. *J Interpers Violence* 2005;20:922-40.
499. *Diabetes report 2005. Assessing provincial, territorial and federal government policies and programs for Canadians with diabetes*. Ottawa (ON): Canadian Diabetes Association; 2009. Available: www.diabetes.ca/files/diabetesreport2005/CDA-diabetesreport-2005-en.pdf (accessed 2009 Oct. 27).
500. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. *Ann Intern Med* 1996;125:221-32.
501. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2008;148:846-54.
502. Cauchi S, ElAchhab Y, Choquet H, et al. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. *J Mol Med* 2007;85:777-82.
503. Kunz R, Bork JP, Fritsche L, et al. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. *J Am Soc Nephrol* 1998;9:1653-63.
504. Ludovico O, Pellegrini F, Di Paola R, et al. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. *Obesity (Silver Spring)* 2007;15:1076-81.
505. Peek ME, Cargill A, Huang ES. Diabetes health disparities: a systematic review of health care interventions. *Med Care Res Rev* 2007;64(5 Suppl):101S-56S.
506. Kirk JK, D'Agostino RB Jr, Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. *Diabetes Care* 2006;29:2130-6.
507. Caban A, Walker EA. A systematic review of research on culturally relevant issues for Hispanics with diabetes. *Diabetes Educ* 2006;32:584-95.
508. Whitmore R. Culturally competent interventions for Hispanic adults with type 2 diabetes: a systematic review. *J Transcult Nurs* 2007;18:157-66.
509. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. *Can J Diabetes* 2008;32(Suppl 1):S1-201.
510. US Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. *Ann Intern Med* 2003;138:212-4.
511. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet* 2009;373:1765-72.
512. Kandula NR, Diez-Roux AV, Chan C, et al. Association of acculturation levels and prevalence of diabetes in the multi-ethnic study of atherosclerosis (MESA). *Diabetes Care* 2008;31:1621-8.
513. Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). *Diabetes Care* 2001;24:1167-74.
514. Koopman RJ, Mainous AG 3rd, Diaz VA, et al. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. *Ann Fam Med* 2005;3:60-3.
515. Ramachandran A, Snehalatha C, Latha E, et al. Rising prevalence of NIDDM in an urban population in India. *Diabetologia* 1997;40:232-7.
516. Vazquez G, Duval S, Jacobs DR Jr, et al. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. *Epidemiol Rev* 2007;29:115-28.
517. Sargeant LA, Bennett FI, Forrester TE, et al. Predicting incident diabetes in Jamaica: the role of anthropometry. *Obes Res* 2002;10:792-8.
518. Clinical Guidelines Taskforce. *Global guideline for type 2 diabetes*. Brussels (Belgium): International Diabetes Federation; 2005. Available: www.idf.org/webdata/docs/IDF%20GGT2D.pdf (accessed 2011 May 6).
519. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome: a new worldwide definition. A consensus statement from the International Diabetes Federation. *Diabet Med* 2006;23:469-80.
520. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. *Diabet Med* 2007;24:333-43.
521. Harris R, Donahue K, Rathore SS, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2003;138:215-29.
522. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering

- regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med* 2005;165:1410-9.
523. Orozco LJ, Buchleiner AM, Gimenez-Perez G, et al. Exercise or exercise and diet for preventing type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2008;(3):CD003054.
 524. Glazier RH, Bajcar J, Kennie NR, et al. A systematic review of interventions to improve diabetes care in socially disadvantaged populations. *Diabetes Care* 2006;29:1675-88.
 525. Norris SL, Kansagara D, Bougatso C, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2008;148:855-68.
 526. American Diabetes Association. Standards of medical care in diabetes — 2010. *Diabetes Care* 2010;33(Suppl 1):S11-S61.
 527. Recommendations to prevent and control iron deficiency in the United States. *MMWR Recomm Rep* 1998;47:1-29.
 528. Sachdev H, Gera T, Nestel P. Effect of iron supplementation on physical growth in children: systematic review of randomized controlled trials. *Public Health Nutr* 2006;9:904-20.
 529. Sachdev H, Gera T, Nestel P. Effect of iron supplementation on mental and motor development in children: systematic review of randomised controlled trials. *Public Health Nutr* 2005;8:117-32.
 530. Li R, Chen X, Yan H, et al. Functional consequences of iron supplementation in iron-deficient female cotton mill workers in Beijing, China. *Am J Clin Nutr* 1994;59:908-13.
 531. U.S. Preventive Services Task Force. *Screening for iron deficiency anemia — including iron supplementation for children and pregnant women: recommendation statement*. Rockville (MD): Agency for Healthcare Research and Quality; 2006. Available: www.ahrq.gov/clinic/uspstf06/ironsc/ironrs.htm (accessed 2008 Jun. 30).
 532. Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. *Am J Clin Nutr* 2007;85:778-87.
 533. Gera T, Sachdev HP. Effect of iron supplementation on incidence of infectious illness in children: systematic review. *BMJ* 2002;325:1-10.
 534. Hassan K, Sullivan KM, Yip R, et al. Factors associated with anemia in refugee children. *J Nutr* 1997;127:2194-8.
 535. Brotanek JM, Gosz J, Weitzman M, et al. Iron deficiency in early childhood in the United States: risk factors and racial/ethnic disparities. *Pediatrics* 2007;120:568-75.
 536. López-Vélez R, Huerga H, Turrientes MC. Infectious disease in immigrants from the perspective of a tropical medicine referral unit. *Am J Trop Med Hyg* 2003;69:115-21.
 537. Pena-Rosas JP, Viteri FE. Effects of routine oral iron supplementation with or without folic acid for women during pregnancy. *Cochrane Database Syst Rev* 2007;(3):CD004736.
 538. Reveiz GL, Cuervo LG. Treatments for iron-deficiency anaemia in pregnancy. *Cochrane Database Syst Rev* 2007;(1):CD003094.
 539. Sloan NL, Jordan E, Winikoff B. Effects of iron supplementation on maternal hematologic status in pregnancy. *Am J Public Health* 2002;92:288-93.
 540. Feightner JW. Prevention of iron deficiency anemia in infants. In: *Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care*. Ottawa (ON): Health Canada; 1994. p. 244-55.
 541. Basta SS, Soekirman, Karyadi D, et al. Iron deficiency anemia and the productivity of adult males in Indonesia. *Am J Clin Nutr* 1979;32:916-25.
 542. Edgerton VR, Gardner GW, Ohira Y, et al. Iron-deficiency anaemia and its effect on worker productivity and activity patterns. *BMJ* 1979;2:1546-9.
 543. Menon P, Ruel MT, Loechl CU, et al. Micronutrient sprinkles reduce anemia among 9- to 2-mo-old children when delivered through an Integrated Health and Nutrition Program in rural Haiti. *J Nutr* 2007;137:1023-30.
 544. Anderson J, Kirkham RS. Constructing nation: the gendering and racialization of the Canadian health care system. In: Strong-Boag V, Grace S, Eisenberg A, et al., editors. *Painting the study: essays on race, gender and the constructions of Canada*. Vancouver (BC): UBC Press; 1998. p. 242-61.
 545. World Health Organization. *Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers*. Geneva (Switzerland): The Organization; 2001. Available: www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/WHO_NHD_01.3/en/index.html (accessed 2009 Nov. 1).
 546. Petersen PE, Bourgeois D, Ogawa H, et al. The global burden of oral diseases and risks to oral health. *Bull World Health Organ* 2005;83:661-9.
 547. Kay E, Locker D. A systematic review of the effectiveness of health promotion aimed at improving oral health. *Community Dent Health* 1998;15:132-44.
 548. Sutherland S, Matthews DC. Emergency management of acute apical periodontitis in the permanent dentition: a systematic review of the literature. *J Can Dent Assoc* 2003;69:160. [to be incorporated into numbering scheme]
 549. Fedorowicz Z, Keenan JV, Farman AG, et al. Antibiotic use for irreversible pulpitis. *Cochrane Database Syst Rev* 2005;(2):CD004969.
 550. Azarpazhooh A, Main PA. Fluoride varnish in the prevention of dental caries in children and adolescents: a systematic review. *J Can Dent Assoc* 2008;74:73-9.
 551. Marinho VC, Higgins JP, Sheiham A, et al. Combinations of topical fluoride (toothpastes, mouthrinses, gels, varnishes) versus single topical fluoride for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2004;(1):CD002781.
 552. Marinho VC, Higgins JP, Sheiham A, et al. One topical fluoride (toothpastes, or mouthrinses, or gels, or varnishes) versus another for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2004;(1):CD002780.
 553. Marinho VC, Higgins JP, Logan S, et al. Fluoride mouthrinses for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2003;(3):CD002284.
 554. Marinho VCC. Topical fluoride (toothpastes, mouthrinses, gels or varnishes) for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2003;(4):CD002782.
 555. Ahovuo-Saloranta A, Hiiri A, Nordblad A, et al. Pit and fissure sealants for preventing dental decay in the permanent teeth of children and adolescents. *Cochrane Database Syst Rev* 2004;(4):CD001830.
 556. Hiiri A, Ahovuo-Saloranta A, Nordblad A, et al. Pit and fissure sealants versus fluoride varnishes for preventing dental decay in children and adolescents. *Cochrane Database Syst Rev* 2010;(3):CD003067.
 557. Griffin SO, Oong E, Kohn W, et al.; CDC Dental Sealant Systematic Review Work Group. The effectiveness of sealants in managing caries lesions. *J Dent Res* 2008;87:169-74.
 558. Griffin SO, Regnier E, Griffin PM, et al. Effectiveness of fluoride in preventing caries in adults. *J Dent Res* 2007;86:410-5.
 559. Ricketts DN, Kidd EA, Innes N, et al. Complete or ultraconservative removal of decayed tissue in unfilled teeth. *Cochrane Database Syst Rev* 2006;(3):CD003808.
 560. Locker D, Clarke M, Murray H. Oral health status of Canadian-born and immigrant adolescents in North York, Ontario. *Community Dent Oral Epidemiol* 1998;26:177-81.
 561. Full report: *Emergency management of acute apical periodontitis in adults*. Canadian Collaboration on Clinical Practice Guidelines in Dentistry; 2003. Available: www.cda-adc.ca/_files/dental_profession/practising/clinical_practice_guidelines/FULL_VERSION.pdf (accessed 2010 Nov. 5).
 562. Barden J, Edwards JE, McQuay HJ, et al. Relative efficacy of oral analgesics after third molar extraction. *Br Dent J* 2004;197:407-11; discussion 397.
 563. Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. *Cochrane Database Syst Rev* 2008;(1):CD000396.
 564. Bedos C, Brodeur J, Benigeri M, et al. [Utilization of preventive dental services by recent immigrants in Quebec]. *Can J Public Health* 2004;95:219-23. French.
 565. Cruz GD, Shore R, Le Geros RZ, et al. Effect of acculturation on objective measures of oral health in Haitian immigrants in New York City. *J Dent Res* 2004;83:180-4.
 566. Ma M, Lindsell CJ, Jauch EC, et al. Effect of education and guidelines for treatment of uncomplicated dental pain on patient and provider behavior. *Ann Emerg Med* 2004;44:323-9.
 567. Lewis CW, Grossman DC, Domoto PK, et al. The role of the pediatrician in the oral health of children: a national survey. *Pediatrics* 2000;106:E84.
 568. Lawrence HP, Binguis D, Douglas J, et al. A 2-year community-randomized controlled trial of fluoride varnish to prevent early childhood caries in aboriginal children. *Community Dent Oral Epidemiol* 2008;36:503-16.
 569. Scottish Intercollegiate Guidelines Network. *SIGN 47: Preventing dental caries in children at high caries risk targeted prevention of dental caries in the permanent teeth of 6-16 year olds presenting for dental care*. Edinburgh (Scotland): The Network; 2000. Available: www.sign.ac.uk/guidelines/fulltext/47/index.html (accessed 2010 Nov. 5).
 570. Scottish Intercollegiate Guidelines Network. *SIGN 83: Prevention and management of dental decay in the pre-school child*. Edinburgh (Scotland): The Network; 2005. Available: www.sign.ac.uk/pdf/sign83.pdf (accessed 2010 Nov. 5).
 571. Chiang PP, Keeffe JE, Le Mesurier RT, et al. Global burden of disease and visual impairment. *Lancet* 2006;368:365.
 572. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* 2006;367:1747-57.
 573. West SK, Munoz B, Rubin GS, et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury Eye Evaluation. *Invest Ophthalmol Vis Sci* 1997;38:72-82.
 574. Rovner BW, Ganguli M. Depression and disability associated with impaired vision: the MoVies Project. *J Am Geriatr Soc* 1998;46:617-9.
 575. Klein BEK, Klein R, Lee KE, et al. Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time. *Ophthalmology* 1998;105:160-4.
 576. Dandona L, Dandona R. What is the global burden of visual impairment? *BMC Med* 2006;4:6.
 577. Vedula SS, Krzysztolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. *Cochrane Database Syst Rev* 2008;(2):CD005139.
 578. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. *Arch Ophthalmol* 2001;119:1417-36.
 579. Taylor HR, Keeffe JE. World blindness: a 21st century perspective. *Br J Ophthalmol* 2001;85:261-6.
 580. Smeeth L, Iliffe S. Community screening for visual impairment in the elderly. *Cochrane Database Syst Rev* 2006;(3):001054.
 581. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006;90:262-7.
 582. Varma R, Wang MY, Ying-Lai M, et al. The prevalence and risk indicators of uncorrected refractive error and unmet refractive need in Latinos: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci* 2008;49:5264-73.
 583. Varma R, Mohanty SA, Deneen J, et al. Burden and predictors of undetected eye disease in Mexican-Americans: the Los Angeles Latino Eye Study. *Med Care*

- 2008;46:497-506.
584. Wilson MR, Eezzuemhoi DR. Ophthalmologic disorders in minority populations. *Med Clin North Am* 2005;89:795-804.
 585. Munoz B, West SK, Rodriguez J, et al. Blindness, visual impairment and the problem of uncorrected refractive error in a Mexican-American population: Proyecto VER. *Invest Ophthalmol Vis Sci* 2002;43:608-14.
 586. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA* 1991;266:369-74.
 587. Harris MI, Klein R, Cowie CC, et al. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. *Diabetes Care* 1998;21:1230-5.
 588. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. *N Engl J Med* 1991;325:1412-7.
 589. Vitale S, Cotch MF, Sperduto RD. Prevalence of visual impairment in the United States. *JAMA* 2006;295:2158-63.
 590. Ederer F, Krueger DE, Mowery RL, et al. Lessons from the Visual Acuity Impairment Survey pilot study. *Am J Public Health* 1986;76:160-5.
 591. Ferris FL 3rd, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. *Am J Ophthalmol* 1982;94:91-6.
 592. Loewenstein JJ, Palmberg PF, Connett JE, et al. Effectiveness of a pinhole method for visual acuity screening. *Arch Ophthalmol* 1985;103:222-3.
 593. Williams C, Harrad RA, Harvey I, et al. Screening for amblyopia in preschool children: results of a population-based, randomised controlled trial. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. *Ophthalmic Epidemiol* 2001;8:279-95.
 594. *Foundations for a Canadian Vision Health Strategy: towards preventing avoidable blindness and promoting vision health*. Toronto (ON): National Coalition for Vision Health; 2007.
 595. Lewallen S, Courtright P. Gender and use of cataract surgical services in developing countries. *Bull World Health Organ* 2002;80:300-3.
 596. Holden BA, Sulaiman S, Knox K. The challenge of providing spectacles in the developing world. *Community Eye Health* 2000;13:9-10.
 597. Feldman W, Fletcher AE. Well-baby care in the first two years of life. In: Goldbloom R, editor. *The Canadian Task Force on the Periodic Health Examination. The Canadian guide to clinical preventive health care*. Ottawa (ON): Health Canada; 1994. p. 258-66.
 598. Feightner JW. Routine preschool screening for visual and hearing problems. In: Goldbloom R, editor. *The Canadian Task Force on the Periodic Health Examination. The Canadian guide to clinical preventive health care*. Ottawa (ON): Health Canada; 1994. p. 298-304.
 599. Eye examination in infants, children, and young adults by pediatricians. *Pediatrics* 2003;111(4 pt 1):902-7.
 600. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1995 update: 3. Screening for visual problems among elderly patients. *CMAJ* 1995;152:1211-22.
 601. Blustein JFD. Screening for visual impairment. In: Digiseppi C, Atkins D, Woolfe S, et al., editors. *Guide to clinical preventive services—report of the U.S. Preventive Services Task Force*. 2nd ed. Alexandria (VA): International Medical Publishing; 1996. p. 373-82.
 602. Dandona L, Dandona R. Revision of visual impairment definitions in the International Statistical Classification of Diseases. *BMC Med* 2006;4:7.
 603. Atkins D, Patterson C. Screening for glaucoma. In: Digiseppi C, Atkins D, Woolfe S, et al., editors. *Guide to clinical preventive services—report of the U.S. Preventive Services Task Force*. 2nd ed. Alexandria (VA): International Medical Publishing; 1996. p. 383-91.
 604. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. *Can J Diabetes* 2003;27:S76-80.
 605. *Programme of action of the United Nations International Conference on Population and Development (ICPD)*. 1994 Sept. 5-13; Cairo (Egypt). New York (NY): United Nations Department of Public Information; 1995.
 606. Glasier A, Gulmezoglu AM, Schmid GP, et al. Sexual and reproductive health: a matter of life and death. *Lancet* 2006;368:1595-607.
 607. Ross JA, Winfrey WL. Unmet need for contraception in the developing world and former Soviet Union: an updated estimate. *Int Fam Plan Perspect* 2002;28:138-43.
 608. Sedgh G, Hussain R, Bankole A, et al. *Women with an unmet need for contraception in developing countries and their reasons for not using a method*. New York (NY) and Washington (DC): Guttmacher Institute; 2007. Available: www.policyarchive.org/handle/10207/5945 (accessed 2010 Mar. 9).
 609. Moos MK, Bartholomew NE, Lohr KN. Counseling in the clinical setting to prevent unintended pregnancy: an evidence-based research agenda. *Contraception* 2003;67:115-32.
 610. Paine K, Thorogood M, Wellings K. The impact of the quality of family planning services on safe and effective contraceptive use: a systematic literature review. *Hum Fertil (Camb)* 2000;3:186-93.
 611. Becker D, Koenig MA, Kim YM, et al. The quality of family planning services in the United States: findings from a literature review. *Perspect Sex Reprod Health* 2007;39:206-15.
 612. U.S. Preventive Services Task Force. Counseling to prevent unintended pregnancy. In: *Guide to clinical preventive services*. 2nd ed. Rockville (MD): Agency for Healthcare Research and Quality; 1996. p. 739-53.
 613. *One to one interventions to reduce the transmission of sexually transmitted infections (STIs) including HIV, and to reduce the rate of under 18 conceptions, especially among vulnerable and at risk groups*. NICE Public Health Intervention Guidance 3. London (UK): National Institute for Health and Clinical Excellence; 2007. Available: www.nice.org.uk/PHI003 (accessed 2010 Mar. 9).
 614. Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. *Contraception* 2001;63:143-6.
 615. Shlay JC, Mayhugh B, Foster M, et al. Initiating contraception in sexually transmitted disease clinic setting: a randomized trial. *Am J Obstet Gynecol* 2003;189:473-81.
 616. Winter L, Breckenmaker LC. Tailoring family planning services to the special needs of adolescents. *Fam Plann Perspect* 1991;23:24-30.
 617. Nawar L, Kharboush I, Ibrahim MA, et al. *Impact of improved client-provider interaction on women's achievement of fertility goals in Egypt*. FRONTIERS final report. Washington (DC): Population Council; 2004. Available: www.popcouncil.org/pdfs/frontiers/FR_FinalReports/Egypt_CPI.pdf (accessed 2010 Mar. 9).
 618. Mendez F, Lopez F, Brambila C, et al. Screening family planning needs: an operations research project in Guatemala. *BMC Int Health Hum Rights* 2004;4:2.
 619. Foreit JR, Vernon R, Hamel PR. *Use of systematic screening to increase the provision of reproductive health services in Bolivia*. FRONTIERS final report. Washington (DC): Population Council; 2005. Available: www.popcouncil.org/pdfs/frontiers/FR_FinalReports/Bolivia_Screen.pdf (accessed 2010 Mar. 9).
 620. Lindstrom DP, Hernandez CH. Internal migration and contraceptive knowledge and use in Guatemala. *Int Fam Plan Perspect* 2006;32:146-53.
 621. Wolff H, Stalder H, Epiney M, et al. Health care and illegality: a survey of undocumented pregnant immigrants in Geneva. *Soc Sci Med* 2005;60:2149-54.
 622. Jones RK, Finer LB, Singh S. *Characteristics of US abortion patients, 2008*. New York (NY): Guttmacher Institute; 2010.
 623. Moreau C, Bouyer J, Gilbert F, et al. Social demographic and situation characteristics associated with inconsistent use of oral contraceptive; evidence from France. *Perspect Sex Reprod Health* 2006;38:190-6.
 624. Steiner MJ, Dalebout S, Condom S, et al. Understanding risk: a randomized controlled trial of communicating contraceptive effectiveness. *Obstet Gynecol* 2003;102:709-17.
 625. *Medical eligibility criteria for contraceptive use*. 3rd ed. Geneva (Switzerland): World Health Organization; 2004. Available: <http://whqlibdoc.who.int/publications/2004/9241562668.pdf> (accessed 2010 Mar. 9).
 626. *World contraceptive use 2007*. New York (NY): United Nations, Department of Economic and Social Affairs, Population Division; 2007. Available: www.un.org/esa/population/publications/contraceptive2007/contraceptive_2007_table.pdf (accessed 2009 Aug. 24).
 627. Gagnon A, Merry L, Robinson C. A systematic review of refugee women's reproductive health. *Refuge Can Period Refug* 2002;21:6-17.
 628. Busza J, Lush L. Planning reproductive health in conflict: a conceptual framework. *Soc Sci Med* 1999;49:155-71.
 629. Stephenson R, Baschieri A, Clements S, et al. Contextual influences on modern contraceptive use in sub-Saharan Africa. *Am J Public Health* 2007;97:1233-40.
 630. Fisher W, Boroditsky R, Morris B. The 2002 Canadian contraception study: part 1. *J Obstet Gynaecol Can* 2004;26:580-90.
 631. Martin K, Wu Z. Contraceptive use in Canada: 1984-1995. *Fam Plann Perspect* 2000;32:65-73.
 632. Sedgh G, Henshaw SK, Singh S, et al. Legal abortion worldwide: incidence and recent trends. *Int Fam Plan Perspect* 2007;33:106-16.
 633. Legardy JK, Curtis KM. Progestogen-only contraceptive use among women with sickle cell anemia: a systematic review. *Contraception* 2006;73:195-204.
 634. Manchikanti A, Grimes DA, Lopez LM, et al. Steroid hormones for contraception in women with sickle cell disease. *Cochrane Database Syst Rev* 2007;(2):CD006261.
 635. Cleland J, Bernstein S, Ezech A, et al. Family planning: the unfinished agenda. *Lancet* 2006;368:1810-27.
 636. Mulvihill MA, Mailloux L, Atkin W. *Advancing policy and research responses to immigrant and refugee women's health in Canada*. Winnipeg (MB): Centres of Excellence in Women's Health; 2001.
 637. *Preventive services for adults*. 15th ed. Bloomington (MN): Institute for Clinical Systems Improvement; 2009.
 638. International Agency for Research on Cancer (IARC). *Cervix cancer screening. IARC handbooks for cancer prevention*. Vol 10. Lyon (France): IARC Press; 2005.
 639. Yang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. *Int J Cancer* 2004;109:418-24.
 640. *Screening for cervical cancer: recommendations and rationale*. Washington (DC): US Preventive Services Task Force; 2003. p. 101-9.
 641. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. *Lancet* 1987;1:1247-9.
 642. Hyman I, Singh PM, Meana M, et al. Physician-related determinants of cervical cancer screening among Caribbean women in Toronto. *Ethn Dis* 2002;12:268-75.
 643. *Canadian human mortality database*. Montréal (QC): Université de Montréal, Department of Demography; 2007. Available: www.demo.umontreal.ca/chmd/ (accessed 2008 Oct. 10).
 644. *Screening for cervical cancer. Systematic evidence review no. 25*. Rockville (MD): Agency for Healthcare Research and Quality; 2002.
 645. McLachlin CM, Mai V, Murphy J, et al. Cervical Screening Guidelines Development Committee. *Cervical screening: a clinical practice guideline*. Toronto (ON): Cancer Care Ontario; 2005.
 646. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for

- the early detection of cervical neoplasia and cancer. *CA Cancer J Clin* 2002; 52:342-62.
647. Rabout L, Hopkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. *CMAJ* 2007;177:469-79.
 648. Markowitz LE, Dunne EF, Saraiya M, et al. *Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP)*. Atlanta (GA): Centers for Disease Control and Prevention; 2007. Available: www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm (accessed 2008 Oct. 2).
 649. Barr E, Tamms G, Gellin B, et al. Quadrivalent human papillomavirus vaccine. *Clin Infect Dis* 2007;45:609-17.
 650. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. *CA Cancer J Clin* 2007;57:7-28.
 651. Arbyn M, Kyrgiou M, Simoons C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. *BMJ* 2008;337:a1284.
 652. Peto J, Gilham C, Fletcher O. The cervical cancer epidemic that screening has prevented in the UK. *Lancet* 2004;364:249-56.
 653. Quinn M, Babb P, Jones J, et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. *BMJ* 1999;318:904-8.
 654. Rieck GC, Tristram A, Hauke A, et al. Cervical screening in 20–24 year olds. *J Med Screen* 2006;13:64-71.
 655. Raffle AE, Alden B, Mackenzie EF. Detection rates for abnormal cervical smears: What are we screening for? *Lancet* 1995;345:1469-73.
 656. Brotherton JM, Gold MS, Kemp AS, et al.; New South Wales Health HPV Adverse Events Panel. Anaphylaxis following quadrivalent human papillomavirus vaccination. *CMAJ* 2008;179:525-33.
 657. Miller BA, Kolonel LN, Bernstein L, et al., editors. *Racial/ethnic patterns of cancer in the United States 1988–1992*. NIH Publ. No. 96-4104. Bethesda (MD): National Cancer Institute; 1996.
 658. McDermott S, DesMeules M, Lewis R, et al. Cancer incidence among Canadian immigrants, 1980–1998: results from a national cohort study. *J Immigr Minor Health* 2011;13:15-26.
 659. de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. *Lancet Infect Dis* 2007;7:453-9.
 660. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:1157-64.
 661. Mayrand MH, Duarte-Franco E, Rodrigues I, et al.; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. *N Engl J Med* 2007;357:1579-88.
 662. Galaal KA, Deane K, Sangal S, et al. Interventions for reducing anxiety in women undergoing colposcopy. *Cochrane Database Syst Rev* 2007;(3):CD006013.
 663. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. National Coordinating Network for Cervical Screening Working Group. *Br J Cancer* 1996;73:1001-5.
 664. Austoker J. Cancer prevention in primary care. Screening for cervical cancer. *BMJ* 1994;309:241-8.
 665. Grewal S, Bottorff JL, Balneaves LG. A Pap test screening clinic in a South Asian community of Vancouver, British Columbia: challenges to maintaining utilization. *Public Health Nurs* 2004;21:412-8.
 666. Matin ML, Lebaron S. Attitudes toward cervical cancer screening among Muslim women: a pilot study. *Women Health* 2004;39:63-77.
 667. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. *Prev Med* 2007;45:107-14.
 668. Bottorff JL, Balneaves LG, Sent L, et al. Cervical cancer screening in ethnocultural groups: case studies in women-centered care. *Women Health* 2001;33:29-46.
 669. Canadian Immunization Committee. *Recommendations on a human papillomavirus immunization program*. Ottawa (ON): Public Health Agency of Canada; 2007. Available: www.phac-aspc.gc.ca/publicat/2008/papillomavirus-papillome/papillomavirus-papillome-index-eng.php (accessed 2010 Jul. 21).
 670. Murphy KJ, Howlett R. Canadian consensus guidelines on human papillomavirus. Chapter 5: screening for cervical cancer. *J Obstet Gynaecol Can* 2007;29:S1-60.
 671. Morrison BJ. Screening for cervical cancer. In: *Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care*. Ottawa (ON): Health Canada; 1994. p. 870-81.
 672. *Fiftieth anniversary of the Universal Declaration of Human Rights*. New York (NY): United Nations Office of Public Information; 1998. Available: www.un.org/rights/50/decla.htm (accessed 2010 Jul. 21).
 673. Caulford P, Vali Y. Providing health care to medically uninsured immigrants and refugees. *CMAJ* 2006;174:1253-4.
 674. Gagnon AJ. The responsiveness of the Canadian health care system towards newcomers. In: Forest PG, Marchildon GP, McIntosh T, editors. *Changing health care in Canada*. Toronto (ON): University of Toronto Press; 2004. p. 349-88.
 675. Bowen S. *Language barriers in access to health care*. Ottawa (ON): Health Canada; 2000.
 676. *Reproductive health in refugee situations*. Geneva (Switzerland): United Nations High Commissioner for Refugees; 1999.
 677. *Saving mothers' lives: reviewing maternal deaths to make motherhood safer — 2003–2005*. London (UK): Confidential Enquiry into Maternal and Child Health; 2007. Available: www.cmace.org.uk/getattachment/927cf18a-735a-47a0-9200-cdea103781c7/Saving-Mothers—Lives-2003-2005_full.aspx (accessed 2010 Apr. 26).
 678. Sword W, Watt S, Krueger P. Postpartum health, service needs, and access to care experiences of immigrant and Canadian-born women. *J Obstet Gynecol Neonatal Nurs* 2006;35:717-27.
 679. Dejin-Karlsson E, Ostergren PO. Country of origin, social support and the risk of small for gestational age birth. *Scand J Public Health* 2004;32:442-9.
 680. *Gender-based violence*. Minneapolis (MN): Reproductive Health Response in Conflict Consortium; 2007. Available: www.rhrc.org/rhr_basics/gbv.html (accessed 2010 Apr. 26).
 681. Vichinsky EP, MacKlin EA, Wayne JS, et al. Changes in the epidemiology of thalassemia in North America: a new minority disease. *Pediatrics* 2005;116:e818-25.
 682. Longlois S, Ford J, Chitayat D. Carrier screening for thalassemia and hemoglobinopathies in Canada. Joint SOGC–CCMG Clinical Practice Guideline No. 218. Society of Obstetricians and Gynaecologists of Canada and Canadian College of Medical Geneticists; 2008.
 683. Giordano PC, Dihal AA, Harteveld CL. Estimating the attitude of immigrants toward primary prevention of the hemoglobinopathies. *Prenat Diagn* 2005;25:885-93.
 684. *Innocenti Digest: changing a harmful social convention: female genital mutilation/cutting*. Florence (Italy): UNICEF Innocenti Research Centre; 2005. Available: www.unicef-irc.org/publications/pdf/fgm_eng.pdf (accessed 2010 Apr. 26).
 685. *Management of pregnancy, childbirth and the postpartum period in the presence of female genital mutilation*. Geneva (Switzerland): World Health Organization; 2001.
 686. World Health Organization. Female genital mutilation and obstetric outcome: WHO collaborative prospective study in six African countries. *Lancet* 2006;367:1835-41.
 687. *Female genital mutilation (FGM). Legal prohibitions worldwide*. New York (NY): Center for Reproductive Rights; 2007. Available: <http://reproductiverights.org/en/document/female-genital-mutilation-fgm-legal-prohibitions-worldwide> (accessed 2010 Apr. 26).
 688. Chalmers B, Omer-Hashi K. What Somali women say about giving birth in Canada. *J Reprod Infant Psychol* 2002;20:267-82.
 689. Hjelm K, Bard K, Nyberg P, et al. Swedish and Middle-Eastern-born women's beliefs about gestational diabetes. *Midwifery* 2005;21:44-60.
 690. Thornton PL, Kieffer EC, Salabarria-Pena Y, et al. Weight, diet, and physical activity-related beliefs and practices among pregnant and postpartum Latino women: the role of social support. *Matern Child Health J* 2006;10:95-104.
 691. van Eijsden M, van der Wal MF, Bonsel GJ. Folic acid knowledge and use in a multi-ethnic pregnancy cohort: the role of language proficiency. *BJOG* 2006;113:1446-51.
 692. Haelterman E, Qvist R, Barlow P, et al. Social deprivation and poor access to care as risk factors for severe pre-eclampsia. *Eur J Obstet Gynecol Reprod Biol* 2003;111:25-32.
 693. Rodríguez MA, Bauer HM, Flores-Ortiz Y, et al. Factors affecting patient-physician communication for abused Latina and Asian immigrant women. *J Fam Pract* 1998;47:309-11.
 694. Ottani PA. Embracing global similarities: a framework for cross-cultural obstetric care. *J Obstet Gynecol Neonatal Nurs* 2002;31:33-8.
 695. Small R, Yelland J, Lumley J, et al. Immigrant women's views about care during labor and birth: an Australian study of Vietnamese, Turkish, and Filipino women. *Birth* 2002;29:266-77.
 696. Thierfelder C, Tanner M, Bodiang CM, et al. Female genital mutilation in the context of migration: experience of African women with the Swiss health care system. *Eur J Public Health* 2005;15:86-90.
 697. Caulford P, Vali Y. Providing health care to medically uninsured immigrants and refugees. *CMAJ* 2006;174:1253-4.
 698. Reyners M. Health consequences of female genital mutilation. *Gynecol Prat* 2004;4:242-51.
 699. Health Canada. *Family-centred maternity and newborn care: national guidelines*. Ottawa (ON): Health Canada; 2000.
 700. Reid AJ, Biringier A, Carroll JD, et al. Using the ALPHA form in practice to assess antenatal psychosocial health. Antenatal Psychosocial Health Assessment. *CMAJ* 1998;159:677-84.
 701. Wathen CN, MacMillan HL; Canadian Task Force on Preventive Health Care. Prevention of violence against women: recommendation statement from the Canadian Task Force on Preventive Health Care. *CMAJ* 2003;169:582-4.
 702. ACOG Committee on Obstetrics. ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy. *Obstet Gynecol* 2007;109:229-37.

Competing interests: Elizabeth Barnett has received grant funding (through her institution) from Sanofi Pasteur and InterCell for work unrelated to this publication; funding for lectures from Merck; royalties from Elsevier; and funding for development of educational presentations from PubMed. She has also received payment for expert testimony. Jennifer Blake is the associate chair of the Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, which has received unrestricted educational grants from pharmaceutical companies in support of educational services; she is vice-chair of Genesis Research Foundation, which receives philanthropic donations from many organizations and which funds research trainees; she is chair of the Canadian Foundation for Women's Health, which receives philanthropic gifts and funds research; and she has served on advisory boards in contraception and has received honoraria for lectures. Marc Deschenes has attended meetings of the Gilead Sciences Advisory Board. Sheila Dunn was on the advisory board of Trimedic in 2008, received speaker fees from Paladin Labs in 2008, received research grants for clinical trials of contraceptives from Organon (Schering-Plough) and provided information (without compensation) to the National Drug Safety and Advisory Committee, in collaboration with Paladin Labs, to support deregulation of emergency contraception in 2007. John Feightner has advised and consulted with the Canadian Task Force on Preventive Health Care. Elizabeth Harvey has served as a national advisory board member for Sanofi Aventis and as a consultant for Lifescan; and her institution receives program funding from the Ontario Diabetes Strategy. In addition, Pfizer, Becton Dickinson, Novo-Nordisk, Eli Lilly, Sanofi Aventis, Bayer, Merck, Astra Zeneca and Bristol Myers Squibb have provided grants to her institution and payments for lectures related to the development and presentation of educational programs about diabetes for primary care providers. Jenny Heathcote has served as a consultant to Axcen Pharma, Gilead Sciences, Hoffmann-La Roche, Merck, Schering-Plough and Tibotec; has received restricted grants from Axcen Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Debio Pharma, Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Human Genome Sciences, Intercept Pharmaceuticals, Schering-Plough, Tibotec and Vertex; has received unrestricted grants from Axcen Pharma, Boehringer Ingelheim, Gilead Sciences, Hoffmann-La Roche, Schering-Plough and Vertex; and has received speaker's fees from Axcen Pharma, Gilead Sciences, Hoffmann-La Roche, Schering-Plough and Tibotec. Charles Hui has received grant support through his institution, as well as payment for lectures and travel expenses, from Abbott International; has also served on a scientific advisory board for Novartis. Jay Keystone has received speaker fees and payments for development of educational presentations from GlaxoSmithKline, Sanofi Pasteur and Merck. Stan Kutcher occasionally serves as an expert witness. Noni MacDonald, Section Editor, Population and Public Health, *CMAJ*, is a coauthor of this article; she was not involved in the vetting of this article before publication. Anne McCarthy has served as an ad hoc consultant on travel medicine to Shorelands Inc. Lavanya Narasiah received speaker fees from GlaxoSmithKline for presentations on travel health. Pierre Plourde received speaker fees from GlaxoSmithKline for presentations on travel health and tropical medicine. Peter Tugwell, chair of the CMA Journal Oversight Committee, is a coauthor of this article; he was not involved in the vetting of this article before publication. David Wong has received educational grants related to hosting the University of Toronto Sheila Sherlock Liver Research Day and the University of Toronto Hepatology Update; he also has received honoraria for educational sessions from Roche, Schering, Gilead, Bristol-Myers Squibb and Novartis (in all instances, the slides used for sessions have been his own). No competing interests declared by Deborah Assayag, Beverly Brockest, Ralf Buhrmann, Giovanni Burgos, Glenn Campbell, Andrea Chambers, Angie Chan, Marianne Cheetham, Walter Delpero, Shafik Dharamsi, Arunmozhi Dominic, Ann Duggan, Nancy Durand, Allison Eyre, Anita Gagnon, Jennifer Grant, Christina Greenaway, Doug Gruner, Sinclair Harris, Stewart Harris, Ghayda Hassan, Christine Heidebrecht, William Hodge, Danielle Hone, Susan Hum, Praseedha Janakiram, Khairun Jivani, Tomas Jurcik, Kamran Khan, Laurence Kirmayer, Ian Kitai, Srinivasan Krishnamurthy, Susan Kuhn, Robert LaRoche, Carmen Logie, Michelle Martin, Dominique Elien Massenet, Debora Matthews, Barry Maze, Mary McNally, Dick Menzies, Marie Munoz, Félicité Murangira, Amy Nolen, Kevin Pottie, Meb Rashid, Cécile Rousseau, Hélène Rousseau, Andrew Ryder, Amelia Sandoe, Kevin Schwartzman, Jennifer Sears, William Stauffer, Helena Swinkels, Brett Thombs, Patricia Topp, Andrew Toren, Sara Torres, Erin Ueffing, Ahsan Ullah, Sunil Varghese, Bilkis Vissandjee, Vivian Welch, Michel Welt, Wendy Wobeser, Phyllis Zekowitz, Jianwei Zhong, Stanley Zlotkin.

Contributors: *Section 1 (Review):* Kevin Pottie, Christina Greenaway, John Feightner, Vivian Welch, Helena Swinkels, Meb Rashid, Lavanya Narasiah, Laurence J. Kirmayer, Erin Ueffing, Noni E. MacDonald, Ghayda Hassan,

Mary McNally, Kamran Kahn, Ralf Buhrmann, Sheila Dunn, Arunmozhi Dominic, Anne E. McCarthy, Anita J. Gagnon, Cécile Rousseau, and Peter Tugwell contributed as members of the steering committee and/or lead authors on reviews and played an active role in formulating the recommendations. The other coauthors of the Canadian Collaboration for Immigrant and Refugee Health (see complete list on the title page) provided substantive contributions for the individual systematic reviews as listed below.

Section 2 (Selection of potentially preventable and treatable conditions): Helena Swinkels, Kevin Pottie, Peter Tugwell, Meb Rashid and Lavanya Narasiah contributed to the conception and refinement of the study design and to the analysis and interpretation of the data. Helena Swinkels drafted the initial manuscript, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 3 (Evaluation of evidence-based literature): Peter Tugwell, Kevin Pottie, Vivian Welch, Erin Ueffing, Andrea Chambers and John Feightner contributed to the conception, writing and critical revision of the manuscript and approved the final version submitted for publication.

Section 4 (Measles, mumps, rubella, diphtheria, tetanus, pertussis and polio): Christina Greenaway, Marie Munoz, Elizabeth Barnett, Amelia Sandoe, Erin Ueffing, Kevin Pottie, Susan Kuhn and Jay Keystone contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Christina Greenaway drafted the initial draft and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 5 (Varicella): Christina Greenaway, Meb Rashid, Elizabeth D. Barnett, Amelia Sandoe, Erin Ueffing, Helena Swinkels, Marie Munoz, Kevin Pottie and Jay Keystone contributed to the conception and refinements of the study design and the analysis and interpretation of the data. Christina Greenaway drafted the initial manuscript, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 6 (Hepatitis B): Christina Greenaway, Lavanya Narasiah, Pierre Plourde, Erin Ueffing, Kevin Pottie, Marc Deschenes, David K.H. Wong, Susan Kuhn and Jenny Heathcote contributed to the conception and refinement of the study design and to the analysis and interpretation of the data. Christina Greenaway drafted the initial manuscript, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 7 (Tuberculosis): Christina Greenaway, Amelia Sandoe, Bilkis Vissandjee, Ian Kitai, Doug Gruner, Kevin Pottie, Erin Ueffing, Wendy Wobeser, Dick Menzies and Kevin Schwartzman contributed to the conception and refinement of the study design and to the analysis and interpretation of the data. Christina Greenaway drafted the initial manuscript, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 8 (HIV): Kevin Pottie, Bilkis Vissandjee, Jennifer Grant, Carmen Logie, Ahsan Ullah, Félicité Murangira and Vivian Welch contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Kevin Pottie wrote the initial draft, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 9 (Hepatitis C): Christina Greenaway, David K.H. Wong, Deborah Assayag, Marc Deschenes, Chuck Hui, Erin Ueffing, Kevin Pottie, Amelia Sandoe, Meb Rashid and Jenny Heathcote contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Christina Greenaway wrote the initial draft, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 10 (Intestinal parasites): Kamran Khan, Christine Heidebrecht, Jennifer Sears, Angie Chan, Meb Rashid, Christina Greenaway, William Stauffer, Lavanya Narasiah and Kevin Pottie contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Kamran Khan drafted the initial manuscript, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 11 (Malaria): Anne E. McCarthy, Sunil Varghese, Ann Duggan, Glenn Campbell, Kevin Pottie and Susan Kuhn contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Anne E. McCarthy drafted the initial manuscript and all authors provided critical feedback and approved the final manuscript submitted for publication.

Section 12 (Depression): Laurence J. Kirmayer, Lavanya Narasiah, Andrew G. Ryder, Giovanni Burgos, Phyllis Zekowitz, Kevin Pottie and Stan Kutcher contributed to conception and refinement of the study design and the analysis and interpretation of the data. Laurence J. Kirmayer drafted the initial manuscript and all authors provided critical feedback and approved the final manuscript submitted for publication.

Section 13 (Post-traumatic stress disorder): Cécile Rousseau, Kevin Pottie, Brett D. Thombs, Marie Munoz and Tomas Jurcik contributed to the conception and refinement of the study design and the analysis and interpretation

of the data. Cécile Rousseau and Kevin Pottie drafted the initial manuscript and all authors provided critical feedback and approved the final manuscript submitted for publication.

Section 14 (Child maltreatment): Ghayda Hassan, Brett D. Thombs, Cécile Rousseau, Laurence J. Kirmayer, John Feightner, Erin Ueffing and Kevin Pottie contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Ghayda Hassan drafted the initial manuscript and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 15 (Intimate partner violence): Ghayda Hassan, Brett D. Thombs, Cécile Rousseau, Laurence J. Kirmayer, John Feightner, Erin Ueffing and Kevin Pottie contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Ghayda Hassan drafted the initial manuscript, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 16 (Diabetes mellitus): Arunmozhi Dominic, Kevin Pottie, Dominique Elien Massenet, Elizabeth Harvey, Jianwei Zhong and Stewart B. Harris contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Arunmozhi Dominic drafted the initial manuscript, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 17 (Iron-deficiency anemia): Kevin Pottie, Andrea Chambers, Beverly Brockest, Vivian Welch and Stanley Zlotkin contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Kevin Pottie drafted the initial manuscript and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 18 (Dental disease): Mary McNally, Debora Matthews, Kevin Pottie, Barry Maze, Shafik Dharamsi, Helena Swinkels, Khairun Jivani, Vivian Welch and Ahsan Ullah contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Mary McNally drafted the initial manuscript, and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 19 (Vision health): Ralf Buhmann, Andrew Toren, William Hodge, Allison Eyre, Michelle Martin, Walter Delpero, Robert Laroche and Kevin Pottie contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Ralf Buhmann and Andrew Toren drafted the initial manuscript and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 20 (Contraception): Sheila Dunn, Praseedha Janakiram, Jennifer Blake, Susan Hum, Marianne Cheetham, Vivian Welch and Kevin Pottie contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Sheila Dunn led the evidence review and all authors provided critical revisions and approved the final manuscript submitted for publication.

Section 21 (Cervical cancer): Kevin Pottie, Amy Nolen, Patricia Topp, Sara Torres, Vivian Welch and Nancy Durand contributed to the conception and refinement of the study design and the analysis and interpretation of the data. Amy Nolen and Kevin Pottie drafted the initial manuscript and provided critical revisions and approved the final manuscript for publication.

Section 22 (Pregnancy): Anita J. Gagnon, Hélène Rousseau, Michel Welt, Sinclair Harris, Danielle Hone, Srinivasan Krishnamurthy and Kevin Pottie contributed to the conception, writing and critical revision of the manuscript and approved the final version submitted for publication.

Funding: The Public Health Agency of Canada (PHAC) contributed funding for the development and publication of reviews of the scientific evidence on select topics related to PHAC programs of work. The conclusions and recommendations made in the guidelines were independently developed by the Canadian Collaboration for Immigrant and Refugee Health. The views expressed in this report are the views of the authors and do not necessarily reflect those of PHAC or any other agency that provided funding support. In addition to the support from PHAC, the Canadian Collaboration for Immigrant and Refugee Health acknowledges funding support for this project from

the Canadian Institutes of Health Research (Institute of Health Services and Policy Research), the Champlain Local Health Integrated Network and the Calgary Refugee Program. The Calgary Refugee Program, the Champlain Local Integrated Network and the Canadian Institutes of Health Research (Canadian Institute of Health Services and Policy Research) contributed to dissemination of the guidelines. The Office of the Chief Dental Officer, Health Canada, provided support for the evidence review on dental health (section 18). Anita J. Gagnon's participation in the project was supported by McGill University through a William Dawson Scholarship. Christina Greenaway receives salary support from the Fonds de la recherche en santé du Québec (FRSQ) through the Chercheur Boursier Clinicien. Carmen Logie receives funding support from the Social Sciences and Humanities Research Council of Canada through a doctoral fellowship. Dick Menzies receives salary support from the FRSQ through the Chercheur National program. Brett Thombs is supported by a New Investigator Award from the Canadian Institutes of Health Research and an Établissement de Jeunes Chercheurs award from the FRSQ.

Acknowledgements: The authors acknowledge the participation of the following primary care practitioners: Jessica Audley (Toronto), Rolando Barrios (Vancouver), Ricardo Batista (Ottawa), Denis Bédard (Québec), Angela Carol (Hamilton), Juan Carlos Luis Chirgwin (Montréal), Tyler Curtis (Toronto), Gilles de Margerie (Montréal), Mike Dillon (Winnipeg), Pierre Dongier (Montréal), Omar Ezzat (Newfoundland and Labrador), Lynn Farrales (Vancouver), Mariella Ferreyra (Toronto), Susanne Fremming (Vancouver), Carol Geller (Ottawa), Réka Gustafson (Vancouver), Susan Hoffman (Toronto), Lanice Jones (Calgary), Valerie Krinke (Edmonton), Britta Laslo (Hamilton), Kay Lee (Ottawa), Lise Loubert (Vancouver), Kathie McNally (Charlottetown), Marie-Jo Ouimet (Montréal), Bill Pegg (Toronto), Eva Purkey (Kingston), Leslie Rourke (St. John's), Millaray Sanchez (Ottawa), Kerry Telford (Vancouver), Gail Webber (Ottawa) and Ed White (Charlottetown). The authors also thank immigrant community stakeholder partners Yvonne Chiu and Lucenia Ortiz, who provided feedback on behalf of the Edmonton Multicultural Health Brokers Cooperative.

The authors thank Patricia Thille, Jennifer Creer, Roo Deinstadt and Ayesha Ratnayake for writing and formatting support, assistance in developing the section on cultural considerations and assistance with the literature reviews; Karin Okrainec for her assistance in launching the Delphi process; other staff members at the Institute of Population Health, University of Ottawa — Erika Espinosa, Belinda Smith, Liz Lacasse, Maria Benkhalti, Leanne Idzerda, Govinda Dahal and Jessie McGowan — for their general project support and assistance in retrieving articles; Lynn Dunikowski, MLS, Director of Library Services, College of Family Physicians of Canada, for expert medical librarian support and for designing the literature searches; Jocelyne Andrews and Teodora Constantinu for conducting certain of the bibliographic searches; Kay Berckmans and Antonella Clerici for secretarial support; Hilary Elkins, Lisa Merry and Diane Habbouche for general support; Sarah McDermott for feedback on the evidence review for diabetes mellitus; Glenda Dare for helpful comments on an earlier version of the HIV review; Sudeep Chaklabanis for assistance in coordinating the review process for depression; Michaela Baeder, Cristiano Martello, Vincenzo Spigonardo and Lorin Young for help in reviewing the literature on depression; Radmika Santhanam-Martin and Yasir Khan for assistance with the evidence review for post-traumatic stress disorder; Megan Galeucia and Vanessa Lecompte for help in reviewing the literature on child maltreatment; Juan Carlos Luis Chirgwin for helpful feedback on earlier drafts of the evidence reviews; Rimma Ormnan, Megan Galeucia and Mylène Boivin for contributions to the literature review on intimate partner violence; and Sheila Innis for helpful feedback on an earlier draft of the evidence review for iron-deficiency anemia. The authors also thank Holger Schünemann, Nancy Santesso, Andy Oxman and Gordon Guyatt for their help with GRADE methods and presentation of findings.